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ABSTRACT
Dengue has been a public health problem in over 120 tropical and subtropical countries. It 
is estimated that there are approximately 3.6 billion of the world’s population at risk of 
dengue virus (DENV) infection, and about 70-500 million DENV infections annually. 
Every year, about 36 million cases of dengue fever, of which about 2.1 million cases are 
dengue haemorrhagic fever and dengue shock syndrome (DHF/DSS) resulting in 21,000 
deaths among children and young adults, are reported [1]. The disease pathogenesis is still 
poorly understood. Effective antiviral drug, vaccine and animal model for the disease are 
not available. We conducted two global gene expression microarray studies and a genome- 
wide association study in order to identify prognostic markers of severe dengue in 
Vietnamese, patients and to identify genetic markers that confer susceptibility to dengue 
and DSS. The results show that acute DENV infection is associated with over-presentation 
of transcripts that are related to interferon-inducible transcripts and canonical gene 
ontology terms that included response to virus, immune response, innate immune response 
and inflammatory response. Pathway and network analysis identified STAT1, STAT2, 
STAT3, IRF7, IRF9, IRF1, CEBPB and SP1 as key transcriptional factors mediating the 
early response. Interestingly, the only differences in the transcriptional signatures of early 
DSS and uncomplicated dengue cases were the greater abundance of several neutrophil- 
associated transcripts in patients who progressed to DSS. Host genetic study identified 
several single nucleotide polymorphisms (SNPs) that show strong evidence for association 
with dengue or DSS. None of the SNPs was significant at suggestive genome-wide level 
but ontology analysis of genes implicated by associated SNPs suggests biologically 
plausible functional relationships between the genes. This thesis provides insights into host 
gene response in DENV infection and also host genetic susceptibility to dengue which in 
turn could be useful hint for future studies in the field.
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Chapter 1: Introduction
1.1 Dengue
Dengue is an acute disease caused by one of four antigenically distinct serotypes of dengue 
virus (DENV). It is presently the most common arthropod-borne viral disease of humans. 
Dengue has been a public health problem in many countries. It is estimated that there are 
approximately 3.6 billion of the world’s population in over 124 nations that are at risk of 
DENV infection, and about 70-500 million DENV infections annually. Every year, about 
36 million cases of dengue fever, of which about 2.1 million cases are dengue 
haemorrhagic fever and dengue shock syndrome (DHF/DSS) resulting in 21,000 deaths 
among children and young adults, are reported [1], Dengue fever (DF) epidemics have 
occurred not only in Asia, but also in other countries and regions such as the South Pacific, 
Australia, and Central and South America [3-5], Figure 1.1 shows the countries and areas 
that are at risk of dengue. Dengue is characterized by fever, rash, headache, eye pain, 
arthralgias, myalgias, and haemorrhagic manifestation. These symptoms normally appear 
within 3-5 days of infection.
Figure 1.1: Countries and areas at risk of dengue transmission [1],
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The first well-documented outbreak of DHF took place in Manila in 1953/1954 and was 
followed by a larger outbreak in Bangkok in 1958 [6], During the rest of the 20th century, 
the disease has spread widely to many countries across Southeast Asia and America, 
increasing both the number of countries affected and case numbers [7, 8], The number of 
countries reporting dengue outbreaks has been increasing yearly, from 35 countries from 
1990-1999 to nearly 70 countries from 2000 to 2005 [9], Figure 1.2 shows global burden 
of dengue in terms of case prevalence and number of countries affected.
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Figure 1.2: The global burden o f dengue in terms of case prevalence and number of 
countries affected. Average yearly number of dengue cases is depicted by bars, and the 
number of countries reporting dengue is shown in the line.
1.2 Dengue epidemiology in Vietnam
1.2.1 Historical information
A dengue-like illness was first recorded in Vietnam in 1913 and epidemics occurred in the 
north and the central provinces [10], The first DF1F outbreaks occurred in 1963. After 
1975, many district and commune level health posts were established; doctors and nurses 
received improved training and acquired experience in diagnosing and treating dengue and
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consequently the mortality rate has declined significantly [11]. These efforts, however, 
could not prevent the geographic expansion of dengue epidemics throughout Vietnam.
1.2.2 Dengue epidemiology in the south of Vietnam since 1998
Dengue has been a public health problem in Vietnam for over 30 years with tens of 
thousands of cases reported every year. The majority of hospitalised cases of dengue occur 
in the 20 southern provinces. Figure 1.3 summarises the morbidity and mortality of dengue 
in the last 10 years from 1998 to 2007. The mortality rate has declined from approximately 
0.3% to less than 0.1% during this period. The disease is reported every month of the year 
but the peak o f transmission occurs during the rainy season (from May to November). In 
2007, patients with DHF or DSS represented 85% of all hospitalised dengue cases reported 
with the majority o f them being children less than 15 years of age [12]. All four serotypes 
of DENV were found to co-circulate in Vietnam but each serotype has been dominant for 
different periods of time. DENV3 was dominant in the epidemic in 1998 but DENV2 was 
the main serotype in 2003-2006 period followed by DENV1 from 2007 until now.
4
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Figure 1.3: Dengue case burden and mortality rates in the southern Vietnam from 1998 to 
2007 [12]. The grey bars represent case number by year and the line represents the 
mortality rate.
1.3 Dengue vector
Mosquitoes were demonstrated as vectors o f DENV through epidemiologic and 
experimental observations by Graham in 1903 [13]. Up to now, all the known DENV 
vectors belong to the genus Aedes, particularly A. aegypti- the principal vector, and A. 
albopictus- the secondary vector [13-15]. Mosquitoes belonging to the genus Aedes have 
African, Asian, or Australian origins. Most of them breed in the forest, in tree holes or 
other natural water containers. The male mosquitoes only suck the juice from plants while 
the females need a blood meal to lay eggs. Female mosquitoes feed on a variety of animals, 
monkeys and occasionally humans. In contrast, A. aegypti and albopictus have adapted to 
live in peri-urban and urban environments with humans as a major feeding target. Their 
larvae can be found in artificial and natural water containers indoors or outdoors. 
Compared to A. albopictus, A. aegypti is more domesticated [13]..A  aegypti prefer to lay 
their eggs into clean water, where their eggs hatch into larvae within 48 hours. The larvae 
become pupae -  a short resting, non-feeding period before emerging as adult mosquitoes.
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This cycle takes approximately 7-14 days. The mosquito lives for 15 days on average 
though it can be as long as 174 days [13]. A. aegypti usually feeds in mid-morning and late 
afternoon biting 2-3 times for a single blood meal [16]. These feeding habits of Ae. aegypti 
assist in the transmission of DENV, with multiple persons living in the same household at 
risk of exposure. Although the dispersal of adult mosquitoes from their place of hatching is 
reported as limited [16], mosquitoes infected with DENV can appear in another distant 
place or another continent, consistent with movement of people by train, bus, boat or 
airplane. Persons with dengue may introduce the virus to a new population when they go 
travelling if suitable vectors are available.
Ambient temperature is considered a critical factor in DENV transmission. It influences 
the mosquitoes’ breeding and their lifespan, and affects the dynamics of virus replication in 
vectors such that higher temperatures favour more rapid dissemination of DENV in the 
mosquitoes’ body [17]. The density of A. aegypti additionally depends on artificial 
breeding sites because of their domesticated characteristics. After DENV infection, 
mosquitoes retain the capacity to transmit DENV for life [18]. Evidence for vertical 
transmission of DENV has been collected in the laboratory and to a limited extent in the 
field [19, 20], but its wider importance in the epidemiology of dengue is poorly 
understood.
1.4 Dengue case classification [1]
With a wide spectrum of clinical presentations, the outcomes and clinical evolution of 
dengue are unpredictable. While the majority of patients recover from dengue, a small 
proportion progress to severe disease which is characterized by plasma leakage with or 
without haemorrhagic manifestations. Appropriate treatment could help to prevent patients 
from progressing from non-severe to severe disease. However, to define the group of 
patients who progress to severe disease is very difficult. WHO classify dengue cases into 2
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main groups - severe dengue and mild dengue, which in turn is subdivided into 2 groups -  
dengue with and without warning signs. Figure 1.4 summarises dengue case classification 
by WHO.
DENGUE £ WARNING SIGNS SEVERE DENGUE
+ 4J w
CRITERIA FOR DENGUE ± W ARNING SIGNS
Probable  dengue
live in /travel b  dengue endemic area. 
Fever and 2 of the following criteria:
•  N ausea, vomiting
• Rash
•  Aches and pains
•  Tourniquet test positive
•  Leukopenia
•  Any warning sign
Laboratory-confirm ed dengue
llmporlant when no sign of plasm a leakage!
W arning signs*
•  Abdominal pain or tenderness
•  Persistent vomiting
•  Clinical fluid accumulation
•  Mucosal bleed
•  Lethargy, restlessness
•  Liver enlargment > 2  cm
•  Laboratory: increase in HCT 
concurrent with rapid decrease  
in platelet count
• (requiring strict observation and  medical 
Intervention!
CRITERIA FOR SEVERE DENGUE 
Severe p lasm a leakage
leading to:
•  Shock (DSS)
•  Fluid accumulation with respiratory 
distress
Severe bleeding
as evaluated by clinician
Severe o rg an  involvement
•  Liver: AST or ALT > = 1 0 0 0
•  CNS: Impaired consciousness
•  Heart and other organs
Figure 1.4: WHO Dengue case classification. WHO classify dengue cases into 2 main groups - 
severe dengue and mild dengue, which in turn is subdivided into 2 groups -  dengue with and 
without warning signs. [1]
After the incubation period of 4 to 10 days after the bite of an infected mosquito, the
disease begins abruptly [1]. In the febrile phase, which usually lasts 2-3 days, patients
often present themselves with facial flushing, skin erythema, body ache, myalgia,
arthralgia and headache, anorexia, nausea and vomiting. Mild haemorrhagic manifestations
may also be observed including petechia and mucosal membrane bleeding (e.g. nose and
gums). Laboratory findings in this phase will show a progressive decrease in total white
cell and platelet count. The critical phase is normally around the time of defervescence
(when the body temperature drops to 37.5 -38°C) on days 3-7 of illness. The beginning of
this phase is associated with a measurable increase in capillary permeability often revealed
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by an increased haematocrit level. Plural effusion and acites may be detectable depending 
on the degree of plasma leakage. When plasma leakage is critical, patients can develop 
shock. During prolonged shock, progressive organ impairment, metabolic acidosis and 
disseminated intravascular coagulation may occur as the result of organ hypoperfusion. 
Organ impairment such as severe hepatitis and encephalitis may also occur without severe 
plasma leakage or shock. The recovery phase occurs 24 - 48 hours after critical phase and 
is characterised by the return of laboratory findings to a normal range and clinical 
improvement. These phases of dengue illness are depicted in figure 1.5.
D ays o f illness 
Temperature
Potential d in ical issues
Laboratory ch an ges
Serology and virology  
Course o f d en g u e  illness
Figure 1.5: The course of dengue illness. There are three main stages of the disease which 
are febrile phase, critical phase and recovery phase. The febrile phase normally occurs in 
the first 72 hours which is followed by the critical phase in the next 72 hours.
-  40 ;
Dehydration Reabsorpfion  
fluid overload
O rgan  impairment
Platelet
Hematocrit
IgM /IgG
Viraemia
Febrile Recovery phases
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1.5 Clinical management
There are no specific anti-viral therapies available to treat dengue. Supportive care is the 
mainstay of dengue treatment. Using analgesics with acetaminophen is recommended, but 
not aspirin to avoid Reye’s syndrome associated with dengue. Early plasma volume 
replacement by oral fluid or fluid transfusion (Ringer’s lactate or dextran 40) can modify 
the severity and prevent shock. Dengue mortality can be reduced with regular monitoring 
of vital signs, careful fluid management when required, and good nursing care. [21]. 
Recently, several randomised control trials have been conducted to evaluate the efficiency 
of the immunomodulators chloroquine [22] and predsinolone (unpublished data) and o f the 
first antiviral drug (a polymerase inhibitor, developed for the treatment of Hepatitis C virus 
infection) in the treatment o f dengue. This indicates that there is a research interest and that 
are developments in the treatment of dengue, and that treatment for dengue other than 
supportive care may become available in the near future.
1.6 Laboratory diagnosis of DENV infection
Dengue can be diagnosed by different methods which include serology, virology and 
molecular techniques. A patient can be laboratory confirmed with dengue if he/she has 
dengue-like clinical symptoms and the presence o f a) IgM seroconversion or high and 
rising levels of DENV-reactive IgM/IgG in paired plasma specimens or b) DENV viremia 
detected by virus isolation or RT-PCR or c) NS1 antigenemia.
1.6.1 MAC ELISA
The IgM antigen capture (MAC) ELISA is a sensitive and relatively specific method used 
for detecting DENV-reactive IgM in serum or plasma [21]. The antigens used in this assay 
are usually inactivated viral particles [23]. Acute dengue is defined by rising levels o f IgM 
antibodies and/or by fourfold or greater increase in IgG in paired sera/plasma samples [21]. 
Primary and secondary dengue can be defined by the molar ratio of IgM to IgG ratio in
9
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acute illness [23, 24]. In this context, the term “secondary dengue” describes the 
serological profile of the immune response rather than definitively determining that this 
was the patient’s 2nd DENV infection, since it could also be the 3rd or even 4th exposure 
[25]. The advantage of the MAC ELISA is that it is relatively inexpensive and simple [23, 
24] . The main limitation of serology for dengue is that it is poorly sensitive in the first few 
days of illness and in places where multiple antigenically-related flaviviruses co-circulate 
appropriate specificity controls must be included in each assay. The WHO/TDR recently 
reviewed the performance of several commercial assays for the detection of dengue IgM. 
The main findings were that the test sensitivities (61.5% to 99%) and specificities (79.9% 
to 97.8%) vary in different commercial tests [26]
1.6.2 DENV nucleic acid detection
Dengue can be diagnosed by detecting DENV RNA in tissue or plasma samples using 
reverse-transcriptase polymerase chain reaction (RT-PCR) methods [27, 28]. Infecting 
serotypes of DENV can be detected based on the differences in amp 1 icon sizes [28]. 
Alternatively, real time RT-PCR using specific primers and fluorescent probes can be used 
[29, 30]. Primers and probes for DENV detection have targeted conserved sequences in the 
C-prM junction or NS5 region or the 3’ non-coding region [28, 31, 32]. RT-PCR can detect 
DENV RNA in the early days o f illness when the patient is still viraemic [21, 33]. 
However, it is not suitable for routine diagnosis in all settings because it is expensive in 
terms o f specialized training, equipment and reagents.
1.6.3 DENV NS1 protein detection
DENV NS1 can be detected in peripheral blood in the acute phase and has been detected 
until the 9 day of illness, even when DENV RNA could not be detected by polymerase 
chain reaction (PCR) [34]. In general, the specificity of NS1 commercial tests is high 
(-100% ) but the sensitivity has varied in different studies. The sensitivity of NS1 tests also
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depends on the day of illness the sample was collected [35, 36]. The highest sensitivity was 
documented within the first three days of illness [36]. Primary dengue is usually associated 
with higher NS1 detection sensitivity [36, 37] relative to secondary dengue as measurable 
DENV-reactive IgG/M in plasma may reduce NS1 sensitivity in secondary dengue 
infection [36, 37]. Combining NS1 and MAC ELISA diagnostic tests can increase the 
positive rate o f diagnosis in the acute phase of illness [38, 39] .
1.6.4 Virus isolation in cell culture
DENV from serum, plasma, blood or tissue is isolated by inoculating the clinical specimen 
into suitable cell lines followed by identification with serotype-specific anti-DENV 
monoclonal antibodies (mAb) by immuno-fluorescence assay [21]. A mosquito cell line 
(e.g. C6/36) is most commonly used because o f greater sensitivity than mammalian cells 
(e.g. Vero, BHK) [40, 41]. Although viral isolation gives a definitive diagnosis of dengue, 
it is not suitable for routine diagnostic laboratories because it is time consuming (taking > 
5 days for cultures to become positive) [40, 42].
1.7 Dengue virus
There are four antigenieally distinct serotypes of dengue virus (DENV 1-4) that have been 
identified so far. Dengue virus belongs to genus Flavivirus within the Flaviviridae family. 
Flavivirus genus consists of about 70 flaviviruses, many o f which are arthropod-borne 
human pathogens causing a variety of diseases, such as West Nile virus, Japanese 
Encephalitis virus, and Yellow fever virus [43]. DENV is a small, enveloped virus with a 
diameter of about 50 nanometres. The virus is a single-stranded genomic RNA of positive 
polarity approximately llk b  in length [44]. The genomic RNA of the virus is surroundecl 
by an icosahedral or isometric nucleocapsid about 30nm in diameter (review [45]). The 
nucleocapsid is surrounded by a lipid bilayer about lOnm deep into which the viral 
structural protein M and the envelop glycoprotein (E) are embedded [46]. The genome of
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DENV contains a 5’ untranslated region (UTR; 100 nucleotides), a single open reading 
frame encoding for the viral polyprotein and a 3’ untranslated region (3’-UTR; -400 
nucleotides). The 5’ and 3’ UTR are very important in both viral replication or translation 
[47-50]. The open reading frame of DENV encodes for a polyprotein , which is co- and 
post-translationally processed into three structural proteins (C, M and E) and seven non- 
structural proteins (NSl, NS2A, NS2B, NS3, NS4A, NS4B and NS5) [45]. The highly 
basic 12-14 kDa capsid (C) protein forms the viral nucleocapsid together with the genomic 
RNA. This protein is rich in lysine and arginine residues and contains 114 amino acids. 
During infection, the C protein localises to the nuclei of infected cells [51]; the premature 
M (PrM), a glycoprotein precursor (18.1 -19kDa, 166 amino acid), prevents the E protein 
undergoing low-pH induced conformational changes prior to viral maturation by forming 
prM -  E heterodimers [52]. E protein (55 -  60 kDa, 493 -  495 amino acid) which is 
exposed on the surface of the virion, is associated with virus binding and fusion of viral 
and cellular membranes during receptor-mediated endocytosis [53, 54]. Most of the non- 
structural proteins are involved in viral replication. NS5 is a RNA-dependent RNA 
polymerase and carries an additional N-terminal methyltransferase domain important for. 
viral replication [55]. NS3 acts as the viral serine protease, which requires the cofactor 
NS2B for full activity. Furthermore, NS3 contains an RNA helicase and nucleotide 
triphosphatase activity important for replication o f the viral RNA [56, 57]. Functions of the 
other proteins (NSl, NS2A, NS2B, NS4A and NS4B) are poorly understood. NSl protein 
(46-50 kDa, 352 amino acid) is secreted by infected cells or associated with the infected 
cell membrane [58, 59]. N Sl is also assumed to act at early stage in viral RNA replication 
and may also be important for the pathogenesis o f DHF [60-62],
12
Chapter I: Introduction
1.8 Immunopathogenesis in DENV infections
1.8.1 Humoral response in DENV infection
DENV-reactive antibodies may be involved in virus neutralization, complement lysis, and 
antibody-dependent cellular cytotoxicity (ADCC). Antibodies neutralize the virus through 
inhibiting viral fusion and viral membrane attachment [63]. Antibodies against E proteins 
are elicited in the early phase of illness and are amongst the most abundant populations of 
antibodies following DENV infection [64]. Animal models have revealed that passive 
transfer of antibodies against structural and non-structural proteins may protect against 
lethal DENV challenge [65-67]. Antibody can have viral neutralizing activity through 
inhibiting viral fusion and viral membrane attachment [63] and can involve in antibody- 
mediated cell lysis through ADCC, a mechanism through which DENV infected cells are 
recognized and lysed by natural killer cells with promotion by specific antibody and 
complement. ADCC may be associated with dengue pathogenesis because this mechanism 
was observed in acute sera from DHF/DSS patients but not from DF patients [68]. ADCC 
has been postulated to be a host immune mechanism of controlling DENV infection in the 
very early phase of disease [69].
1.8.2 Cellular immune responses in dengue
The innate immune response plays a very important role in antiviral immunity to DENV in 
both primary and secondary dengue. The role of ADCC in dengue pathogenesis is not well 
understood but early activation of NK cells was found in DHF/DSS patients [70-72]. 
Moreover, the percentage of CD8 T cells and NK cells expressing CD69, a transient cell 
activation marker, was higher in children with DHF than in those with DF [70].
Specific T cell proliferation against DENV and other flaviviruses was observed when 
healthy adult volunteers received a monovalent live-attenuated candidate vaccine. CD8+ 
cytotoxic T cells can recognise DENV N Sl, NS3 and E protein [73]. DENV-reactive
13
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CD4+/ CD8+ T cells can produce IFN-y, TNF and chemokines that were efficient at lysing 
DENV-infected cells in-vitro [74], Memory serotype cross-reactive T cells were 
hypothesized to contribute to the pathogenesis in secondary infection by producing high 
levels of inflammatory cytokines during the acute phase [75, 76].
1.8.3 Cytokine and Chemokine responses in dengue
Host gene-expression studies of acute dengue patients indicated that cytokine-related genes 
were up-regulated in patients with severe dengue relative to patients with mild dengue [77, 
78]. In-vitro and ex-vivo studies showed that DENV infection can induce the secretion of 
several cytokines and chemokines such as tumor necrosis factor alpha (TNFa), interferon 
(IFNy), interleukin-6/8/10 (IL-6, IL-8, and IL-10), or RANTES [79-81]. The 
overproduction o f pro-inflammatory and anti-inflammatory cytokines was also observed in 
Vietnamese infants with dengue [82].
Elevated levels o f cytokines and chemokines during secondary infection by infected and 
activated mononuclear phagocytes and T cells, and driven by the viral antigenic burden, 
can partly explain the vascular leakage phenomenon, the hall mark of severe dengue. In 
primary dengue in infants, memory DENV-reactive T cells are not relevant to the 
immediate host response. Nonetheless, elevated levels of inflammatory cytokines have 
been described in Vietnamese infants with primary dengue [82]. Molecules such as MCP-1 
and TNFa, which are elevated in DHF/DSS cases, have well characterized vasodilatory 
effects in animal models and endothelial cell monolayers [83, 84]. TNFa enhanced 
endothelial cells to produce reactive nitrogen and oxygen species which may then induce 
the haemorrhagic manifestation [85]. Interestingly, an in-vitro study has revealed that the 
chemokine IP-10 competes with DENV in binding heparan sulphate on the cell surface. IP- 
10 is also abundantly expressed during acute DENV infection [86, 87]. Generally, there is
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a widely held view that cytokines and chemokines contribute to the immunopathogenesis 
o f dengue.
1.9 Risk factors for severe dengue
1.9.1 Viremia
Higher peak viremia titres were observed in children with DHF relative to children with 
DF, and in secondary infections relative to primary infections [33, 88]. Higher viremia was 
also observed in adults with DHF relative to those with DF. Furthermore, viremia was 
demonstrated to persist longer in DHF patients than in DF patients [89]. The kinetics of 
DENV infection prior to disease onset remains poorly characterised and very difficult to 
study. Studies in Vietnamese patients with DSS showed that the viremia declined to a very 
low level at the time o f shock (B. Wills personal communication). A majority o f studies 
have described viremia in plasma so that the results may not be representative of infection 
in other organs of the body [90, 91].
1.9.2 Virulence
Dengue virus serotypes are hypothesised to have evolved independently [92]. All four 
serotypes can cause DHF/DSS but DENV2 is more frequently associated with severe 
dengue [93-95] followed by DENV1 and DENV3 [96-98] and DENV4 [99]. There are 
many different genotypes and strains within each genotype, each of which may contribute 
differently to disease outcomes. For example, the DENV2 American genotype was 
demonstrated to be associated with DF and very few DHF/DSS cases in Peru during an 
epidemic in 1995 where the majority of patients had secondary dengue [100]. In 
comparison, the 1981 epidemic o f DENV2 Asian 2 genotype in Cuba resulted in about
300,000 infections and around 30,000 cases of DHF/DSS with 158 deaths [101, 102] . This 
suggested that certain serotypes or genotypes may be more virulent than the others. This 
may be because certain serotypes or genotypes have high replication fitness [103]. ADE
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may also play a role in this phenomenon as it provides competitive advantages to viruses 
that undergo enhancement through increasing viral replication [104]. Natural positive 
selection may also contribute to the fitness of the DENV as it was shown that this selection 
was different between serotypes [105]. However, the virulence of DENV is very hard to 
assess because there is no good animal model of DHF/DSS.
1.9.3 Antibody-dependent enhancement (ADE)
Antibody-dependent enhancement (ADE) is a phenomenon in which non-neutralizing, 
cross-reactive antibodies elicited by a primary DENV infection, or acquired passively by 
vertical transmission, enhance the infectivity o f DENV for Fc receptor-bearing cells [106]. 
This model postulates that sub-neutralizing levels o f DENV-reactive IgG enhance the 
infectivity of virus for Fc receptor bearing cells. This process would then theoretically 
result in increased viral burdens and more severe clinical symptoms. The ADE 
phenomenon is well established in vitro and was first described by Halstead et al in 1977 
[107]. The target cells in these experiments were usually primate cell lines expressing Fc 
receptors on their surfaces. Incubating Flavivirus antisera with DENV2 could enhance 
viral infection in human peripheral blood mononuclear phagocytes [108]. ADE activity has 
also been observed in Fc-receptor positive K562, U937, and Raji-1 cells [109]. ADE 
activity has been documented in rhesus monkeys which had been passively transferred 
diluted human anti-DENV immune serum. Subsequent DENV infection o f these monkeys 
showed the ratio of infection enhancement ranged from 2.7 to 51.4 [110]. Similarly, a 
significantly greater vireamia titre was observed in monkeys which received non­
neutralising o f monoclonal anti-DENV antibody compared with those receiving PBS 
[109].
The evidence to support the ADE hypotheses has been mostly inferred from 
epidemiological data that demonstrates secondary infection is a risk factor for severe
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disease. In one prospective study of Thai children, the DENV infection enhancing activity 
of pre-infection sera for primary human monocytes positively correlated with clinical 
outcome, i.e. children with pre-illness sera that showed high levels of infection-enhancing 
activity developed more severe disease [111]. However, this study has not been replicated. 
In a more recent study of Thai children, there was no correlation between the DENV- 
infection enhancing activity of pre-infection sera for K562 cells and the clinical phenotype 
of these children when they were exposed to DENV [112]. In infants, Kliks et al showed a 
correlation between the age o f disease onset in Thai infants (n=13) and the dilution at 
which cord sera maximally enhanced infection o f primary monocytes [113]. It was also 
shown that infants at 6-9 months old are more vulnerable to DHF/DSS. This may be 
because o f the decline o f maternal-derived anti-DENV antibody to a subneutralising level 
that enhances infectivity of DENV [114]. However, ADE cannot solely explain disease 
pathogenesis as there are still DHF/DSS cases with primary DENV infections [93] and 
only a small proportion of all secondary dengue infections develop DHF/DSS.
1.9.4 Dengue and genetic predisposition
Genetic polymorphisms include single nucleotide polymorphisms (SNPs), gene copy
number variants and genetic deletions. These subtle changes might very well have
important consequences for susceptibility to disease [115]. Genome-wide association
studies have been used to identify genetic variations that confer susceptibility to viral
diseases such as HIV and HCV infection. A polymorphism near the IL28B gene was
shown to be associated with a two-fold change in response to treatment in both the
European and African population [116] and with better clearance of the virus in the same
populations [117]. A polymorphism in the IL28B gene was also demonstrated to be
associated with the response to treatment in the Japanese population [118]. Polymorphisms
in the HLA-DP gene were also shown to be associated with susceptibility to HBV infection
in Han-Chinese and Thai people [119]. In DENV infection, indirect evidence implicating
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host genetic background to DHF/DSS was observed in Cuban dengue epidemics whereby a 
reduced risk for DHF/DSS was observed in those with an African ancestry compared to 
those with European ancestry [94, 102, 120-124]. These Cuban observations are of 
significant epidemiological interest,- as the differences in susceptibility to DHF among 
racial groups in Cuba coincide with the low susceptibility reported in African and Black 
Caribbean populations [125, 126].
Although dengue virus has been repeatedly isolated in Africa, and DF is known to be 
presented in 19 countries in this continent, there are only sporadic reports of DHF cases 
[125, 127, 128]. An additional observation is that in Haiti, despite the presence of viral risk 
factors, no DHF/DSS cases have been reported [126]. The dengue epidemiological 
observations related to ethnicity in Africa, Cuba and Haiti could indicate the sharing o f a 
common genetic background that moderates the clinical outcome of DENV infection in 
individuals who have an African genetic background. Bearing in mind the central role o f 
immunological mechanisms in the pathogenesis of DHF, the genes associated with the 
immune response must be considered carefully in the context of human genes regulating 
dengue disease severity, which might be distributed unequally in Black individuals and 
White individuals.
HLA genes have been among the most studied polymorphic genes in dengue. Early case- 
control studies of serologically determined HLA class I alleles in DENV-infected patients 
were performed in Cuba during the 1981 DENV2 outbreak. A positive association of 
HLA-A1, HLA B and HLA CW1 with DHF was shown [129]. Other serological studies of 
HLA class I alleles have been performed in ethnically and geographically distinct 
populations in Thailand, suggesting an increase in the frequency o f class I serotype HLA- 
A2 in DHF patients [130].
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The study o f the HLA association with dengue illness was reconsidered again in 2001 by 
Hsin et al. using molecular analysis o f HLA class I allele profiles in Vietnamese patients. 
These authors demonstrated evidence for association of alleles of the HLA-A locus with 
susceptibility to DHF [131]. More recently, a second and larger case-control study in 
ethnic Thai cases confirmed the association of classical HLA class I alleles (A2, A*0207, 
B46, B51) with the clinical outcome, in previously dengue immunologically primed 
individuals [132].
A molecular approach to HLA case-control studies was reconsidered in Cuba, which 
represents a unique scenario to perform genetic studies of DHF resistance/susceptibility 
[121, 122, 133]. A significantly increased frequency o f HLA I alleles A*31 and B*15 was 
found in Cuban individuals with a history of symptomatic DENV infection compared to 
controls. HLA II alleles DRB1*07 and DRB1*04, on the other hand, showed an elevated 
frequency in controls compared with dengue cases. Genes in the class III region encode a 
number of proteins, including complement proteins (C4A, C4B, C2), TNFa and TNFp and 
heat shock proteins [134]. Hsin et al. studied promoter polymorphisms in the TNFa gene 
but did not find an association with DHF, and Fernandez-Mestre et al. reported a 
significant increase of the TNF-308A allele in patients with DHF [135]. Table 1.1 
summarises the association of HLA polymorphisms with the outcomes of dengue.
The number o f studies on polymorphisms within non-HLA genes remains low. Hsin and 
colleagues investigated the association between susceptibility to DHF and polymorphic 
non-HLA alleles such as vitamin D receptor (VDR), Fey receptor II (FcyRII), IL-4), IL- 
1RA, and mannose-binding lectin [136]. They found that variant at position 352 of the 
vitamin D receptor (VDR) gene was associated with resistance to severe dengue (P = 0.03) 
and variant at position 131 of Fey receptor II may be associated with protection from DHF.
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It has been reported that there is a stronger association of the allelic variant of a DC-SIGN1 
codifying gene CD209, DCSIGN1-336, and the risk of DF compared to DHF or population 
controls. DC-SIGN1 is a dendritic cell-specific ICAM-3 grabbing non-integrin which are 
essential for productive infection of dendritic cells [137].
Recently associations between TAP and HPA gene polymorphism and dengue were 
described, suggesting that the heterozygous pattern at the TAPI 333 locus and H PA la/la  
and HPA2a/2b genotypes confer susceptibility to DHF. The H PA la/lb  genotype was 
determined to be a genetic risk factor for DSS [138].
As the aforementioned studies demonstrate, investigations into the genetic basis of 
susceptibility to dengue have made enormous strides since the completion of the human 
genome sequencing project. Nevertheless, this field of research is dominated by case- 
control association studies of small sample sizes, uncertain case ascertainment and with 
unknown levels of population stratification (genetic admixture in one population that 
obscures any meaningful study of genetic association). Typically, these studies examined 
polymorphisms in a limited number of candidate genes for which there was some a priori 
rationale for their investigation. For the vast majority o f case-control association studies, 
there was never an attempt to replicate the genetic association in either the same or 
different population.
Improvements in technology that permit high-throughput genotyping of genetic 
polymorphisms have allowed a genome-wide approach to investigating host genetic 
susceptibility. Essential to this approach are large sample sizes in order to make statistical 
correction o f the number o f comparisons being made. Replication of the genetic 
association in a second population is now considered an essential validation step.
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Table 1.1: Summary of association of HLA genes with outcome of dengue [2].
HLA o f Interest Case in ) vs Control” in) frcq. in
ca.se
frcq. in 
control
p  value Country Citation
HLA e lm s  I
HLA-A
HLA-A1 1° DHF (8) vs control (138) 0.25 0.03 0.035 Thailand Chiewsilp et al., 1981 {571
HL.A-A2
DSS (87) vs control (276) 
2° DSS (41) vs control
0.31
0.68
0.08
0.51
< 10  4 
0.047
Cuba
Thailand
Paradoa-Pcrez et al.. 1987 [58] 
Chiewsilp et al.. 1981
HLA-A*0203
2° DF (106) vs control (140)
. 2° DHF (103) vs control (140) - 
2° DF (106) vs control (140)
0.57
0.51
0.34
0.34
.0 .3 4
0.19
0.0005 .
0.0076
0.00048
Thailand
Thailand
Thailand
Stephens et al., 2002 [59] 
Stephens et al.
Stephens ct al.
HLA-A*02Q3 • 2° DHF (103) vs 2° DF (106) 0.17 0.34 0.01 Thailand Stephens et al.
HLA-AH1207 2° DHF (103) vs control (140) 0.28 0.14 0.012 Thailand Stephens ct al.
lfLA-A’ 24 DHF (309) vs conirol (251) 0.35 • 0.259 0.021 Vietnam Loke et al., 2001 [60]
HLA-A*24 DSS (53) vs control (62) 0.35 0.25 0.04 HCMC Vietnam Lan ei al.. 2008 [61]
HLA-A*24 DSS (37) vs control (50) 0.375 0.25 0.029 Vihn Long Vietnam Lan et al., 2008
HLA-A*29 DSS (87) vs control (276) 0.62 0 .0 1 <0.001 Cuba Paradoa-Pcrez et al., 1987
HLA-A*3I DF and DHF (120) vs control (189) 0.045 0.008 < 10  4 Cuba Sierra et al., 2007 [62]
■HLA-A*3 DHF (309) vs control (251) 0.11 0.183 0.014 Vietnam Loke et al.. 2001
HLA-B
HLA-B blank All DSS (41) vs control (138) 0.07 0.01 <0.02 Thailand Chiewsilp ct al.. 1981
DSS (87) vs control (276) 0.36 0.11 <nr Cuba Paradoa-Perez et al., 1987
HLA-B 13
2° DSS (41) vs control (138) 
DF and DHF (120) vs heathy
0.07
0.15.6
0.23
0.044
< 0 0 5
0.01X105
Thailand
Cuba
Chiewsilp et al., 1981 
Sierra et al., 2007
HLA-B 1.5 . .
control (189)
2° DF (106) vs control (1.40) 0.05 0.16 0.012 Thailand Stephens ct a!., 2002
HLA-B62 2° DF and DHF (209) vs control (140) 0.005 0.05 0.016 Thailand Stephens ct al.
HLA-B76 2° DF and DHF (209) vs control (140) 0.01 0.07 0.005 Thailand Stephens et al.
HLA-B77 2° DF (106) vs control (140) 0.17 0.06 0.009 Thailand Stephens et al.
HLA-B5 . . 2° DF (103) vs control (140) 0.17 0.06 0.021 Thailand Stephens ct al.
HLA-B *51 2° DHF (103) vs 2° DF (106) 0.16 0.06 0.036 Thailand Stephens ct al.
HLA-B*5I 2° DHF (103) vs control (140) 0.16 0.04 0.0052 Thailand Sicphens et al.
HLA-B-52 2° DF (106) vs control (140) 0.11 0.02 0.0067 Thailand Stephens et al.
•HLA-B*52 2° DHF (103) vs 2° DF (106) 0.01 0.11 0.0049 Thailand Stephens et al.
HLA c lass II 
HLA-DR
HLA-DR 1 ■ DF (64) vs control 0.328 0.159 0.0057 Brazil Polizel ct al., 2004 [63]
HKA-DRBF04 2° DF and DHF (77) vs control (.189) 0.081 0.142 0.001 Cuba Sierra ct al., 2007
DF (47) vs DHF 0064 0.35 0.011 Mexico L aF lcuretal., 2002 164]
HLA-DRBH07 DF and DHF (120) vs healthy 0.07 0.197 0.0001 Cuba Sierra et al., 2007
HLA-DRBF0901
control (189)
DSS (14) vs control (61) 0.15 0.32 0.0018 Vietnam Lan ct al., 2008 .
HLA-DR 11 DF (47) vs DHF (34) 0.02 0.12 0.003 Mexico LaFleur ct al., 21X12
H LA-DQ  
HLA DQI DF (64) vs control (201) 0.796 0.577 0.0052 Brazil Polizel ct al., 21X14
“ Control groups arc comprised of sympatric, healthy, age and sex matched individuals o f the same ethnicity as DENV patient cohorts.
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1.9.5 Global host gene response and prognostic markers of severe dengue
With a wide spectrum of clinical presentations, the outcome and clinical evolution of 
dengue are unpredictable. While the majority o f patients recover from dengue, a small 
proportion progress to severe disease which is characterized by plasma leakage with or 
without haemorrhagic manifestations. At the present, there are no specific therapies for 
dengue and treatment of patients with DSS is limited to supportive care. Early diagnosis 
which helps to decide appropriate intervention might help to prevent patients from 
developing DSS. However, to define the group o f patients who progress to DSS is very 
difficult [1]. Complications o f dengue (e.g. cardiovascular shock) typically occur between 
the 4th and 6th days o f illness. There is thus a window of time in the first few days of 
illness where it should be possible to establish a diagnosis [36] and potentially, make a 
prognosis o f disease severity with a host or viral biomarker. The identification and 
development o f tools to detect prognostic markers o f DSS could allow for improved 
patient triage, closer clinical monitoring, or in the future, treatment with anti-viral or 
immune modulating therapies.
Gene expression microarrays may provide a comprehensive understanding of the host gene
response in infectious diseases. Whole blood samples or samples which are a
subpopulation o f cells (PBMCs, Neutrophiles, B and T cells) were often used for these
methods. The use of whole blood involves less manipulation of the specimen. Furthermore,
the use of whole blood gives a comprehensive picture o f gene expression during the
systemic host response to infection and reflects the overall interaction within a complex
system. However, two challenges remain when choosing whole blood samples. Firstly, an
important gene expression pattern may be undetectable in samples that contain many cell
types like whole blood, particularly, a pattern generated by a rare cell population.
Secondly, the gene expression data might not be a reflection of the real difference between
two groups o f samples if  there are differences in the number of sub-cell types between the
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groups. This means that the resulting gene transcript data may simply be a reflection of the 
sum of the unique, constitutive transcript profiles from each cell type, rather than an actual 
increase or decrease in transcript levels within a given cell type in the response to the 
infection or stimulus [139] [140]. It was also shown that different cell types (Neutrophiles, 
lymphocytes, etc) in whole blood contribute to variations in gene expression in whole 
blood samples in healthy people. However, it was also demonstrated that intrinsic 
individual differences are not the dominant source of variation in gene expression among 
healthy people and that it is feasible o f using gene expression in whole blood as a basis for 
detection and diagnosis o f disease in human patients [141].
Recently, several studies have been performed that describe gene expression profiles in 
blood samples from dengue patients [77, 78, 142-145]. Simmons et al described whole 
blood transcriptional signature in Vietnamese adults with DHF enrolled around the time of 
defervescence [78]. The timing o f sample collection is clearly a major factor in studies of 
the transcriptional signature, with samples collected during the febrile phase having a 
characteristic anti-viral profile, i.e. with interferon-stimulated genes highly prominent [78]. 
Studies of PBMC (i.e. minus the neutrophil population) have also been described [142, 
143]. Nascimento et al. used PBMC isolated from patients infected with DENV at different 
times in the disease course. PBMC samples were collected from patients with DF, DHF 
and non-dengue patients on illness days ranging from day 1 to day 11. All DHF patients 
were grade I and II according to WHO classification. The author determined 4 genes 
(PSMB9, MT2A, C3aRl and HLA-F) that distinguish DF from DHF based on Linear 
Discrimination Analysis (LDA). Caveats to this result are that the majority of samples used 
in this study were collected 7 days after onset of disease and patients with life-threatening 
DSS were not present in the study population.
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In a gene expression array study in Thailand, Ubol et al used samples that were collected 
from 5 DF and 4 DHF patients at various times before defervescence (ranging from day -1 
to day -4)). The standout features were the up-regulation of interferon-related genes, CD59 
and IP-10 in PBMC from DF patients compared to PBMC from DHF patients. The author 
hypothesised that mild dengue (DF) developed because of a more robust IFN response 
leading to a reduction in the number o f virus-infected cells, virus production and cell 
damage. However, given the very small sample size and inconsistencies in timing of the 
samples, this study was unable to determine prognostic markers of DSS.
1.10 Knowledge Gap
In the context of host genetic susceptibility to dengue, despite many candidate gene studies 
having been performed, there is still a major lack of understanding from a genome-wide 
perspective o f the genetic determinants of susceptibility. A major limitation of previous 
studies has been relatively small sample sizes.
In the context of understanding gene expression and identifying prognostic markers, most 
previous studies (including from Viet Nam) have been small in sample size and rarely 
included patients with life-threatening DSS. Sample timing is also an issue that must be 
taken into account. Investigating samples collected on day 4 of illness may only help 
explain the consequence of what happened well before the patients developed shock and 
could not be used to predict disease outcomes.
1.11 Objectives of the thesis
The pathogenesis of severe dengue remains incompletely understood and effective drugs 
and vaccines are currently not available. Predicting the outcome o f a DENV infection is an 
important goal that could help to determine disease mechanism and also help to improve 
treatment. Clinical experience has identified several features (e.g. abdominal pain, 
persistent vomiting) as being associated with DSS, however many of these manifestations
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occur near the time o f shock rather than early in the illness. In this thesis, we aim to 
determine prognostic markers of severe dengue by using global gene expression 
microarray. The first study (Chapter 3) focuses on exploring differences in acute responses 
between uncomplicated dengue and DSS on day 4 of illness. This study looks at 
differences in the whole blood transcriptional profiles between children with DSS and 
children with uncomplicated dengue on day 4 o f illness.
The study described in Chapter 4 was designed to identify prognostic markers o f DSS by 
looking at differences in early transcriptional profiles in the whole blood of dengue 
patients with uncomplicated dengue and patients with severe dengue (DSS). These patients 
were classified based on the most up-to-date WHO clinical guideline [1]. Furthermore, the 
samples were collected at less than 72hrs after disease onset and the DSS samples were, 
very well matched with uncomplicated dengue patients by age, sex and infecting DENV 
serotype. To our knowledge, this study has the largest sample size to investigate early in 
vivo transcriptional profiles of dengue patients with different and highly relevant clinical 
presentations. We also showed in the study that there was no evidence of viral 
phylogenetic structure that related to clinical outcomes. Key molecules of acute dengue 
were also identified using network analysis of differential expressed transcripts in acute 
dengue samples relative to convalescent dengue samples.
In this thesis, we also aimed to identify SNPs that are associated with dengue and also 
SNPs that distinguish severe dengue from uncomplicated dengue. We performed genome 
wide association case control study to investigate frequency o f 250K SNPs in cases 
(including DSS patients and uncomplicated dengue patients) and in population controls 
(cord blood samples). The aim of this study was to determine SNPs that confer the 
susceptibility to dengue. The most significant SNPs were followed up in a new cohort. In 
addition, to identify SNPs that are associated with severity of dengue, we conducted a
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genome wide association case control study to investigate 500K SNPs in cases (severe 
dengue patients) and in controls (mild dengue patients). The top significant SNPs were 
genotyped again in a new set o f samples with larger sample size. Despite no genome-wide 
significant SNP was identified, we identified several SNPs that showed strong evidence for 
association with susceptibility to dengue and DSS
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CHAPTER 2
2. M ATERIALS AND M ETHODS
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2.1 Methods
2.1.1 Patient diagnosis
2.1.1.1 Serology for Detection of DENV-reactive IgM/IgG by Panbio ELISA
DENV antigen (Dengue 1-4 recombinant E proteins) was first diluted 250 times with 
antigen diluent (Phosphate buffered saline) by mixing 10 pi o f antigen with 2.5 ml of 
antigen diluent. The diluted antigen was then mixed with an equal amount of MAb Tracer 
(Horseradish peroxidase conjugated monoclonal antibody) and kept at room temperature 
until used. At the same time, plasma samples, positive controls, negative controls and 
calibrators were diluted 100 times with sample diluent (Tris buffered saline (pH 12-1.6)) 
by adding lOul o f sample to 1000 pi of sample diluent. The diluted samples, controls and 
calibrators were pipetted into the assay plate (Anti-human IgM/IgG Coated Microwells) 
and incubated for lhr at 37°C. After incubation, the assay plate was washed 6 times with 
Wash buffer (20x concentrate o f phosphate buffered saline (pH 7.2-7.6) with Tween 20) 
before lOOul of the antigen-Mab was pipetted into the assay plate which was subsequently 
incubated for lhr at 37°C and washed 6 times with Wash buffer. After washing, lOOul of 
TMB (a mixture of 3,3’,5,5'-tetramethylbenzidine and hydrogen peroxide in a citric-acid 
citrate buffer (pH 3.5-3.8)) was added into each well and incubate for 10 minutes at room 
temperature for blue color to develop. The reaction was stopped by adding 100 pi of Stop 
solution into each well. Finally, the absorbance of each well was measured at the 
wavelength of 450 nm.
Data calculation and interpretation
Panbio units = Index value x 10.
Index value was calculated by dividing the sample absorbance by the cut-off value. Cut­
off value was calculated by multiplying the average of the triplicates of the Calibrator by 
the calibration factor, which is specific for each batch.
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Table 2.1: Panbio Elisa data interpretation
IgG Panbio Units IgM Panbio Units Results
< 9 < 18 Negative
9 - 11 1 8 - 2 2 Equivocal
>9 >22 Positive
2.1.1.2 Serology for Detection of DENV-reactive IgM /IgG by MAC/GAC ELISA
Supernatant from DENV 1-4 or JEV (Japanese Encephalitis virus) infected C6/36 cells and 
anti-DENV or JEV mouse monoclonal antibodies were supplied by Venture Technologies 
(UNIMAS Research Park, University Malaysia Sarawak, Malaysia). Briefly, ELISA plates 
(Maxisorp, Nunc) were coated with lOOpl anti-human IgM (A0425-Dako Company) or 
anti-human IgG (12136-Sigma Company) at a dilution at 1:2000 overnight at 4°C. Plates 
were washed and then blocked with 200 pi phosphate buffer saline (PBS) 3% Bovine 
Serum Albumin (BSA) per well for at least 2 hours at room temperature. Samples, positive 
and negative controls were diluted at 1:100 in PBS 0.05% Tween 20. After the 2nd wash, 
lOOpl of diluted plasma (1/100) and controls were added and incubated for 2 hours at room 
temperature. After washing five times, lOOpl of antigen (pooled supernatants'from C6/36 
cultures of DENV1-4 or o f JEV) was added to each well and incubated at 4°C overnight. 
After washing, the assay was continued with a 1-hour incubation with a cocktail o f mouse 
monoclonal antibodies to DENV 1-4 E protein and JEV E protein and then bound mAb 
detected by lOOpl of a 1:2000 dilution of anti-mouse Ig Horseradish Peroxidase (HRP) 
(P260-DAKO Company). After washing, substrate o-phenylenediamine dihydrochloride 
(OPD) was used to develop colour metric reaction which then being stopped by addition of 
50pl 10% H2 SO4 . The Optical Density (OD) was read at 490nm.The IgM and IgG positive 
control sample was a pool of acute plasma from Vietnamese dengue patients. The negative
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control sample was a mixture of plasma collected from healthy adult Vietnamese blood 
donors with no recent history of dengue. Wells with PBS in place of DENV antigen were 
used to define the background absorbance value. Negative control value (ODNC) was 
defined by mean OD value of 3 negative controls minus mean OD of 3 background wells 
(ODB). The assay cut-off (ODCO) was defined as 5x ODNC. The sample ratio (RS) was 
calculated by taking the sample OD (ODS) minus mean background (ODB) and dividing 
by the assay cut-off i.e.: RS = (ODS -  ODB)/ ODCO]. The interpretation of results was as 
follows:
- If RS <0.8, result was interpreted as negative
- If RS > 1.2, result was interpreted as positive
- If RS from 0.8 -  1.2, result was interpreted as equivocal
2.1.1.3 N Sl antigen-capture ELISA
2.1.1.3.1 Assay procedure
The Platelia Dengue N Sl Ag kit is a one step sandwich -  format microplate
enzyme immunoassay for the qualitative or semi-quantitative detection of DENV-NS1
antigen in human plasma or serum. Tests were carried out according to the manufacturer’s
instructions. Briefly, 50 pi of plasma or control sera [including cut-off (in duplicates), one
negative and one positive control sera were incubated directly and simultaneously with
50 pi of diluent and 100 pi of diluted conjugate at 37° C for 90 min in microplate wells.
The plate was washed six times with lx  washing solution (TRIS-NaCl - p H  7.4, 1%
Tween 20), then immune-complexes were detected by using a color development
reaction [160 pi, Mix of TMB Substrate Solution (citric acid and sodium acetate pH 4.0,
H202 - 0.015%, and DMSO - 4%), and TMB hromogen (0.25% of 3,3’,5,5’
tetramethylbenzidine)]. After 30 mins of incubation in the dark at room temperature, the
enzymatic reaction was stopped by 100 pi o f IN sulfuric acid solution. The OD was read at
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dual 450/620 nm. The presence o f N Sl antigen was based on comparison of the OD of the 
sample with the cut-off of control. All samples were tested in a single well.
2.1.1.3.2 Calculation and interpretation of results
The sample ratio (RS) was expressed by the following formula: RS = ODS/ODCO, where
- ODS: Optical density (OD) obtained on the sample
- ODCO: Cut-off value corresponding to the mean OD values of the duplicate control 
wells, and which must be >0.2.
Result interpretation:
* If sample ratio was <0.5: sample was non-reactive for dengue N Sl antigen, 
and interpreted as negative
* If sample ratio ranged between 0.5 and 1.0: sample was considered 
equivocal for dengue N Sl antigen, and interpreted as equivocal.
* If sample ratio was >1.0: sample was reactive for dengue N Sl antigen, and 
interpreted as positive.
2.1.1.4 DENV serotype identification and vireamia quantification
2.1.1.4.1 RNA extraction and cDNA generation
In initial experiments, a diluted suspension of equine arteritis virus (EAV) was added to 
each plasma sample prior to RNA extraction. The EAV served as an internal control for 
both cDNA generation and real time RT-PCR. We defined the dilution of EAV suspension 
and the volume of this diluted suspension following our standard operating procedure. 
DENV RNA was extracted from patient’s plasma using the QIAamp Viral RNA Mini Kit 
(Catalogue No. 52906, Qiagen, US) [146]. We performed the experiment according to 
manufacturer’s handbook. For each sample, we used 50pl plasma specimen and
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approximately 20pl EAV diluted suspension and then harvested 60pl stock of concentrated 
DENV/EAV RNA. RNA was reverse transcribed to cDNA through two steps with reagents 
described in table 2.2. Mix 1 (lOpl) and RNA (16pl) was incubated at 65°C for 5 minutes 
and then instantly put on ice while adding mix 2 (14pl) in. The cDNA was made at 50°C 
for 60 minutes and finally stored in -20°C.
2.1.1.4.2 DENV serotypes identification by real-time RT-PCR
A real-time quantitation Taq Man RT-PCR assay was performed based on a method 
described by Laue et al [147]. DENV specific primers/probes were also adapted from Laue 
et al and described in Simmons et al [148]. Briefly, 2pl cDNA from each sample was used 
in multiplex real-time RT-PCR that contained both DENV and EAV specific primers and 
probes. Primer sequences for DENV and EAV are described in table 2.3. Reagents 
(volume/reaction) using in this assay was listed in table 2.4. A linearized plasmid 
containing the cloned target amplicon was used to make a standard curve for each assay. 
Results were expressed as cDNA equivalents per milliliter of plasma. The limit of 
detection for DENVl, DENV2, and DENV3 was 10 copies/ reaction. For DENV4, the 
detection limit was 100 copies/ reaction. The detectable signal from the internal control 
amplicon defined the validity of the assay (Ct value range from 30-35). PCR cycling 
conditions were 95°C for 14 min and then 95°C for 30 sec, 60°C for 30 sec, and 72°C for 
30 sec for 45 cycles.
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Table 2.2: Reagents for reverse transcriptase PCR
Mix 1 Reagents Volume
(concentration)/
reaction
Supplier
Random hexamers (lOOpg/ml) 2pl Roche, Lewes, UK
lOmMdNTP 2 pi QIAgene
De-ionized water 6 pi
Mix 2 5X buffer 8 pi Invitrogen
DTT 2 pi Invitrogen
Rnase Inhibitor (40U/pl) 0.8pl Invitrogen Cat No. 
10777019
Superscript III reverse 
transcriptase (200U/ptl)
0.4 pi Invitrogen Cat No. 
18080-094
De-ionized water 2.8pl
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Table 2.4: Reagents for real time PCR
Reagents
(Cat. No., Company)
Concentration Volume (til)
DEN VI DENV2 DENV3 DENV4
FW+ RV DENV Primer 55nM . 3 3 3 3
FW + RV EAV Primer 55nM 3 3 3 3
MgC12 25mM 2.5 3.5 3.8 2.5
Buffer 10X 2.5 2.5 2.5 2.5
dNTP (3622614001, Roche) lOmM 1 1 1 1
DENV Probe lpM 5 2 6 5
EAV Probe 5pM 1.5 1.5 1.5 1.5
Taq (203209, Qiagen) 5U/pl 0.2 0.2 0.2 0.2
H20 (W4502, Sigma) 4.3 6.3 2 4.3
DENV serotype-specific quantitative RT-PCR was performed to determine viral serotype
and viremia in the enrolment plasma samples collected from each patient.
2.1.1.5 Algorithm for laboratory confirmation of dengue
The laboratory confirmation of dengue was based on the results from IgM/IgG captured 
Panbio ELISA. In brief, patients who with negative serology results in paired samples 
collected at least 4 days apart and with the second sample being collected on day 6 of 
illness Onward were regarded dengue negative. A patient was determined to have recent 
dengue (but not acute dengue) if there was no IgM response and IgG unit are between 10- 
20 units with second sample being collected at least on day 6 of illness. A patient is highly 
suggestive to have primary dengue infection if there is only IgM response (>11 units) and 
IgG negative (<18 units) with second sample being collected after day 6 of illness. A 
patient is highly suggestive to secondary dengue infection if he/she is positive with IgG 
(>22) and negative with IgM (<9).
The laboratory confirmation of dengue could also based on algorithm that were developed 
based on results from either: 1/ capture IgM and IgG ELISA using DENV/JEV antigens 
and mAb reagents, which was provided by Venture Technology (Sarawak, Malaysia); 2/ 
internally-controlled and serotype-specific real time reverse transcriptase PCR (RT-PCR) 
assays to express the cDNA equivalents per milliliter of plasma; 3/ NSl Platelia ELISA- 
based assay provided by BioRad (Hercules, CA) to detect DENV N Sl proteins in plasma.
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A summary of the criteria for “laboratory-confirmed acute dengue” acute dengue 
confirmation is shown in figure 2.1. Primary and secondary infection was distinguished by 
the magnitude of IgG ELISA Units in early convalescent plasma samples taking into 
account the day of illness.
O rj
y e s
Plasma samples For serological diagnosis require 2 samples with 2nd 
sample collected 6 or more days after illness onset. Any of the first 4 
parts is sufficient for a “lab confirmed diagnosis.
 I
RT PCR or NS1 positive 
Or I
IgM Seroconversion in MAC ELISA from SI to 
S2 (IgM DENV^JEV IgM)
Or 1
IgM positive in MAC ELISA in SI or S2 and 
GAC. seroconversion
y e s
y e s
y e s
Lab Confirmed 
acute dengue
IgM positive in MAC ELISA in SI and S2, and Units in S2 
>20 and S2 at least 1.2 x SI and IgM DENV>IgM JEV
N o i
IgM positi ve in MAC ELISA in a single specimen OR IgM 
positive in paired specimens but no significant rise in Units 
and IgM DENV>IgM JEV
N o i
IgG seroconversion in GAC ELISA from SI to S2 
N o i
IgG positive in GAG ELISA in SI and S2 
N o i
No laboratory evidence of acute or recent dengue if virologicaly and 
serologically negative in paired samples with 2nd sample collected 6 or more 
days after illness onset and >2 days after 1st sample. If samples are negative 
but do not meet these timing criteria then call “indeterminate”
y e s
y e s
y e s
Recent DENV 
infection
Acute flavivirus infection. In 
Vietnam, propably DENV
Recent flavivirus 
infection
Figure 2.1: Algorithm for laboratory confirmation o f dengue
2.2 Classification of patients
Disease severity was determined based on WHO classification criteria [1]. Dengue infected 
patients were divided into 2 groups: uncomplicated dengue and dengue shock syndrome. 
Uncomplicated dengue was the term used to classify patients with DENV infections that 
were treated in the general ward and that no special treatment is needed.
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CHAPTER 3
3. PATTERNS OF GENE TRANSCRIPT ABUNDANCE IN THE BLOOD OF 
CHILDREN WITH SEVERE OR UNCOMPLICATED DENGUE
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3.1 Introduction
Dengue haemorrhagic fever (DHF) is a severe presentation of DENV infection. DHF is 
characterized by fever, myalgia, thrombocytopaenia and a capillary leak syndrome. At its 
most severe, capillary leak results in hypovolemic shock or dengue shock syndrome 
(DSS); this requires urgent intravenous fluid resuscitation to restore intravascular volume. 
A risk factor for DHF/DSS is secondary infection by a DENV serotype distinct from the 
individual’s previous DENV infection history [93, 149, 150]. The basis for secondary 
infection as a risk factor for severe disease has been ascribed to the infection-enhancing 
potential o f sub-or non-neutralising antibodies from a previous infection [106], cross­
reactive memory T cells that secrete vasodilatory cytokines [75, 131, 151], and host 
genetic pre-disposition [132, 136] . Studies to investigate the pathogenesis of dengue are 
made more challenging by the absence o f a robust animal model of disease.
There remains considerable uncertainty as to how the DENV-host interaction results in 
vascular leak, the most important clinical characteristic o f DHF. Early viral load in vivo 
appears to be important as DHF patients have significantly higher serum viral loads and 
NS1 concentrations, possibly driven by antibody dependent enhancement, than DF cases 
[33, 88]. DHF has also been associated with a robust host inflammatory immune response; 
significantly greater plasma concentrations of inflammatory cytokines [79, 152, 153] and 
activated lymphocytes are found in patients with DHF than in cases with DF [75, 152]. 
Type I interferons (IFN-a/p) are likely to contribute to host defense against DENV 
infection. Mice deficient in IFN-a/p receptors are more susceptible to DENV infection 
[154] and in vitro, IFN-a/p can protect cells against DENV infection [155]. Once infected 
however, DENV non-structural proteins can functionally attenuate the activity o f IFN-a/p- 
mediated antiviral mechanisms, suggesting an evolved viral strategy for escaping early 
innate immune defenses [156, 157]. Finally, the process o f antibody-dependent 
enhancement o f infection may result in attenuation of a/p-interferon-mediated
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upregulation of transcription factors important to innate antiviral effector mechanisms 
[158].
Genome-wide gene expression studies represent an opportunity to identify novel markers 
associated with dengue immunity and disease pathogenesis. Ubol et al [142] demonstrated 
an early difference in the transcriptome between children with DF and DHF, and we 
previously found that transcripts from Type 1 interferon stimulated genes (ISGs) were less 
abundant in adult DSS patients [78].
3.2 Purposes of the study
The present cross-sectional study describes global patterns of gene transcript abundance in 
whole-blood from two groups of pediatric dengue patients who exhibit markedly different 
clinical phenotypes after identical illness durations. The key goal was to identify 
transcripts that distinguish severe dengue from uncomplicated dengue.
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3.3 Materials and Methods
3.3.1 Samples collection
Patients for microarray and quantitative PCR experiments were enrolled at the Hospital for 
Tropical Diseases, Ho Chi Minh City, Viet Nam between July and November 2005. All the 
patients were children (less than 15 years of age). For each patient, blood samples were 
collected at four time points; at admission (study day 1), day 2, day 4 and convalescence (1 
month after discharge from hospital). Whole blood samples used for microarray were 
collected into Paxgene blood RNA tube (Qiagen). The sample collection and storage 
procedures were as instructed by the manufacturer. Samples used for diagnosis and 
laboratory tests were collected into EDTA tubes (BD). Daily haematocrit and platelet 
count data were collected from hospital notes and recorded into standard case record 
forms. WHO classification criteria [21] were applied to each case after review of study 
notes. Written informed consent was obtained from the parent or guardian of each patient. 
The study protocol was approved by the Scientific and Ethical Committee of The Hospital 
for Tropical Disease and the Oxford University Tropical Research Ethical committee.
3.3.2 Expression microarray
In this experiment, RNA was converted into cRNA, labelled and hybridized to the gene 
chip. Figure 3.1 summarises the cRNA synthesis procedure.
3.3.2.1 Extraction of whole blood RNA for gene expression microarray
Whole-blood (2.5ml) was collected directly into PAXgene RNA tubes (Qiagen, Sussex, 
UK). RNA extraction was performed using Paxgene RNA kits (Qiagen, Sussex, UK). RNA 
quantity and quality was assessed by spectrophotometry (Nanodrop).
3.3.2.2 Reverse transcription to synthesize first strand cDNA
RNA samples were brought to 1 lp l (containing approximately 500ng RNA) using RNase- 
free water and then placed into non-stick, sterile, RNase-free, 0.5ml microcentrifuge tubes.
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For a single sample, 9|il of the reverse transcription master mix ( lpl  T7 Oligo(dT) primer, 
2pl 10X first strand buffer, 4pl dNTP mix, lp l RNase inhibitor, lp l ArrayScript) was 
used. After the reaction tube was mixed 2 or 3 times by pipetting up and down and by 
flicking, followed by a brief centrifugation to collect the reaction in the bottom of the tube, 
it was incubated for 2 hours at 42°C. After incubation, the tube was centrifuged briefly (~5 
sec) to collect the reaction mixture at the bottom of the tube.
T 7 Oligo<cJT> P r im e r
T'TT'T -T 7  iS S S
TTTT - T7 2  h r
  ------A « . « A  3 . '
TTTT-T7
3 ’------------
cDNA
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dsD N A  t r a n s c r  ip t ion t e m p l a t e
. AAAA- T7—3.’ 
TTTT - T 7 -5 ‘
enzym es 
sa  Its 
RNAs
e x ce ss  prim ers
3 '--------------------------------------------------------------------------
d sD N A  t r a n s c r i p t io n  t e m p l a t e  
fSgM 4 - 1 4  h r
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TTTT-T7-5'
3 ' -
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Figure 3.1: cRNA synthesis procedure. mRNA in the total genomic RNA was first 
reversed transcribed into first strand of cDNA. The first strand cDNA product served as the 
template for the double- strand cDNA synthesis. After purification, the double-stranded 
cDNA was in vitro transcribed into antisense RNA which was biotin labelled.
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3.3.2.3 Second strand cDNA synthesis
For each sample, 80|il o f the second strand master mix (63pl nuclease free water, lOpl 
10X second strand buffer, 4pl dNTP mix, 2pl DNA polymerase, lp l Rnase H) was 
prepared in a nuclease-free tube followed by transfer to each sample and mixed by 
pipetting up and down 2-3 times and by flicking the tube 3-4 times. The reaction tube was 
then centrifuged briefly to collect the reaction to the bottom of the tube before incubated at 
16°C for 2 hours. After incubation, the reaction was put on ice immediately before cDNA 
purification.
3.5.1.1 cDNA purification
The double stranded cDNA product was purified by mixing 250pl with cDNA binding 
buffer before being passed through a cDNA filter cartridge by centrifugation (1 minute at
10,000 rpm) followed by washing with 500 ml of wash buffer through centrifugation (1 
minute at 10,000 rpm). Next, the cDNA filter cartridge was transferred to a cDNA elution 
tube and eluted by lOpl preheated (at 50 -55°C) nuclease free water by centrifugation for
1.5 minute at 10,000g until the nuclease free water is through the filter. Second elution Was 
performed by using 9pl of nuclease free water and centrifuge for 2 minutes at 10,000g. 
Finally the purified, double stranded cDNA sample (-17.5 pi) was collected.
3.3.2.4 In vitro transcription to synthesize antisense RNA
Antisense RNA was synthesized using in vitro transcription technology. The IVT master
mix (2.5pi T7 10X reaction buffer, 2.5pl T7 enzyme mix, 2.5 biotin-NTP mix)
(www.ambion.com) was prepared at room temperature into a nuclease-free
microcentrifuge tube and mixed by gently vortexing. 7.5pl of IVT master mix was
transferred to each sample then the reaction tube was mixed by pipetting up and down 2-3
times or by flicking. The tube was centrifuged briefly to collect the reaction mixture in the
bottom of the tube. To enable the in vitro transcription process, the reaction tube was
incubated at 37°C for 4 to 14 hours using a hybridization oven to prevent condensation.
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After incubation, 75pl of nuclease free water was added to the cRNA sample to bring the 
final volume to lOOpl.
3.3.2.5 cRNA purification
cRNA product was purified in order to remove enzymes, salts, and unincorporated 
nucleotides from the cRNA. 350gl of cRNA binding buffer was first added to each sample 
then 250pl of 100% ethanol was added before the mixture was mixed by pipetting up and 
down 3 times. The mixture was then transferred to a cRNA filter cartridge 
(www.Ambion.com) followed by a 1 minute centrifugation at 10,000g. After the flow 
through was removed, the cartridge was placed into a cRNA collection tube before being 
washed two times with 650pl wash buffer by centrifugation for 1 minute at 10,000g. After 
the cRNA filter cartridge was placed to a new cRNA collection tube, cRNA was eluted 
from the cRNA filter cartridge by applying lOOpl preheated Nuclease free water (50 -  
60°C) to the centre of the cRNA filter cartridge and centrifugation for 1.5 minutes at 
10,000g until the nuclease free water was through the filter. At the end, approximately 
lOOgl of the cRNA was collected in the cRNA collection tube.
3.3.2.6 A rray hybridization
Hybridize
Sample
Ethanol
Wash1st Wash 2nd Wash
Detect
Signal Bloch3rd Wash
Figure 3.2: Array hybridization, washing, staining and scanning steps
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The procedures of hybridization, washing and staining o f the bead chip were described in 
figure 3.2. For each array, 850ng cRNA sample was prepared in 11.3 pi of RNase free 
water and left at room temperature for 10 minutes to resuspend cRNA. For each bead chip 
of 8 samples, a hybridization mixture was prepared by mixing 125pl of HYB El buffer 
(preheated in 55°C for 10 minutes) with 75pl of formamide. Firstly, 22.7pl of 
hybridization mix (HYBE1 + formamide) was added to 11.3 pi of cRNA sample. Next, the 
mixture (34pl) was preheated at 65°C for 5 minutes before being loaded onto the centre of 
the array. After all 8 samples were loaded, the beach chip was loaded into the Hyb 
cartridge before being placed on the Beadchip Hyb wheel in preheated oven and incubated 
for 16 to 20 hours at 55°C. After the incubation, the chip was washed by using 250 ml of 
Wash E1BC solution on the orbital shaker for 15 minutes, 250ml of absolute ethanol for 10 
minutes, and the second 250 ml of Wash E1BC buffer for 2 minutes. After being washed, 
the beadchip was blocked with 4 ml of block E l buffer in 10 minutes, stained with 2 ml of 
Block E l buffer and streptavidin-Cy3 (2pl of 1 mg/ml stock per chip) in 10 minutes, 
washed again by 250 ml of wash E1BC buffer for 5 minutes, and dried for four minutes by 
centrifugation at 275 ref at room temperature. Finally the beadchip was scanned on the 
Illumina BeadArray Reader. The gene expression data was extracted from images collected 
from Iliumina BeadArray Reader.
3.3.3 Quantitative RT-PCR
RNA samples used in this experiment were extracted from whole blood using Paxgene 
blood RNA kit. The RNA concentration was first normalized to the same concentration of 
250ng/pl using RNase free water. Next, RNA was reversed transcribed into cDNA by 
mixing 50pl of 2X of reverse transcription master mix (lOpl reverse transcription buffer, 
4pl 25X dNTPs, lOpl 10X random primer, 5pl MultiScribe Reverse transcriptase (50U/pl 
), and 50pl nuclease free water) with 50pl of 250ng/pl RNA. The reaction tube was then 
loaded to the thermal cycler. The cDNA cycling conditions were 25°C for 10 minutes and
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37°C for 120 minutes. The cDNA sample was mixed with Taqman universal PCR master 
mix and loaded into micro fluidic cards (Applied Biosystems). The micro fluidic card was 
then run in the ABI Prism 7900HT Sequence Detection System. The data was obtained and 
analyzed using SDS enterprise software.
3.3.4 Microarray data analysis and statistics
3.3.4.1 Data extraction and quality control
The raw expression intensity data was extracted from the arrays using Beadstudio software 
(Illumina Inc.). This software was used for data quality control (QC) and for obtaining raw 
intensity data of transcripts included in the array. The raw intensity data exported from 
Beadstudio includes probe intensity data or gene intensity data. Both of the data formats 
can be used for analysis. The raw data was normalized to the background by subtracting 
the background signal.
3.3.4.2 Data normalisation and analysis
After removing the noise by subtracting the background, the data was then normalized 
using standard normalization procedures (Genespring GX7.3 software, Silicon Genetics, 
CA) for one colour array data. In brief, data transformation was corrected for low signal, 
with values recorded at less than 0.01 increased to the minimum (0.01). Per-chip (mean) 
normalization accounted for chip variability by dividing all of the measurements on each 
chip by a 50 percentile value. Per-gene normalization accounted for variability between 
probe sets for different genes. Finally, the data was filtered by which only genes that have 
the detection confidence of greater then 0.999 (or P value < 0.001) in at least one sample 
will be used for further analysis. ANOVA t-test (unequal variances, non-multiple 
corrections, false discovery rate less than 5%) built in Genespring software was used for all 
comparisons. The t-test criteria were: (1) 5% of false discovery rate; (2) Fold change 
greater or equal to 1.5.
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3.3.4.3 Ingenuity Pathway Analysis
Ingenuity Pathway analysis (IPA) (www.ingenuitv.com) is an approach that helps to 
determine canonical biological pathways that interested genes are associated. Canonical 
pathways are well-characterized metabolic and cell signaling pathways. The information 
contained in canonical pathways comes from specific journal articles, review articles, text 
books, and KEGG Ligand. These sources were put together and formed the knowledge 
base. The ratio of canonical pathway was calculated by dividing the number of molecules 
in a given pathway in the input gene list to the total number of molecules that make up that 
pathway. To determine whether a canonical pathway formed by the genes in the upload 
gene list are by chance or biological associated, P value for each pathway was determine 
based on Right-tailed Fisher’s Exact Test. The significance of the test depends on the* 
number of canonical pathway eligible genes in investigating gene list, and the total number 
o f genes that are known to be associated with that canonical pathway in the knowledge' 
base. In our analysis, we use cut-off o f P value at 0.05.
3.3.4.4 PCR Data analysis
The cycle threshold (Ct) value of each transcript obtained in real-time PCR assay was 
analyzed manually through checking the amplification curves to remove the spurious 
signal. Transcripts with too low amplification signals (Ct > 36) were also removed. The 
expression data was then analyzed using SDS software and RQ manager software (Applied 
Biosystemsj. Relative quantification value (RQ value) was calculated as described below: 
Transcript abundance data (threshold (Ct) value) for each gene was manually checked to 
remove the false positive values using SDS2.2 software and RQ Manager (Applied 
Biosystems). Relative transcript abundance was determined using the delta-delta Ct 
method (Livak et al 2001). In brief, this method uses a single sample, termed the calibrator 
sample, as a comparator for every unknown sample's gene expression level. The calibrator 
can be any sample chosen to have all of the genes expressed (Ct value o f less than 36
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cycles). The calibrator is analyzed on every assay plate with the unknown samples of 
interest. The relative fold difference is calculated using the formula: Fold induction = 2‘ 
[AACtl, where AACt = [Ct of gene of interest in unknown sample -  Ct of 18S gene in 
unknown sample] -  [Ct gene o f interest in calibrator -  Ct of 18S gene in calibrator]. The 
fold-difference in transcript abundance in samples derived from patients with different 
clinical phenotypes was compared using the Mann-Whitney test using Multi-experiment 
Viewer software (http://www.tm4.org’).
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3.4 Results
3.4.1 Gene expression microarray
3.4.1.1 Sample collection
From July to November 2005, we prospectively enrolled 111 children with acute dengue 
into a study of transcriptional responses in whole-blood at The Hospital for Tropical 
Diseases (HTD), HCMC, Viet Nam. Using WHO classification criteria, 27 patients had 
DSS (pulse pressure <20 mmHg with poor peripheral perfusion and rapid, weak pulse), 
and were admitted to the intensive care unit and received appropriate resuscitation. The 
remaining 84 patients had dengue without evidence of cardiovascular compromise, 
including patient groups with Dengue Fever, DHF grades I and II. We have used the term 
uncomplicated dengue to refer to these hospitalized patients as they did not require any 
significant clinical interventions and were managed throughout on the general dengue 
ward. From the 27 patients with DSS, we selected RNA samples from 9 patients who 
presented to hospital with DSS on the 4 day of illness (with the day of onset of symptoms 
taken as day 1) for microarray analysis. For each DSS patient, an age- and (where possible) 
sex-matched control patient with uncomplicated dengue, and with an identical duration of 
illness, was selected. Table 3.1 summarises the baseline characteristics of patients used for 
microarray study.
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Table 3.1: Baseline characteristics o f patients included in microarray study
Variable Uncomplicated dengue 
(N = 9)
DSS 
(N = 9)
P-valuea
N (%) or Median 
(range)
N (%) or Median 
(range)
Male sex 5 (55.6%) 4(44.4%)
Age(years) 9-14 10-14
Day of illness 4 4
Febrile 9 (100%) 0 (0%)
Fever dayc -2.5 (-4 to -1) 0
Infecting serotype
DENV-1
DENV-2
DENV-3
DENV-4
4 ■
5 
0 
0
1
7
0
1
Clinical severity 
DF
DHF II 
DHF III 
DHF IV
7
2
8
1
Mean viraemia 
cDNA copies/ml
48317364 
(19775- 163000000)
819735
(24-4234125)
0.006
Secondary infection 9 (100%) 9(100%)
Platelet nadir 44,000
(34,000-110,000)
24,000
(11,000-86,000)
% haemoconcentration 15.11 (-9-22) 28 (13-53) 0.001
CD3+ T cells b . 649 (262 - 1097) 845 (5 9 9 - 1387)
CD3+/CD4+ T cells 331 (161 -649) 371 (155 - 561)
CD3+/CD8+ T cells 207(67-309) 417 (293 - 752) 0.01
CD19+ B cells 196(75 -352) 229 (109 - 502)
CD16+/CD56+ NK cells 124 (37 - 424) 148 (51 -236)
Notes:
a Mann-Whitney test
b The absolute count (cells/pl) o f lymphocyte subsets in each sample was determined by 
flow cytometry
c the day o f defervescence was regarded as fever day 0
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The aim o f this study was to describe early whole-blood transcriptional responses in two 
groups o f paediatric patients (n=9 per group) comparing, a) children with uncomplicated 
dengue, and b) children presenting with DSS. All patients recovered fully. The clinical and 
haematological characteristics, including absolute counts of the major lymphocyte subsets, 
o f the 18 dengue patients are described in table 3.1. Patients with DSS had lower platelet 
nadirs and, on the basis of changes in haemoconcentration, significantly greater vascular 
leakage than uncomplicated dengue patients (table 3.1). On the 4th day of illness, when 
blood samples for microarray analysis were collected, patients presenting with DSS had 
significantly higher absolute counts of CD3+CD8+ T cells (table 3.1), but significantly 
lower plasma viraemia levels, than patients with uncomplicated dengue (table 3.1).
3.4.1.2 RNA for microarray experiments
The total RNA amount required in gene expression microarray was 500ng in total 1 lul of 
water. RNA were isolated from the whole blood of the patients and measured by 
Nanodrop. The quality and quantity of RNA samples used for microarray assay is 
summarized in table 3.2.
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Table 3.2: Quantity and quality of RNA in samples used for microarray experiment
Sample code Patient group Time point RNA (ng/pL) OD (260/280)
DF1093 DSS Day 4 54.51 1.91
DF1097 DSS Day 4 72.94 2.04
DF1105 DSS Day 4 149.20 1.96
DF1106 DSS Day 4 32.89 2.01
DF1107 DSS Day 4 102.91 2.13
DF1108 DSS Day 4 177.49 1.65
DF1110 DSS Day 4 114.58 2.09 .
DF1114 DSS Day 4 113.36 2.08
DF1115 DSS Day 4 69.46 2.15
DF1093 DSS Convalescence 40.78 2.01
DF1097 DSS Convalescence 84.93 2.11
DF1105 DSS Convalescence 94.21 2.12
DF1106 DSS Convalescence 78.75 2.17
DF1107 DSS Convalescence 66.86 2.17
DF1114 DSS Convalescence 219.2 2.11
MD1589 UC dengue Day 4 117.74 2.11
MD1590 UC dengue Day 4 66.82 1.95
MD1591 UC dengue Day 4 71.43 1.87
MD1594 UC dengue Day 4 66.56 2.10
MD1605 UC dengue Day 4 49.21 2.14
MD1613 UC dengue Day 4 71.10 2.15
MD1639 UC dengue Day 4 85.07 1.92
MD1640 UC dengue Day 4 114.75 1.98
MD1641 UC dengue Day 4 68.46 2.05
MD1589 UC dengue Convalescence 78.26 2.16
MD1591 UC dengue Convalescence 59.37 2.08
MD1640 UC dengue Convalescence 85.11 2.09
MD1639 UC dengue Convalescence 109.84 2.17
MD1605 UC dengue Convalescence 127.84 2.12
MD1613 UC dengue Convalescence 99.32 2.1
3.4.1.3 Differentially expressed genes
Gene expression microarray was performed for -24,000 genes in each patient using 
Illumina technology. Analysis was focused on identifying transcripts that were 
differentially abundant between acute and convalescent samples and was restricted to those 
transcripts that were detected in at least one specimen. For the resulting 13,535 gene 
transcripts, we applied the following criteria in all comparisons:
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a) Gene transcripts were detected in at least 50% of samples. Detection confidence 
was calculated based on the proportion o f probes that were successfully detected relative to 
the total number of probes for each transcript.
b) Mean fold-change between two conditions was greater than 1.5 fold. The fold 
difference was calculated based on the difference in mean of average normalised intensity 
signal in each group for each transcript.
c) False discovery rate was less than 5%.
By these criteria, microarray data analysis revealed 3,092 gene transcripts that were 
differentially abundant (523 less abundant, 2569 enriched) in acute (day 4) samples from 
DSS patients compared to six matched convalescent samples, and 2,471 gene transcripts 
that were differentially abundant (267 less abundant, 2204 enriched) in acute (day 4) 
samples from uncomplicated dengue patients compared to six matched convalescent 
samples. There were 1197 genes common to the two gene lists.
3.4.1.4 Uncomplicated dengue: acute versus convalescent samples
Unsupervised pathway analysis of transcripts either significantly enriched (n=2204) or 
under-represented (n=267) in acute samples (relative to six matched convalescent samples) 
was used to identify biological themes in the transcriptome of patients with uncomplicated 
dengue. Amongst transcripts significantly enriched in acute samples, genes in pathways 
associated with oxidative metabolism and mitochondrial dysfunction were over­
represented, suggesting a highly active metabolic state consistent with a host response to 
infection (figure 3.3). Of immune response pathways, the interferon pathway was most 
prominent, followed by IL-10, antigen presentation, and IL-6 signaling pathways. In 
contrast, amongst transcripts that were significantly under-abundant in acute samples, there 
were no significant molecular themes arising from pathway analysis, most likely because
of the small number (n=267) of elements for analysis. Thus, the biological processes
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highlighted in the enriched population o f transcripts are consistent with a metabolically 
demanding host response in which interferon-driven immune processes and cytokine 
networks are prominent.
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Figure 3.3: Pathway analysis of transcripts enriched in acute samples from uncomplicated 
dengue patients. Shown are the top twenty canonical pathways identified by unsupervised 
pathway analysis o f filtered microarray data (Ingenuity Systems©) representing transcripts 
enriched (n=2204) in acute samples (4th day of illness) from uncomplicated dengue 
patients relative to matched convalescent samples (day 30). The strength of the statistical 
association is indicated by the length of the bars. The ratio value reflects the proportion of 
gene elements in the enriched gene list that belong to one of these canonical pathways.
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3.4.1.5 DSS: acute versus convalescent samples
Surprisingly, unsupervised pathway analysis of transcripts significantly enriched (n=2569) 
in acute samples from children with DSS did not identify any prominent pathway or 
biological process. Unsupervised analysis of under-represented transcripts in acute samples 
(n=523) implicated the death receptor, apoptotic and IL-10 signaling pathways as being 
features of this “down-regulated” transcriptome (figure 3.4). However, the strength of the 
association between these pathways and samples was not as robust as was observed 
between acute and convalescent samples in children with uncomplicated dengue (figure 
3.3). Remarkably then, at a time when capillary leakage had precipitated hypovolemic 
shock in these afebrile DSS patients, the whole-blood transcriptome appeared benign.
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Figure 3.4: Pathway analysis of transcripts under-abundant in acute samples from DSS 
patients. Shown are the top twenty canonical pathways identified by unsupervised pathway 
analysis of filtered microarray data (Ingenuity Systems©) representing transcripts under-
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abundant (n=523) in acute samples (4th day of illness) from DSS patients relative to 
matched convalescent samples (day 30). The strength of the statistical association is 
indicated by the length of the bars. The ratio value reflects the proportion of gene elements 
in the enriched gene list that belong to one of these canonical pathways.
The absence of a strong transcriptional signature in the blood of children with DSS is in 
stark contrast to the prominent molecular themes identified in acute samples in febrile 
children with uncomplicated dengue (figure 3.3). These differences between acute and 
convalescent samples were not because of intrinsic differences between convalescent 
samples in the two patient groups; unsupervised comparison of these convalescent samples 
identified just 138 differentially abundant transcripts amongst 13535 transcripts analyzed. 
Collectively, these data suggest fundamental differences in the evolution o f the 
transcriptional response between these two groups of children with identical durations of 
illness, but with different clinical phenotypes.
3.4.1.6 Uncomplicated dengue versus DSS
The transcriptional profiles of acute (day 4) samples from patients with uncomplicated 
dengue and those with DSS (day 4) were compared directly to identify differentially 
expressed gene transcripts. The rationale for this comparison was to compare the host 
response in these two groups of patients with identical illness histories, but distinct clinical 
phenotypes and disease evolution. In unsupervised analysis, 1,749 transcripts were 
differentially abundant between acute uncomplicated dengue and DSS patients; transcripts 
from 1,030 genes were enriched and 719 less-abundant in uncomplicated dengue patients.
Unsupervised pathway analysis of transcripts significantly enriched in uncomplicated 
dengue patients implicated the death receptor, interferon, apoptosis, IL-6, NF-kB and IL- 
10 signaling pathways as immune-function related processes distinguishing uncomplicated 
dengue from DSS (figure 3.5). Unsupervised pathway analysis of transcripts less abundant 
in uncomplicated dengue patients identified a diverse set of pathways (figure 3.6), with the 
majority associated with cellular metabolic activities and not immune function.
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Collectively, and in the context of the samples available, these data identify apoptotic and 
immune-function related molecular pathways as defining the transcriptional difference 
between these two groups o f children with identical durations o f illness, but with different 
clinical outcomes.
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Figure 3.5: Pathway analysis o f transcripts enriched in acute (day 4) samples from patients 
with uncomplicated dengue relative to acute (day 4) samples from DSS patients. Shown 
are the top twenty canonical pathways identified by unsupervised pathway analysis of 
filtered microarray data (Ingenuity Systems©) representing transcripts significantly 
enriched (n = 1030) in acute samples from uncomplicated dengue patients relative to acute 
(day 4) samples from DSS patients. The strength of the statistical association is indicated
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by the length of the bars. The ratio value reflects the proportion of gene elements in the 
enriched gene list that belong to one o f these canonical pathways.
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Figure 3.6: Pathway analysis of transcripts under-abundant in acute (day 4) samples from 
patients with uncomplicated dengue relative to acute (day 4) samples from DSS patients. 
Shown are the top twenty canonical pathways identified by unsupervised pathway analysis 
o f filtered microarray data (Ingenuity Systems©) representing transcripts significantly 
under-abundant (n=719) in acute samples from uncomplicated dengue patients relative to 
acute (day 4) samples from DSS patients. The strength of the statistical association is 
indicated by the length of the bars. The ratio value reflects the proportion of gene elements 
in the enriched gene list that belong to one of these canonical pathways.
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3.4.2 RT-PCR validation of gene transcript abundance
TaqMan RT-PCR assays were used to validate the relative abundance of transcripts 
identified as differentially expressed between, 1) acute versus convalescent samples from 
children with DSS and with uncomplicated dengue and 2), acute samples from children 
with DSS versus uncomplicated dengue. The selection of gene transcripts to validate was 
influenced by two guiding themes- a) they were biologically replicated in the array (i.e. 
relative consistent between patient samples) and b) immune-function related genes should 
be prominent as these pathways distinguished uncomplicated dengue from DSS and in 
general, a focus on the immune transcriptome would serve the wider purpose of informing 
models of immunopathogenesis. Validation of gene transcript abundance was performed 
with acute (day 4) RNA samples from eight DSS patients (6 of who were included in the. 
microarray) and eight matched uncomplicated dengue patients (six were included in 
microarray).
3.4.2.1 Acute versus convalescent samples in uncomplicated dengue
Sixty-nine transcripts were selected for validation by RT-PCR assays from amongst all 
transcripts significantly enriched in acute samples from uncomplicated dengue patients 
relative to convalescent samples. Emphasis was placed on validating canonical ISGs 
(Interferon stimulated genes) as these were highly enriched in the microarray (figure 3.3). 
O f the 69 transcripts selected, 64/69(93%) were also differentially abundant when 
measured by RT-PCR. The heat map in figure 3.7 shows differences in the pattern o f gene 
expressions of samples in DSS and uncomplicated dengue patient. Figure 3.8A and 3.8B 
show the similarity in fold change between expression microarray and from quantitative 
PCR. Table 3.3 shows the list o f the genes validated by taqman PCR
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Acute uncomplicated dengue Convalescent uncomplicated dengue
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Figure 3.7: Shown is a heat map o f individual patients samples filtered on those transcripts 
enriched in acute samples from patients with uncomplicated dengue relative to matched 
convalescent samples (n=69) and which were selected for RT-PCR validation. The gene 
names of canonical ISGs are underlined next to the heat map.
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Table 3.3: RT-PCR validation results of transcripts enriched in acute (day 4) UC dengue 
patients relative to matched control samples (day 30)
Genbank Symbol Function
Microarray Taqman PCR
FC P value FC P value
NM_002982 CCL2 chemokine (C-C motif) ligand 2 771.0 923&-05 423 1.I9E-03
NM 005623 G O 8 chemokine (C-C motif) ligand 8 580.4 1.22E-03 104.5 1.19E-03
NM_001565 cxaio chemokine (C-X-C motif) ligand 10 91.3 2.30E-03 44.1 1.19E-03
NM_ 172369 C1QG complement component 1 51.9 L52&03 38.2 1.19E-03
N M J17414 USP18 ubiquitin specific peptidase 18 21.1 5.01E-03 20.3 I.19E-03
NM 004972 JAK2 Janus kinase 2 (a protein tyrosine kinase) 19.8 2.73E-02 4.0 2.62E-03
NM_000491 C1QB complement component 1 18.0 9.81E-05 22.8 1.19E-03
NM 000063 a coirplement component 2 15.6 8.44E-03 19.3 1.19E-03
NM 014398 LAMP3 lysosomal-associated membrane protein 3 12.1 2.20E-04 10.8 1.I9E-03
NM_003965 CCRL2 chemokine (C-C motif) receptor-like 2 9.7 2.56E-06 10.3 1.19E03
NM 002053 GBP1 guanylate binding protein 1, interferon-inducible, 67kDa 9.3 1.66E-03 5.4 I.19E-03
NM 000062 SERP1NG1 serpin peptidase inhibitor, clade G 8.2 2.67E-04 10.1 1.19E-03
NM 001735 C5 conplem ent component 5 8 .2 , 3.11E02 4.5 1.19E-03
NM_002164 1NDO indoleamine-pvrrole 2,3 diow genase 8.0 3.15E-04 9.1 1.19E-03
NM_003745 SOCS1 suppressor o f  cytokine signaling 1 7.5 6.01E-06 8.8 1.19E-03
NM 080657 cig5 radical S-adenosyl methionine domain containing 2 7.3 6.37E-04 13.8 1.19E-03
NM 022147 1FRG28 28kD interferon responsive protein 7.0 3.01E-06 6.9 1.19E-03
NM_004030 1RF7 interferon regulatory factor 7 6.2 3.65E-06 7.6 1.19E03
m\m\i OAS2 2'-5'-oligoadenylate synthetase 2,69/7 lkDa 5.9 5.28E-04 13.9 I.19E-03
NM_001547 IFIT2 interferon-induced protein with tetratricopeptide repeats 2 5.7 4.00E-03 8.4 1.19E-03
NM_198213 OASL 2'-5'-oligoadenylate svnthetase-like 5.7 4.64E-05 8.2 1.19E-03
NM_ 173842 IL1RN interleukin 1 receptor antagonist 5.3 4.15E-04 6.8 I.19E-03
NM_006417 IF144 interferon-induced protein 44 5.3 5.6 IE-03 5.8 1.19E-03
NM 022168 MDA5 interferon induced with helicase C domain 1 5.2 1.57E03 5.4 1.19E-03
NM 015991 C1QA complement component 1, q subcomponent, alpha polypeptide 5.1 2.63E-05 11.3 1.19E-03
NM 001549 IFIT3 interferon-induced protein with tetratricopeptide repeats 3 4.9 5.30E-04 103 1.19E-03
NM 003810 TNFSF10 tumor necrosis factor (ligand) supcrfamily, member 10 4.8 236E-04 . 5.5 1.19E-03
NM 006187 0AS3 2'-5’-oligoadenyIate synthetase 3 4.7 1.47E-03 6.8 1.19E-03
N M J05533 1FI35 interferon-induced protein 35 4.4 3.44E-05 4.9 1.19B-03
NM 001548 \m\ interferon-induced protein with tetratricopeptide repeats 1 4.4 3.13E-03 7.0 1.19E-03
N M 016816 OASl 2',5'-oligoadenylate synthetase 1,40/46kDa 4.3 .  1.04E-03 6.8 1.18E-03
NM _016562 TLR7 toll-like receptor 7 4.3 4.32E-04 4.8 I.19E-03
NM_052941 GBP4 guanylate binding protein 4 4.2 1.60&03 4.8 1.19E-03
NM _012420 IFIT5 interferon-induced protein with tetratricopeptide repeats 5 4.2 9.48E-03 4.1 1.19E-03
NM_030641 APOL6 apolipoprotein L, 6 4.1 5.13E-03 1 9 1.19E-03
N M J04049 JC L 2 A 1 BCL2-related protein A 1 4.1 4.95E-04 3.5 4.9 IE-02
NM_000593 TAPI transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 3.9 420E-04 2.9 1.19E-03
NM_007315 STAT1 signal transducer and activator o f  transcription 1,91kDa 3.7 4.39E-03 2.6 1.19E-03
NM_004054 C3AR1 complement component 3a receptor 1 3.6 6.33E-06 4.3 1.19E-03
NM_004001 FCGR2B Fc fragment o f  IgG, low affinity lib, receptor (CD32) 3.6 1.04E-03 1.9 2.79E-02
NM_002038 IF16 interferon, alpha-inducible protein (clone IF1-6-16) 3.3 1.13E-03 6.6 1.19E03
NM_002462 MX1 interferon-inducible protein p78 (mouse) 3.2 3.77E-03 5.9 1.19E-03
NM_004223 UBE2L6 ubiquitin-conjugating enzyme E2L6 3.1 2.41 Er03 3.9 1.19E-03
N M J00647 CCR2 chemokine (C-C motif) receptor 2 3.0 7.95E-03 3.1 1.19E-03
NM_002201 1SG20 interferon stimulated exonuclease gene 20kDa 2.9 3.01E-04 3.7 I.19E03
NM_003641 IFlTM i interferon induced transmembrane protein 1 2.9 1.97E-06 4.2 I.I9E-03
NM_005419 STAT2 signal transducer and activator o f  transcription 2, U3kDa 2.8 9.92E-04 3.0 1.19E-03
NM 005531 IFI16 interferon, gamma-inducible protein 16 2.4 9.01E-03 3.0 1.19E-03
NM_006332 1F130 interferon, ganma-inducible protein 30 2.4 3.23E-04 3.6 1.19E-03
NM_002463 MX2 myxDvirus (influenza virus) resistance 2 (mouse) 2.4 2.I8E-03 3.4 1.19E-03
NM_005384 NF1L3 nuclear factor, interleukin 3 regulated 2.4 9.31E-03 2.6 1.78E-03
NM 003877 SOCS2 suppressor o f  cytokine signaling 2 2.3 4.72E-02 2.3 2.79E-02
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3.4.2.2 Acute versus convalescent samples in DSS
Nineteen transcripts were selected for validation by RT-PCR assays from amongst 
transcripts differentially abundant in acute samples from DSS patients relative to 
convalescent samples; of these, 11 transcripts were validated by RT-PCR, with transcripts 
from the complement pathway most prominent. The heat map of the 11 transcripts in DSS 
patients and UC patients is shown in figure 3.9. Figure 3.10 shows the fold change 
determined in expression microarray and in taqman PCR. Table 3.4 shows the genes that 
were validated by taqman PCR.
A cu te D SS C onvalescen t
KLRGl
IL13RA1
PSHB8
F13A1
IRF3
IL12RB1 >
C2
BCL2L1
C1QA
C1QB
IL1RAP J
IF IT 2
FCGR3A
TLR8
JAK1
S0CS3
MCP
IllDO
C1QG
Figure 3.9: Heatmap represents 19 transcripts differentially expressed in acute DSS 
patients relative to matched convalescent patients
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Figure 3.10: Reverse-transcription polymerase chain reaction (RT-PCR) validation of 
transcripts enriched or less abundant in acute samples from patients with dengue shock 
syndrome (DSS) relative to that in convalescent samples.
Table 3.4: RT-PCR validation of differential expressed genes in acute DSS patients (day 4) 
relative to their auologous controls (day 30)
Symbol
Microarray Taqman PCR
Function
Fold change P value Fold change P value
C1QB complement component 1, q subcomponent, beta polypeptide 9 0 1.48E-04 15.4 7.78E-04
C1QA complement component 1, q subcomponent, alpha polypeptide 4.8 1.85E-05 63 7.78F.-04
C2 complement component 2 4.0 6.48E-03 4.4 3.28E-03
IRF3 interferon regulatory factor 3 1.6 2.40E-03 15 6.32E-03
PSMB8 proteasome subunit, beta type, 8 15 8.57E-03 16 1.57E-02
IL12RB1 interleukin 12 receptor, beta 1 1.5 1 99E-02 1.6 3.28E-03
BCL2L1 BCL2-like 1 0.5 2.75E-02 0 3 2.32E-03
IL13RA1 interleukin 13 receptor, alpha 1 0 4 2.31E-04 0 6 2.74E-02
F13A1 coagulation factor XIII, A1 polypeptide 0.3 5 55E-03 0.3 8.65E-03
K.LRG1 killer ceil lectin-like receptor subfamily G, member 1 0 3 4.24E-02 0 6 3.57E-02
1L1RAP interleukin 1 receptor accessory protein 0.2 7.97E-05 0.4 7.78E-04
3.4.2.3 Acute uncomplicated dengue versus acute DSS
Fifty-nine transcripts were selected for validation by RT-PCR assays from amongst 
transcripts significantly enriched in acute samples from uncomplicated dengue patients 
relative to DSS patient); this included 47 transcripts also investigated in the comparison of 
acute versus convalescent samples in uncomplicated dengue patients. O f these 59 
transcripts, 30/59 (51%) were also differentially abundant when measured by RT-PCR. 
The expression patents of these 59 genes in each DSS sample and UC dengue sample are 
shown in figure 3.11. Figure 3.12 and table 3.5 show the fold changes of the 30 genes 
determined in expression microarray and in taqman PCR. Collectively, these data generally
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validate one of the central findings in the microarray analysis; the general lack of a host- 
defense profile in patients with DSS.
Acute DSS Acute uncomplicated 
dengue
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Figure 3.11: Heat map o f individual patients samples filtered on those transcripts (n=59) 
enriched in acute samples from patients with uncomplicated dengue relative to DSS 
patients and which were selected for RT-PCR validation. The gene names of canonical 
ISGs are underlined next to the heat map.
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Table 3.5: RT-PCR validation of transcripts differentially expressed in acute UC dengue 
patients (day 4) relative to acute DSS patients (day 4).
Symbol Function
M icroarray Taqman PCR
Fold change P value Fold change P value
e c u chemokine (C-C motif) ligand 8 170.6 6.10E-04 19.6 2.32E-03
CCL2 chemokine (C-C motif) ligand 2 87.0 8.99E-04 12.4 2.32E-03
INDO indoleamine-pyrrole 2,3 dioxygenase 17.4 2.67E-04 8.4 2.32E-03
CXCL10 chemokine (C-X-C motif) ligand 10 16.3 1.75E-04 7 0 1.63E-03
GBP1 guanylate binding protein 1, interferon-inducible, 67kDa 10.7 1.55E-03 2 1 1.13E-03
LAMP3 lysosomal-associated membrane protein 3 7.6 2.34E-04 4.1 1.63E-03
IF1T2 interferon-induced protein with tetratricopeptide repeats 2 6.6 3.39E-05 3.7 1.63E-03
SOCS1 suppressor of cytokine signaling 1 4.3 1.40E-04 2.4.. 7.78E-04
1L1RN interleukin 1 receptor antagonist 4.2 1.80E-03 2.9 3.28E-03
MDA5 interferon induced with helicase C domain 1 ... 4.2 .. 2.24E-05 . 2.3 1.13E-03
C5 complement component 5 , 41 2.09E-04 1.8 1.17E-02
GBP4 guanylate binding protein 4 4.0 9.06E-07 2.5 7.78E-04
IFIT1 interferon-induced protein with tetratricopeptide repeats 1 3.8 1.73E-04 2.6 2.32E-03
USP18 ubiquitin specific peptidase 18 3.7 3.39E-05 2.0 2.32E-03
CCRL2 chemokine (C-C motif) receptor-like 2 3 2 ' L71E-04 2.8 1.57E-02
IFRG28 28kD interferon responsive protein 3T ’ 2.38E-05 1.9 2.32E-03
IFIT5 interferon-induced protein with tetratricopeptide repeats 5 3.0 4.07E-03 L9 3.28E-03
cig5 radical S-adenosyl methionine domain containing 2 2.9 3.09E-03 4 5 7.78E-04
1FI44 interferon-induced protein 44 2.9 1.62E-03 1.6 1.17E-02
OAS3 ■ 2'-5'-ol igoadenylate synthetase 3 2.8 3.08E-04 2.1 3.28E-03
TNFSF10 tumor necrosis factor (ligand) superfamily, member 10 2.8 1.93E-04 3.0 1.13E-03
ST ATI signal transducer and activator of transcription 1 ,91kDa 2.7 1.94E-04 1.7 1.63E-03
OASL 2'-5'-oligoadenylate synthetase-like 2.4 6.79E-03 2 4 7.78E-04
OAS2 2'-5'-oligoadenylate synthetase 2 ,69/71kDa 2.2 4.87E-04 2.2 2.32E-03
SERPING! serpin peptidase inhibitor, clade G 2.0 4.27E-02 1.9 2.09E-02
STAT2 signal transducer and activator o f transcription 2 ,1 13kDa 2.0 1.33E-04 1.8 7.78E-04
IRF7 interferon regulator)' factor 7 2.0 3.39E-03 1.9 1.13E-03
MX2 myxovirus (influenza virus) resistance 2 (mouse) 1.8 2.82E-02 1.8 8.65E-03
MX1 interferon-inducible protein p78 (mouse) 1.6 3.13E-02 1.5 4.57E-03
T1RAP toll-interleukin 1 receptor (TIR) domain containing adaptor protein ’ 1.5.. . 1.07E-02 0.6 8.65E-03
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3.5 Discussion
This study attempted to better understand DSS by defining the whole-blood transcriptome 
at the time o f hypovolemic shock and comparing it to matched convalescence samples and 
to well-matched children with acute uncomplicated dengue. A key and unexpected finding 
was the relatively benign transcriptional profile o f children with DSS relative to their own 
convalescent samples and more starkly, relative to children with acute uncomplicated 
dengue but with an identical duration o f illness. In particular, transcripts belonging to 
pathways associated with apoptosis, cytokine signaling (IL-6, IL-10), NFk-B, and 
interferon were less abundant in patients with DSS at the time of cardiovascular 
compromise, despite the presence of a measurable viraemia. These data highlight 
significant heterogeneity in the type or timing o f host immune responses precipitated by 
DENV infection independent of the duration of illness. Indeed, this study suggests that if a 
whole-blood transcriptional signature contributes to capillary leakage and DSS, then it 
occurs before hypovolemic shock manifests.
Capillary leakage leading to DSS is the commonest serious complication of dengue in 
children living in endemic settings. DSS typically occurs around the time of defervescence 
and at a time when the dengue viral burden is in steep decline. Host immune responses, 
driven at least in part by overall viral antigenic mass, have been repeatedly nominated as 
important in promoting clinically significant capillary leakage (reviewed in [74]). The 
rationale for the current study was to better understand the host response at the time of 
vascular decompensation in paediatric dengue patients. The DSS patients in this study 
were afebrile iat the time of hypovolemic shock (day 4) and on average had significantly 
lower viraemias than the comparison group of children with uncomplicated dengue, who in 
contrast, were all still febrile. In essence then, although matched by duration of illness, 
overall serological response, age and sex, these two groups of children had contrasting 
disease evolutions when samples for microarray analysis were collected.
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Consistent with the concept that the patients in this study had different disease evolutions, 
we observed starkly different whole-blood transcriptional profiles between afebrile 
children with DSS and febrile children with uncomplicated dengue, with the relative 
abundance of transcripts from the type I interferon pathway being one of the distinguishing 
features. For example, transcripts for several canonical ISGs were significantly more 
abundant in samples from children with uncomplicated dengue than in either samples from 
patients with acute DSS or matched convalescent samples. Several of the ISGs (OASl, 
OAS2, OAS3, IRF7, SOCS1, STAT1) identified in this study were also abundant in the 
transcriptome of febrile adult Singaporean patients with uncomplicated dengue [144] and 
in experimentally DENV infected macaque monkeys [159]. Collectively, these data and 
the observation that acute dengue is associated with elevated IFN-a levels [160], supports 
the concept that ISG induction in whole-blood is a feature of the febrile phase of dengue. 
These data are consistent with both in vitro [155-157] and in vivo (murine) [154] studies 
that suggest the IFN-a/p immune pathway makes an important contribution to host defense 
against DENV infection.
This study informs models of dengue pathogenesis in several ways. First, the transcriptome
of uncomplicated, febrile dengue patients was associated with many of the transcriptional
features expected of a systemic viral infection in which the blood is a relevant
compartment in which to monitor host responses. Thus, genes and pathways relating to
oxidative metabolism, IFN-a/p-stimulation, cytokine expression and apoptosis were all
prominent in the transcriptional signature. These prominent genes and pathways may serve
as candidate genes in future host genetic studies o f dengue susceptibility. In contrast, DSS
was associated with an underlying whole-blood transcriptional profile that from an
immunological perspective was benign. A possible explanation for these phenomena is that
the “host defense” transcriptional profile is observed well before the point of defervescence
and cardiovascular decompensation in DSS patients. In this scenario, a very high initial
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viral antigen burden drives a rapid and robust “host defense” transcriptional profile that wanes 
by the time of defervescence and cardiovascular decompensation as viral antigen is cleared by 
secondary humoral and cellular immune responses. Paradoxically, the rapidity and strength of 
this antigen-driven secondary response, along with other risk factors, may largely account for 
the extent of capillary leakage in children with secondary dengue [152]. A conceivable, but 
perhaps less likely explanation for the missing “host defense” profile at the time of 
decompensation in DSS patients is that it is attenuated throughout the course of disease. This 
attenuated response could be related to intrinsic host-genetic influences on gene expression or 
it might also be a virus-mediated phenomenon, either of which could result in higher initial 
viral burdens in vivo. In relation to this, the capacity of dengue virus non-structural proteins to 
inhibit the activation of IFN-stimulated response elements in vitro is well documented [156, 
157]. Finally, the absence of an inflammatory transcriptome at the time of cardiovascular 
decompensation may explain why adjuvant corticosteroid use in patients with established DSS 
has little efficacy- there is essentially little in the way of an inflammatory transcriptional 
response to modulate [161].
This current study extends our previous observations in adults with DSS [78]. In contrast to 
our previous study, the present study was more comprehensive in that it sampled RNA from 
paediatric patients matched by age, sex and duration of illness and validated a wider panel of 
transcripts by RT-PCR. A limitation of our current study is the relatively small sample size and 
lack of samples collected very early in the evolution of disease. In addition, we focused on 
children with DSS on the 4th day of their illness- these “fast progressors” are not representative 
of the general population of DSS patients in our hospital setting who on average experience 
hypovolemic shock on the 5th day of illness. Future studies will focus on the very early host- 
viral events in febrile children who subsequently progress to DSS. Ultimately, a better 
understanding of the molecular evolution of DSS could help identify novel biomarkers with 
prognostic utility and form the rationale for new clinical interventions in this important 
disease.
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Chapter 4: An early whole blood transcriptional signature associated with progression to
Dengue shock syndrome in Vietnamese children
4.1 Introduction
Dengue is the most significant mosquito born viral infection o f humans. The dengue 
pandemic has spread to the extent that between 70-500 million infections occur each year 
in over 100 countries resulting in -40  million clinically apparent cases and -20,000 deaths 
[162]. There are no licensed vaccines for the prevention of dengue.
Severe dengue is characterised by a haemorrhagic diathesis, thrombocytopenia and a 
capillary leakage syndrome. In severe dengue, capillary leakage leads to life-threatening 
complications that can include cardiovascular shock, called dengue shock syndrome 
(DSS), severe bleeding or more rarely, other major organ impairment [1]. DSS is the 
commonest life-threatening complication of dengue in children. Most cases of DSS are 
associated with secondary dengue virus (DENV) infections but the exact mechanism of 
disease pathogenesis is not fully elucidated. The prevailing view is that a combination of 
host and viral characteristics interact and contribute to the expression of the clinical 
phenotype. Host features implicated in susceptibility to severe disease include genetic 
variation [2], previous DENV infection history [93, 96, 149, 150], individual propensity 
for capillary leakage that itself is influenced by age and sex [163]. Viral genetic traits 
might also be important, with some lineages o f DENV being virologically [164] and 
epidemiologically fitter [165] than others and more frequently associated with severe 
disease.
Severe dengue is uncommon given the total number of infections [166, 167]. Nevertheless, 
there are no specific therapies for treatment of severe dengue and management is limited to 
supportive care. In children, the most common complication is cardiovascular shock and 
this typically occurs between the 4th and 6th days of illness, during the so-called critical 
phase where compensatory mechanisms can no longer maintain an adequate intravascular 
volume. There is therefore a window of time in the first few days o f illness where it should
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be possible to establish a diagnosis [36] and potentially, make a prognosis o f disease
severity with a host or viral biomarker before decompensation occurs. The identification of
prognostic markers of disease severity could allow for improved patient triage and
management, or in the future, treatment with anti-viral or immune modulating therapies.
4.2 Aim of the study
The aim of this study was to identify whole blood transcriptional signatures in Vietnamese 
children and adults that were associated with progression to DSS. Intriguingly, our findings 
identified several neutrophil-associated transcripts as more abundant in Vietnamese 
patients who progressed to DSS, suggesting a hitherto unrecognised association between 
neutrophil activation, pathogenesis and the development of DSS.
4.3 Materials and Methods
4.3.1 Sample collection
The study was conducted between 2007 and 2008 at Dong Thap hospital, Dong Thap 
Province, Vietnam. The study protocol was approved by the Scientific and Ethical 
committee of Dong Thap Hospital and the Oxford Tropical Research Ethical committee. 
Subjects for this study were recruited from Dong Thap hospital (Dong Thap province, Viet 
Nam). Patients underwent screening in the outpatient clinic of Dong Thap Hospital if there 
was a clinical suspicion of dengue and illness duration of less than 72hrs. Plasma from 
screened patients was tested with an NS1 ELISA test (Biorad, California, USA). Patients 
that were NS1 ELISA positive were admitted for further observation and participation in 
the study protocol if written informed consent was obtained from the patients (patients 
>14yrs) or from the patient’s parents/guardians (patients <14yrsj. Blood samples for 
analysis o f RNA (Paxgene tube) and plasma were collected at the time of enrolment (study 
day 1), on study day 3 and at the time o f discharge. Haematological data were recorded
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daily and all patients received an ultrasound within 24hrs of defervescence. Clinical and
haematological assessments were performed daily.
4.3.2 Expression m icroarray (see Chapter 3, section 3.3.2)
4.3.3 ELISA assays
Elastase (ELA2) in patient plasma samples was measured using a PMN-Elastase ELISA kit 
(ImmunDiagnostik, Netherland). Plasma Defensin la  (DEF1A), Bactericidal/permeability- 
increasing protein (BPI) and Myeloperoxidase (MPO) were measured using capture ELISA 
assays (Hbt, Hycult Biotechnology, Netherland). The limit of detection was 120pg/ml for 
ELA2, 50pg/ml for DEF1A, 250pg/ml for BPI and 0.4ng/ml for MPO. Plasma albumin 
concentrations were measured by capture ELISA. Briefly, ELISA plates (Maxisorp, Nunc, 
Denmark) were coated with anti-albumin pAb (polyclonal rabbit anti-human albumin 
(Dako Co.) overnight and then blocked with 2% skim milk (Merck) in PBS-T 0.05% for lh  
at 37°Q. Next, samples and standards were added into the wells followed by addition of 
diluted biotinylated anti-albumin antibody solution and incubated for lh r at 37°C. Diluted 
streptavidine HRP (P0397, Dako Co. Japan) was added and incubated for lhr at 37°C 
before the OPD substrate was added (Sigma, , USA). After the reactions were stopped by 
diluted sulphuric acid (10%), the OD value was measured using a plate reader (Biorad, 
California, USA) arid the result was analysed by Microplate software (Biorad, California, 
USA). .
4.3.4 DENV genome sequencing
Viral RNA was isolated from patients’ plasma samples (QIAamp Viral RNA Kit -  Qiagen, 
cat # 52906) and reverse transcribed to cDNA with superscript III reverse transcriptase 
(Invitrogen, USA), random hexamers (Roche) and a specific oligonucleotide targeting the 
3’ end of the target genome sequences. cDNA was then amplified using a high fidelity 
DNA polymerase (FIotstarTaq -  Qiagen, Cat # 203205) and a pool of tagged specific
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primers to produce 14 overlapping amplicons. The details of primer sequences for whole
DENV genome amplification are listed in table 4.1 - 4.3. Table 4.4 shows the Reagents and
thermal cycle conditions for whole DENV genome amplification
Each amplicon was ~2Kb in length. This amplification strategy provided 2-3X physical 
coverage of each nucleotide site. The amplification products were sent to the Broad 
Institute, USA for sequencing. The procedure for whole DENV genome sequencing is 
demonstrated in figure 4.1.
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Figure 4.1: Whole DENV genome sequencing strategy. Viral RNA was first isolated from 
plasma sample, reversed transcribed into cDNA before being amplified into 14 overlapping 
fragments in the first round of PCR. The products of PCR reaction were sent to Broad 
Institute for sequencing.
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Viral genomes were sequenced using the Broad Institute’s ABI directed amplification viral
sequencing pipeline (see http://www.broadinstitute.org/annotation/viral/Dengue).
Amplicons were then sequenced in the forward and reverse directions using primer panels
consisting o f 96 specific primer pairs that produce 500-700bp amplicons from the target
viral genome. Total coverage delivered post amplification and sequencing was ~ 8X.
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Table 4.1: Oligonucleotide primer sequences used for DENV-1 amplification in 14
fragments; Note: Y stands for C/T; R for A/G nucleotide.
5 D E N V -1 Forward P rim er
[agttgttagtctacgtggaccg
[ TTCTAGCCATACCYCCAAC AGO 
1AGC AC ATGCCATAGG AAC ATCC
|D E NV-1 R ev erse  P r im er  _
1AYCACGATGTARCTCTCACCAA 
|cTTCC AC ATTTGAGTT CT CTRCC 
i AYTTGGGTGTAGGAGTCACGCA
TGAGACCC AGC ATGGAAC.YGT iYAGCACCGGAAGCCATGTTGTT
IC YTGGACCATGAAAATAGGAATAGG ATRGTTCC ATCATCTTGGACCTC
j CATATGGYT GAAATT GCGT G ACTC 
j ATGGACTTGC AATGGG YATYATG
j AGTGYTATGGGAC ACACC YAG___
j GC V C AAGCTA AAGC AT C ACARG 
j CACGCYCA YTGGAC AGAAGCAAA 
j T C Y GAAC A AGG AGG AARAGCCT A 
f AAAYT GAGGT GGTTT GTGGAG AG 
gAGTGGAACCAGAGGTAGCCAAC
Satycccatggtcacacaaatagc
1 AAC ACCT CGT C YTC AATCTCT GG
tgcttctgtccaatgrgcgtgrt
T CCAC ACTGGCC ATCC AT ARC A 
AAGGCGAGAAGTGGAACTCCTA 
TC YACC AC ACTT GGC AT GTARG 
T CT GTT GTCCRAAGGGTGT GGT
R eg ion
1-2073 __
261 - 2469 
856 - 2933 
1873 -4060 
2289 - 4380 
2917-5070 
3849 - 5995 
4525 - 6678 
5015-7116 
5975-8145 
6476 - 8627
7 1ACGGCT G AAC AG ATRGC ATTAGC 7754 - 9918 
IgGTTTTTACATCCCC ACGATGG j S368- 10465
i AGAACCTGTTGATTCAACAGCAC j 8573 - 10735
Table 4.2: Oligonucleotide primer sequences used for DENV-2 amplification in 14 
fragments; Note: Y stands for C/T; R for A/G; W for A/T and K for G/T nucleotide)
DEN V-2 Forward P rim er  
A GTA GTT A GTCT A CGTGGA CCG
DEN V-2 R everse P rim er  
GATCCR A A A TC CC A RGCTGTGTC
R egion  j
2-2207 |
C AGATCTCTG ATGA AT A ACC A A CG GA TCCRA A A TCCCA RGCTGTGTC S7-2207 1
CCA GA A GA C A T A GA YTGTTGGTG TRCCTGC A TGA TTCCTTTRATGTC 619-2718 |
TGCCCA A CA CA A GGRGA A CCYA A TCTTCCA TGTRTC A TTGA GTGC 1156-3056
A TGGTGCA RGCYGA T A GTGGTT TAG GCTCCRTC TT C C'A GTTCRG 2410-4589
YATGA C;A GGA GA CATYA A AGGA A TC CTTCCA RCCTCCTCCA TA YGA T A 2685-4773
A TGCTY A GGA CCCGA GTA GGA A A GRCA AGCTGCTA TRTCA TTTCC 3541-5645
GCA TGGA A RGTGA GYTGCA CA A . T A TTCRCCRTCA A TGGCA TCC A C 3967-6089
GTYA CA A GGA GTGGA RCA T A TGT A GRA GGGGA A CTCCRA TO TCC A 4984-7106
GCA GC YGGGA TTTTYA TGA CA G GTYT CTCCTRTGTT GCCA GTTC 5446-7592
A GATGGYTGGA YGCTAGGA TCTA T A RTGCCA TGA YGTTTCA TGCTC 6301-8450
C T A  GA W C C A A  T A C C YT A T G A T C C GTGA ITCTTGT GTCCC A KCCTG 728S-9197
GTGA CA T A GGGGA RTCRTCA CC GTA RTCTGTGT A TTCCTCA TTGCC 8003-10215
GCCA T A TTCA CYGA TGA GA A CA A R ___ A GA A CCTGTTGA TTCA A CA GC.A C 8S00-10723
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Table 4.3: Oligonucleotide primer sequences used for DENV-3 amplification in 14
fragments; Note: Y stands for C/T; R for A/G nucleotide.
.......................  rT—™
DENV-3 Forward Primer DENV-3 Reverse Primer Region
T GGACCGAC AAG AAC AGTTT C ggctttgtctccaattccaa 16-2086
GCATGATTGTGGGGAAGAAT tgtcgacctgattccgcaca 468-2593
AGCCCTATTTCTTGCCCATT gtgaagactccgaacccgta 844-2904
TTTCAT GC ATTGTGATAGG A GGGTTTGCmTGCCAAGTG 2358-4508
atggagtgtgcggaatcagg TCTCCATCCTCCTCCGTATG 2568-4765
ACATGATTGCAGGGGTTCTC ATTGCCTGAATTCCATGAGC 3561-5560
tggagaacagccaccctgatt TCACCCCTCCTC AT GAGTTC 3962-6138
GT GGGGGTT GG AGT AC A4. AA TTGCTTGTCTTGGGGAGTTC 4619-6769
cattg aaag g g ctcccaata TCCAGCAGCTGTCCTTTTTT 5217-7240
gatgtctcaagccagtgatt CACACTTTTCAGGTGGAAGA 5796-7985
gagacctaggtggcttgatg ATGGTAAGCCCACGTTTTGTA 6289-8479
c cctagccacag gaccaata GTTCTCGAGGTCTGCCTTCG 7404-9469
CATGCCAACTGT gatt gagc CAAATGGCTCCCTCTGACTC SI 19-10263
ACGAAACC AT GGGATGTGGT CATTTTCTGGCGTT CTGT GC 8546-10679
Table 4.4: Reagents and thermal cycle conditions for whole DENV genome amplification
Reagents pl/reaction Final concentration
FW Primer (10 pM) 0.5 0.2 iiM
RV Primer (10 pM 0.5 0.2 pM
DMSO 1.25 5%
lOx HiFiTaq Buffer 2.5 lx
dNTPs lOmM 1 0.4mM
HiFi Taq (5U/pl) 0.2 1 unit
CDNA- 2
H20 up to 25 pi
PCR conditions for W hole G enom e Am plification in 14 fragments
T °(C ) Time Num ber o f cycles
94 2 mills 1 cycle
94 30 sec
25 cycles60 1 mill
72 2 mins
72 10 mins 1 cycle
4 hold
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4.3.5 Microarray data normalisation and analysis
Standard normalisation procedures in Genespring were used (ver.10, Agilent, Santa Clara, 
CA, USA). In brief, array normalisation was performed by dividing the mean of array
thintensity value by the 75 percentile value o f all arrays. Gene normalisation was performed 
by dividing the mean value of the gene in each array by the 75th percentile value of the 
gene in all the arrays. Normalised data was then filtered based on expression data in which 
only transcripts with detection confidence of less than 0.001 in at least one out of 227 
samples (total samples arrayed) under analysis were used. The detection P value was 
calculated by Beadstudio software (Illumina). After normalization, Significance Analysis 
of Microarray (SAM) was used to detect transcripts that were relatively more or less 
abundant in one group of samples. Significant genes were those with False Discovery rate 
o f less than 5 percent and fold difference between 2 groups of at least 2 fold.
4.3.6 MultiExperiment Viewer (MeV)
MeV version 4.2 was used to analyze microarray data. This software contains Significance 
Analysis of Microarray (SAM) (Tusher at al. 2001) in its package. SAM was able to 
provide the False Discovery Rate (FDR) for microarray data, which is the proportion of 
genes likely to have been identified by chance as being significant. SAM can detect 
transcripts that were relatively more or less abundant in one group of samples. Significant 
genes were those with P value of less than 0.05 and fold difference between 2 groups o f at 
least 2 fold.
4.3.7 InnateDB pathway analysis
4.3.7.1 Pathway & Gene Ontology Analysis of DE Genes using InnateDB
Illumina Probe IDs were mapped to NCBI Entrez Gene IDs and these were used to cross- 
reference and upload genes represented on the arrays to InnateDB (www.innatedb.com) 
[168] along with associated gene expression data. A list of pathways mapping to the
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uploaded genes was returned and pathway analysis was undertaken to determine which
pathways were significantly associated with up- and down-regulated genes using the
Hypergeometric distribution test. InnateDB automatically tests for over-representation of
differentially expressed (DE) genes in more than 3,000 pathways from the Kyoto
Encyclopedia of Genes and Genomes (KEGG) database [169], the NCI-Nature Pathway
Interaction Database (PID) (http://pid.nci.nih.gov), Integrating Network Objects with
Hierarchies (INOH) pathway database (http://www.inoh.org/), NetPath
(http://www.netpath.org) and Reactome databases [170]. The Benjamini and Hochberg
(BH) FDR correction [171] was applied to correct for multiple testing. Similarly, the
InnateDB Gene Ontology analysis tool was used to identify Gene Ontology terms [172]
that were significantly associated with DE genes.
4.3.7.2 InnateDB Molecular Interaction Network Analysis
InnateDB pathway analysis can be very powerful in determining which annotated 
pathways are most significantly associated with DE genes. Pathway analysis, however, 
relies on using the association of DE genes to known biological pathways, which are often 
annotated as relatively simple linear cascades. Network analysis has the ability to move the 
investigation from this simple view of the signalling response to a more comprehensive 
analysis o f the molecular interactions between DE genes and their encoded proteins and 
RNAs, potentially allowing one to uncover as yet unknown signalling cascades or 
pathways, functionally relevant sub-networks and the central molecules, or hubs, of these 
networks. By investigating networks that include interactions between DE genes and their 
non-differentially expressed interacting partners, one has the potential to identify key 
regulators of gene expression, even though these regulators themselves may not be 
differentially expressed but regulated at the posttranscriptional level.
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InnateDB contains databases of all human and mouse experimentally-supported molecular
interactions and annotation on more than 10,000 manually curated human and mouse
innate immunity relevant interactions. InnateDB allows one to upload a gene list of interest
along with associated gene expression data, and returns this data integrated in a molecular
interaction network context for visualization and further interrogation and analysis.
4.4 Results
4.4.1 Patient populations
Between June 2006 and Dec-2007, 450 patients with dengue and less than 72 hrs of illness 
were enrolled into this prospective, hospital-based study. Thirty five patients subsequently 
progressed to DSS as defined by WHO criteria (pulse pressure < 20 mmHg with poor 
peripheral perfusion and rapid, weak pulse) [1]. The remaining 415 patients were defined 
as having “uncomplicated dengue” by the recently revised WHO criteria [1] as they did not 
require any clinical interventions and were managed throughout in/at the general infectious 
disease ward. Twenty-four DSS patients were chosen for gene expression microarray 
experiment. For each DSS patient, 1-3 patients with uncomplicated dengue and matched by 
sex, infecting virus serotype, age (within 2 years) and day of illness were selected as 
controls for virological investigations and host gene expression profiling. Subsequently, 56 
patients with uncomplicated dengue infection were selected as controls. The demographic 
and virological characteristics o f the DSS and matched uncomplicated dengue patients are 
summarised in table 4.5. The median day of illness was 3 days (range 2-5) and the median 
time to defervescence was 3 days (range 2-3) (table 4.5). In patients who developed DSS, 
the median time from enrolment to shock was 2 days (range 1-4).
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Table 4.5: Baseline characteristics o f patients included in microarray study
Clinical phenotypes DSS (n = 24) Uncomplicated dengue 
(n = 56)
P value*
Median age (range) 1 1 (2 -3 0 ) 10.5 (2 - 29)
Gender (Male (%)) 16/24(67%) 34/56(61%)
Median day of illness (range) 3 (2 -5 ) 3 (2 - 5)
Fever day (range) -3 (-3 to -2) -3 (-3 to -2) .
Received i.v. fluids 24(100%) 0 (0%)
Median array sample date 
relative to date of shock (range) -2 (-3 -  0) N/A
Primary infection 
Unknown
1 (4%) 
1 (4%)
1 (1.8%) 
0
DENV Serotype
DENV1
DENV2
DENV3
DENV4
Unknown
16(67%)
7(29%)
0(0%)
0 (0%) 
1(4%)
41(73%)
15(27%)
0
0
0
Viremia 
Median (range)
(Missing = 6) 
3.47E+7 
(3.11E+4 - 2.15E+9)
(Mising =14) 
4.18E+07 
(1.27E+5 -  1.46E+9)
0.7
NS1 ng/ml 
Median (range)
(Missing= 3) 
1002(0.01 -3842)
(Missing= 17)
117 (0.01 — 3415)
0.048
Neutrophils 
(xlO3 cells/ul)
(Missing =1) 
2.75 
(0.8 -5 .5 )
(Missing = 6) 
2.48 
(0 .7 -8 .4 )
0.7
Note: a Fever day is the number o ■ days relative to the time point when the patient became
afebrile, defined as fever day 0. * Mann-Whitney test P value.
4.4.2 Virological comparisons between patients with DSS versus uncomplicated 
dengue
Patients with DSS (n=21) had significantly higher plasma NS1 concentrations at the time 
o f enrolment than matched uncomplicated dengue controls (n=39) (table 4.1). Plasma 
viraemia levels were not significantly different between the two groups (table 4.1). The 
consensus genome (nt 30-10649) sequences o f 15 DENV-1 and 3 DENV-2 from patients 
with DSS were determined directly from plasma and compared phylogenetically by 
neighbour joining methods to consensus genome sequences sampled from 31 DENV-1 and 
9 DENV-2 from matched patients with uncomplicated dengue (figure 4.2 and figure 4.3).
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All DENV-1 sequences belonged to the genotype I lineage and there was no evidence of a
phylogenetic structure in the neighbour joining tree that was related to clinical outcome
(figure 4.2). All DENV-2 sequences belonged to the Asian-1 lineage and similarly,
consensus genome sequences from DSS patients were not phylogenetically distinct from
uncomplicated dengue cases (figure 4.3).
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Figure 4.2: Phylogenetic tree (Neighbor Joining method) of DENV-1 genome sequences. 
The NJ tree contains genome sequences deduced from the plasma of 32 DENV-1 infected 
patients with uncomplicated dengue (grey highlighted tip labels) and 15 genomes sampled 
from DENV-1 infected patients with DSS (black highlighted tip labels). Trees are mid­
point rooted and contain sequences from other DENV-1 viruses for reference only (black 
tip labels).
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Figure 4.3: Phylogenetic tree (Neighbor Joining method) of DENV-2.The tree contains 
genome sequences deduced from the plasma of 9 DENV-2 infected patients with 
uncomplicated dengue (grey highlighted tip labels) and 3 genomes sampled from DENV-2 
infected patients with DSS (black highlighted tip labels). Trees are mid-point rooted and 
contain sequences from other DENV-2 viruses for reference only (black tip labels).
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4.4.3 Differences in host gene transcript abundance between the early febrile phase 
of dengue and convalescence
After normalization (see section 4.3.5), we obtained 9870 genes for downstream analysis. 
We undertook an expansive interrogation of the host transcriptional signature in dengue by 
comparing transcriptional profiles o f 9870 genes in samples collected early in the acute 
phase (fever day -2 or -3) from 80 acute dengue patients (24 DSS and 56 uncomplicated 
dengue) with 34 convalescent control samples (18 severe dengue and 16 uncomplicated 
dengue). By SAM analysis with a FDR <5%, we identified 860 differentially expressed 
(DE) transcripts (fold change equal to or greater than 2, q value <5%). O f the 860 
differentially abundant gene transcripts, 309 were less abundant and 551 were more 
abundant in acute samples relative to convalescent samples. InnateDB pathway, ontology 
and network analysis of differentially expressed (DE) transcripts was performed to identify 
the molecular pathways, networks and biological processes that dominate the whole blood 
transcriptional profile, and in particular, the major signalling hubs involved in the early 
immune response.
4.4.4 Pathways and Gene Ontology terms associated with up-regulated genes
Many of the over-abundant DE transcripts are interferon-inducible. Indeed of the 551 up- 
regulated genes, 173 (31%) were annotated as Type I interferon-inducible by the 
InterferOme database [173]. Pathways that were significantly over-represented in up- 
regulated genes after correction for multiple testing (FDR < 5%) included Systemic lupus 
erythematosus (KEGG database); Classical complement pathway (PID BIOCARTA) and 
Complement and coagulation cascades (KEGG). The pathway Systemic lupus 
erythematosus is likely significant due to the overlap between this pathway and the 
complement pathways and because of the large number of histone genes that are up- 
regulated. A number of complement and coagulation related genes were found to be up-
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regulated (C1QA; C1QB; C1QC; C2; C3AR1; C5; F9; PLAUR; PR0S1; SERPINA1; 
SERPING1). Prior to correction for multiple testing (which is conservative given the large 
number of pathways tested) a range o f pathways was identified as being significantly over­
represented. These pathways included Toll-like receptor signaling pathway, IL27-mediated 
signaling events, IL12-mediated signaling events, Chemokine signaling pathway, 
Cytokine-cytokine receptor interaction, Lysosome, RIG-I-like receptor signaling pathway, 
IFN-gamma pathway and the JAK-STAT pathway and regulation pathway. Many o f these 
are likely of biological significance (despite being below the statistical threshold). The top 
20 most significant pathways are highlighted in table 4.6.
The most significant GO terms associated with up-regulated genes (FDR <5%) included 
response to virus, immune response, innate immune response and inflammatory response. 
A full list of GO terms associated with up-regulated genes is described in table 4.7.
4.4.5 Pathways and Gene Ontology terms associated with down-regulated genes
Almost all of the significantly down-regulated pathways were related to translation (table 
4.8). All these pathways are significant due to the down-regulation of genes encoding 
ribosomal subunit proteins. The pathway hemoglobins chaperone was also significantly 
over-represented due to the down-regulation of several genes involved in the heme 
biosynthesis pathway (ALAD; ALAS2; ERAF; FECH; HBB; HMBS). GO analysis paints 
a similar picture to the pathway analysis with a number of terms related to translation all 
being significant (FDR < 5%) (Table 4.9).
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Chapter 4: An early whole blood transcriptional signature associated with progression to
Dengue shock syndrome in Vietnamese children
4.4.6 Network Analysis of Differential Gene Expression Profiles in Acute Vs.
Convalescent dengue
InnateDB ('www.innatedb.com) [168] was used to generate molecular interaction networks. 
The first was a network consisting of only the interactions between differentially expressed 
genes and their encoded products (AcuteDengue_DE network, figure 4.4), while the 
second expanded upon this network by including all non-differentially expressed 
interacting partners of the DE genes (AcuteDengue_All network, figure 4.5). The 
AcuteDengue_DE network has 289 nodes and 429 edges, in comparison to the more 
extensive AcuteDengue_All network, which had 4,364 nodes and 9,094 edges.
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The AcuteDengue_DE network was analysed to identify network hubs and bottlenecks
which may represent the key regulatory nodes in the network. Using the “Degree”
algorithm from the cytoHubba plug-in [174] the top 5 hubs (i.e. genes/proteins that are
highly connected to other DE genes) in this network were identified as the transcription
factors STAT1 and STAT2 (2X up-regulated), the tyrosine kinase SRC (2X up-regulated),
PTPN6 (SHP1) (2.5X down-regulated) and C lorfl03 (2X up-regulated). The Hubba
software also allows one to predict proteins that act as bottlenecks in the network.
Bottlenecks are network nodes that are the key connector proteins in a network and have
many “shortest paths” going through them, similar to bridges or tunnels on a highway map
[175]. Several o f the hubs including STAT1, SRC and PTPN6 (SHP1), were identified as
bottlenecks in the network, further supporting their central role in signalling. TRIP6 and
JAK2 were also identified in the top 5 bottlenecks. Analysis o f the AcuteDengue_All
network, which consists of all interactions involving molecules encoded by DE genes
(regardless of whether interacting molecule is DE), also identified SRC, STAT1, TRIP6,
SHP1, C lorfl03 and JAK2 in the top 20 hub/bottleneck nodes (figure 4.5). SRC is the
highest-ranked hub in this network and SRC and STAT1 are the top 2 bottlenecks.
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STAT1
Figure 4.5: A cuteD engueA L L netw ork - InnateDB Network of known protein-protein 
and protein-DNA interactions encoded by DE genes and all known interacting partners in 
acute Dengue patients in comparison to convalescent control samples. Nodes encoded by 
up-regulated genes are shown in red; down-regulated in green. Analysis of this network 
enables the identification of central regulators (hubs/bottlenecks) that are not necessarily 
regulated at the transcriptional level.
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Two major differentially expressed sub-networks were identified in the AcuteDengue_DE
network. The top-ranked network consisted of 23 nodes (including JAK2, JAK3, SRC,
TLR2, IL2RG, SOCS1, SHP1, TRIP6 and many other JAK/STAT and SRC regulators).
The second-ranked sub-network, also consisting of 23 nodes, was enriched for nuclear-
localised proteins (13 nodes) and in terms such as transcription co-repressor activity
(ATF3; DDIT3 (CEBPZ); ID3; NFIL3) and may represent an important transcriptional
regulatory network.
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4.4.7 Combining the Transcriptional Regulatory Network and the Physical
Interaction Network
InnateDB was also used to construct a network of all predicted transcription factor (TF) 
interactions with DE genes (TF_network). This predicted transcriptional regulatory 
network was then merged with the AcuteDengue_ALL network. This combined network 
provides a much more comprehensive picture of the connection between signalling and 
transcriptional regulation (figure 4.7).
Nodes with significantly more interactions with DE genes than expected by chance were 
highly enriched in transcription factors involved in IFN/NFkB signalling responses 
including STAT1, STAT2, STAT3, IRF7, IRF9, IRF1, CEBPB and S P I.'IR F I, for 
example, although not DE itself, is predicted to interact with 100 DE genes. Similarly, 
CEBPB is predicted to interact with 88 genes and is not itself DE. Gene expression 
analysis alone would not reveal the multitude of transcription factors that are likely the key 
regulators driving the host response to dengue.
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■ a •  •
Figure 4.7: InnateDB Network of known protein-protein and protein-DNA interactions 
encoded by DE genes and all known interacting partners merged with the network of 
CisRed predicted transcription factor-gene interactions involving DE genes in dengue 
acute samples in comparison to convalescent control samples. Nodes encoded by up- 
regulated genes are shown in red; down-regulated in green. Note: Nodes in this network 
are not necessarily DE.
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4.4.8 Differences in early host gene transcript abundance between DSS and
uncomplicated dengue patients
The identification of prognostic markers of severe dengue is an important goal. We 
therefore compared gene transcript abundance on fever day -2 or -3 in the 24 DSS patients 
and their 56 matched controls. By SAM analysis, twenty one transcripts were significantly 
enriched in DSS patients relative to uncomplicated dengue patients (FDR <5%, >2-fold 
difference in abundance). There were no significantly down-regulated transcripts in acute 
DSS patients compared to acute uncomplicated dengue patients. Table 4.10 summarises 
the list of 21 differentially abundant transcripts. Prominent amongst these were transcripts 
that could be linked to activated neutrophils, with 12 of the 21 differentially expressed 
genes associated with activated neutrophils in the shape of membrane-bound integrin 
receptors (CEACAM6, CEACAM8), cytokine decoy receptor (IL1R2), secreted proteases 
(CTSG, ELA2), inflammatory molecules (S100A12), secreted anti-microbial 
proteins/peptides (DEF1, DEF4, BPI, CAMP, PGLYRP1) or oxidative enzymes (MPO). 
We explored possible functional relationships between the 21 differentially expressed 
genes using the Ingenuity Pathway analysis (IPA) knowledge base. Unsupervised IPA 
network analysis identified two clusters of 35 genes each that included 18 of the 21 
differentially, expressed genes (figure 4.8). These two network interactions were highly 
unlikely to have occurred by chance (P=T0‘31 and P =10'21). The first cluster included 12 
differentially expressed genes and the second cluster included 9 differentially expressed 
genes. The neutrophil-associated CAMP and MPO, together with the decoy receptor 
IL1R2, were found in both networks. Cathepsin G (CTSG) and Elastase (ELA), which 
were found in the list o f 21 DE genes, were the key elements of the first network while 
TNF-a and p-estrodiol were the key elements of the second network. Strikingly, these data 
suggest gene expression profiles from members of two overlapping networks discriminate 
between patients who progress to DSS from those with an uncomplicated disease course.
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The differential abundance of neutrophil-associated transcripts in patients who progressed
to DSS was not simply a reflection of neutrophil levels in the sample as the mean absolute
count of neutrophils in each group was not significantly different from one another
(median (95%CI) DSS patients 2.75*103/mm3 (2.22 -  3.33) versus 2.48*103/mm3 (2.27-
3.10) in uncomplicated dengue cases). These results indicated neutrophils are
phenotypically activated in children who subsequently develop DSS and suggests certain
neutrophil-associated transcripts could have prognostic value in identifying patients at risk
of severe disease.
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4.4.9 Plasma concentrations of Bactericidal/permeability-increasing protein (BPI),
Defensin-la, Elastase 2 and Myeloperoxidase (MPO)
To determine if the transcriptional profile o f neutrophil activation extended to the plasma 
proteome, the plasma concentrations of BPI, DEF1A, ELA2 and MPO were measured in 
plasma samples collected at the same study enrolment time point as the RNA used for 
expression array analysis. Plasma concentrations of all four proteins were significantly 
higher at the time of study enrolment in those children who developed DSS relative to 
children with uncomplicated dengue, although the absolute difference was smaH (figure 
4.9A-D). Plasma concentrations o f BPI, DEF1A and ELA2 were also significantly higher 
in children who developed DSS compared to convalescent samples and healthy donor 
samples
To understand if elevated concentrations of these neutrophil-associated proteins were 
independent of early haemoconcentration in children with DSS (i.e. reduced vascular 
volume leading to higher plasma protein concentrations), plasma albumin levels in all 
samples were measured as a surrogate marker of the plasma protein concentration (figure 
4.9E). Levels of BPI, ELA2 and MPO were not significantly correlated with the plasma 
albumin concentration in the same sample, suggesting their elevated levels in plasma were 
not merely a reflection o f haemoconcentration at this time point (Pearson’s correlation; 
([Plasma albumin] vs. [BPI], (r= -0.04, P = 0.6), vs. ELA2 (r=-0.41, P = 0.6), or vs. MPO 
(r=-0.008, P = 0.9). In contrast, concentrations of DEF1A were weakly correlated with the 
plasma albumin concentration ([Plasma albumin] vs. DEF1A (r=-0.176, P = 0.014), 
suggesting at least some component of this measurement might have been influenced by 
the reduced vascular volume.
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4.5 Discussion
This case-control study investigated the early whole blood transcriptional signature in children 
who subsequently developed DSS, the most common life-threatening complication of dengue 
in children. This study was rooted in clinical practice by focusing on the dengue syndrome that 
always requires a clinical intervention, often in the setting of the intensive care unit. 
Strikingly, we identified in the first few days of illness, two overlapping gene networks that 
distinguished patients who developed DSS from those with uncomplicated dengue. A feature 
of these networks was genes associated with neutrophil activation and degranulation, 
suggesting a hitherto unrecognised association of neutrophils with pathogenesis and 
expression of the overall disease phenotype.
Previous studies from our groups have described the whole blood transcriptional signature in 
dengue patients by microarray analysis [78, 144, 176]. The timing of sample collection is 
clearly a major factor in the transcriptional signature, with samples collected during the febrile 
phase having a characteristic anti-viral profile, e.g. with interferon-stimulated genes highly 
prominent [78, 144, 176], whilst those collected during the afebrile stage had a predominantly 
metabolic profile [78, 176]. Studies of PBMC (i.e. minus the neutrophil population) have also 
been described [142, 143]. In short however, all previous microarray studies of the dengue 
host response have been relatively small in size, collected samples at heterogenous time-points 
and rarely included patients with DSS, the commonest life-threatening complication in 
children. Against this backdrop, the current study has a number of strengths, notably the 
matched case-control design, large sample size, early sampling prior to defervescence and 
cardiovascular decompensation and inclusion of detailed genomic scale information on the 
infecting pathogen.
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Previous epidemiological, in vitro and in vivo studies have suggested phenotypic differences
can exist between virus lineages of the same serotype [100, 164, 177]. We determined virus
genome sequences and demonstrated that viruses from DSS patients in this study were not
phylogenetically different from those in patients with uncomplicated dengue, implying that
host factors were more important determinants of the clinical course. In addition, the viremia
(as measured by qRT-PCR) was not significantly higher in children who subsequently
developed DSS, although the plasma NS1 concentration was, suggesting that antigen burden
may be a better correlate of severe clinical outcomes, as has been alluded to previously [60].
Using a large sample size, we defined the major transcriptional features of the acute response 
to DENV infection during the febrile period. Complement, TLR and RIG-I signalling 
pathways, interferon-stimulated genes and cytokine/chemokines and their receptors were the 
major features of the transcriptional signature, consistent with previous studies in smaller 
numbers of febrile dengue patients [142, 144, 176]. Utilising a systems biology approach that 
investigated transcriptional profiles in the context of their molecular interaction networks, we 
identified the transcription factors STAT1 and STAT2, the tyrosine kinase SRC, SHP1, TRIP6 
and JAK2 as key central molecules in these networks. Furthermore, the top-ranked 
differentially expressed sub-network was enriched with molecules involved in cytokine 
signalling and JAK/STAT pathways (including JAK2, JAK3, SRC, TLR2, IL2RG, SOCS1, 
SHP1, TRIP6 and many other JAK/STAT and SRC regulators).
The top hub/bottleneck molecules in these networks form a densely connected network
module, with a variety of known interactions between the nodes, SRC phosphorylates STAT1,
for example, upon IFNastimulation [178]. SHP1 also interacts with SRC and regulates its
activity [179]. SHP1 has been shown to negatively regulate TLR-mediated production of pro-
inflammatory cytokines by inhibiting activation of the transcription factor NF-kappaB and
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MAP kinase while promoting TLR- and RIG-I-activated production of type I interferon by
inhibiting the kinase IRAKI [180]. JAK2 also interacts directly with STAT1 and SHP1. The
interaction between JAK2 and phosphorylated STAT1 is enhanced upon IFNa stimulation
[178] and results in STAT1 homodimer formation [181]. SHP1 (which is down-regulated)
may inhibit JAK-STAT signalling by targeting SOCS1 (which is up-regulated) to JAK2 [182,
183]. TRIP6 interacts with TLR2 and is a signalling component of multiple NF-kappaB
activation pathways [184] and is phosphorylated by SRC [185]. The interactions between the
top hub/bottleneck molecules would support this being a key core signalling module in the
network and a central feature in the host response. Analysis of the transcriptional regulatory
network also identified the STAT and IRF transcription factors as the key regulators of the
transcriptional response.
This provides ex vivo evidence in human infection of the prominence of the STAT mediated 
signalling pathway where it is likely critical for regulating the expression of most ISGs. The 
importance of the STAT1 pathway in control of DENV replication in mice and mosquitoes has 
been demonstrated previously [186, 187] and STAT 1/2 may also be targets of DENV- 
mediated interference in the interferon signalling pathway [156, 157].
We identified 21 genes as differentially expressed (more abundant) in patients who developed 
DSS compared to matched control patients. Remarkably, almost all of these genes belonged to 
one of two overlapping networks, in which some of the interconnecting elements have 
immune response functions. That TNF-a should be a central hub in the 2nd network is striking, 
given that TNF-a has been repeatedly implicated in the pathogenesis of severe capillary 
leakage [152, 188]. Clearly, further studies are needed to understand why these two networks, 
and some of their differentially expressed members, are associated with progression to DSS.
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Neutrophil activation and degranulation was a most prominent theme in the DSS-associated
differentially expressed gene list. We verified that plasma proteins concentrations of CTSG,
BPI, ELA2 and MPO were also higher in early DSS than in control patients, albeit the
absolute difference was small and unlikely to be useful for prognosis. Of the differentially
expressed genes associated with neutrophil degranulation, ELA2, CTSG and the defensins
(DEFA1, DEFA4) are of particular interest. ELA2 and CTSG are serine proteases that can
cleave vascular endothelial cadherin and thereby compromise the integrity o f the vascular
endothelium [189]. These proteases might conceivably play a similar role in perturbing the
endothelium in capillary beds during DENV infection. Accordingly, ELA2 has also been
detected previously at higher concentrations in serum of patients with DSS compared with
patients without shock [190]. DEF1A and DEF4A are neutrophil associated defensins with
anti-viral activity [191-193]. These innate anti-microbial peptides may also functionally
participate in the innate anti-viral response to DENV infection.
The dengue capillary leakage syndrome begins in children with secondary infections within 
the first few 1-2 days of illness and can be measured by ultrasound as early as the 3rd day of 
illness [25]. Commencement of capillary leakage in infants with primary dengue likely occurs 
with similar kinetics and can lead to DSS between illness days 4-6 [78]. The triggering of 
capillary permeability early in the disease evolution in both these clinical settings might be 
mediated by robust innate immune responses rather than acquired responses, particularly since 
pre-existing immunity does not exist in infants with primary infection. We propose that 
activated, degranulating peripheral blood neutrophils could contribute to an early triggering of 
capillary permeability. In this model, neutrophils (which express Fc receptors) are activated by 
immune complexes and/or by high early virus antigen burdens in blood and tissues, where 
they secrete cytokines and chemotactic molecules. High viral antigen burdens in vivo could be
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arrived at by antibody dependent enhancement in secondary infection or in primary infection
of infants bom to dengue immune mothers. Neutrophil activation and degranulation alone is
highly unlikely to be sufficient to drive capillary leakage to the extent seen in patients with
DSS. Instead, neutrophil adherence to endothelial cells and the secretion of soluble mediators
of vascular permeability may represent a small step in the inflammatory cascade that
synergises with other adaptive host responses to mediate capillary permeability in severe
secondary infection. In infants with primary infection and severe dengue, an innate response
that includes neutrophil activation, together with an inherently permeable vascular
endothelium, might be sufficient to trigger clinically significant vascular leak. Further studies
of neutrophils and their response to DENV infection are warranted.
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5.1 Introduction
Epidemiological evidence hinted that genetic background could contribute to susceptibility to 
dengue. Studies in Cuba indicated that only patients of European origin presented with 
DHF/DSS [94, 102, 120-124]. Furthermore, despite the presence of risk factors of DHF/DSS, 
only DF but not DHF/DSS was known across the continent of Africa [125-128].
Polymorphisms on the HLA region have been examined in host genetic susceptibility studies 
of dengue [121, 122, 129-133, 194] but unfortunately, no reproducible conclusions has been 
made, primarily because of small sample sizes. Besides the HLA region, polymorphisms on 
other genes have also been studied such as DC-SIGN, TAP, HPA, Vitamin D receptor, FcyR 
[136-138].
Collectively, the majority of studies into host genetic susceptibility to dengue were case- 
control association studies of small sample size with uncertain case ascertainment and with 
unknown levels of population stratification (genetic admixture in one population that obscures 
any meaningful study of genetic association). Typically, these studies examined 
polymorphisms in a limited number of candidate genes for which there was some a priori 
rationale for their investigation. For the vast majority of case-control association studies, there 
was never an attempt to replicate the genetic association in either the same or different 
populations.
We conducted a genome-wide association case -  control study to investigate host genetic 
susceptibility to dengue. The study was design to have two phases - an exploration and a 
replication phase with stringent genotyping quality control throughout the study.
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5.2 Purposes of the study
1. To identify Single Nucleotide Polymorphisms (SNPs) which confer susceptibility or 
protection to symptomatic dengue. Frequencies of 250,000 SNPs in 366 dengue cases 
and 166 population controls were investigated using Affymetrix 250K genotyping 
technique. The most significant SNPs were selected for replication in a second sample 
set of 1260 cases and 1216 controls using Sequenom genotyping technique.
2. To conduct a GWAS to identify SNPs associated with dengue severity in 376 samples 
(187 severe dengue cases, 189 mild dengue cases) using Affymetrix 500K (NSP and 
STY) SNP genotyping technology. SNPs that were potentially associated with severe 
disease were genotyped in a 2nd, larger sample set containing 488 severe dengue cases 
and 542 mild dengue cases using the Illumina GoldenGate' genotyping platform.
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5.3 Materials and Methods
5.3.1 Study design
The study’s design is depicted in figure 5.1
Sample collection
(Confirmed dengue cases including uncomplicated, severe dengue and 
cord blood samples as population controls)
GWAS: Dengue vs. Population controls GWAS: Severe dengue vs. Uncom plicated dengue
(391 Dengue cases vs. 183 population controls) (187 Uncomplicated dengue vs. 189 Severe dengue)
Affym etrix 250K  Genotyping
(Affymetrix 250K  chipNsp)
Sample OC
Call rate .
Admixture analysis 
Family relationship:
SNPOC 
SNP Call rate 
HWE departure 
MAF
X chromosome
Selection o f the most 179 significant SNPs
(Statistical analysis: PLINK, Exemplar, Haploview)
A ffym etrix 500K  Genotyping
(Affymetrix 500K  chip-Nsp &Sty)
Sample OC
Call rate
Admixture analysis 
Family relationships
SNPOC
SNP Call rate 
HWE departure 
MAF
X chromosome
Selection o f the 1,536 m ost significant SNPs
(Statistical analysis: PLINK, Exemplar, Haploview)
Sequenom Genotyping
(1260 cases vs. 1216population controls) 
Sam ple OC SN POC
Call rate . SNP Call rate
HWE departure
MAF
X chromosome 
Association analysis
Illumina Golden Gate genotyping
(488 DSS cases vs. 542 uncomplicated dengue )
Sam ple OC SNP OC 
Call rate SNP Call rate
HWE departure 
MAF .
X chromosome 
Association analysis
Figure 5.1: Diagram summarising study design. Two GWAS studies were performed to 
identify SNPs that are associated with susceptibility to dengue or SNPs that are associated 
with severe dengue. The GWAS were followed by replication studies with independent 
sample sets and techniques.
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5.3.2 Samples collection
Blood samples from dengue patients who were enrolled in a prospective descriptive study of 
„ dengue at HTD between 1999 and 2007 were used for genetic association studies. Peripheral 
blood (2.0ml) was collected at the time of study enrolment and again at the time of discharge. 
Plasma samples were collected after centrifugation and used for diagnosis and research 
laboratory tests. After plasma was collected, the remaining pellet was kept in a 1.5ml tube and 
stored at -20°C until used for DNA extraction. Blood pellet samples of controls were collected 
from cord blood of babies bom in Hung Vuong Hospital, Ho Chi Minh city, Vietnam in 2003 
and 2007 and stored in -20°C. All protocols were approved by Hospital for Tropical Disease, 
Hung Vuong hospital, Ho Chi Minh City. Approval for the studies was obtained from the 
ethical committees of the Hospital for Tropical Diseases, Hung Vuong hospital and Oxford 
Tropical Research Ethnics committee, UK. All participants provided written informed consent 
to participate.
5.3.3 Affymetrix 500K genotyping
The genotyping process is summarised in figure 5.3. In brief, genomic DNA was digested by 
restriction enzyme (Nsp or Sty) before being ligated with adaptor, amplified by PCR, 
fragmented, labelled and hybridised into the beadchip.
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Figure 5.2: GeneChip Mapping Assay -  Styl; Genomic DNA was digested by Styl, amplified 
by PCR, labeled and hybridized to the chip, then scanned to determine the SNP genotypes.
5.3.3.1 DNA extraction for the GWAS
All DNA extractions were performed using a Nucleon kit (GE Healthcare, UK) according to
the manufacturers’ instructions. The blood pellet was re-suspended in red cell lysis buffer,
reagent A (lOmM Tris-HCl, 320mM surose, 5mM MgC12, 1% Triton-XlOO, pH 8.0), with a
ratio 1:4 blood to buffer. The nucleated cells were pelleted after a 10 minute by centrifugation
at 1300g. Next, the cell pellet was re-suspended and lysed in 350pl of reagent B (40mM Tris-
HCL, 60mM EDTA, 150mM NaCl, 1% SDS, pH 8.0), and incubated for 10 minutes at 70°C.
The cell lysate was then mixed with lOOpl sodium perchlorate, followed by 600pl of
chloroform. The tube was mixed by hand and inverted at least seven times. Without remixing
the phase, 150pl of nucleon resin was added to the tube before being centrifuged at 350g for
one minute. Without disturbing the nucleon resin layer, the upper phase was transferred to a
new tube. Next, two volumes of cold absolute ethanol was added and mixed by inversion until
the precipitate appeared. The tube was centrifuged at top speed for five minutes to pellet the
DNA, and the supernatant was discarded. The pellet was washed with 1ml of cold 70%
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ethanol, re-centrifuged, and the supernatant discarded. The pellet was dried for 10 minutes 
before dissolving in 600 pi TE buffer.
5.3.3.2 DNA Quality Control
1.2pl of genomic DNA was measured by spectrophotometry using a Nanodrop instrument 
(Thermal scientific, USA). Next, 1 pi of genomic DNA was diluted 20 times with TE buffer 
( lpl  of DNA in 19pl of mTE buffer) in 96-wells plate (Sarstedt V-bottom). The plate was then 
shaken at 220 RPM overnight at room temperature to resuspend the DNA thoroughly. After 
shaking overnight, 5 pi of diluted DNA was then used for gel electrophoresis to check the 
quality of the DNA. The DNA was first mixed with 5pl of 2X loading dye then loaded into a
1.2 percent agarose gel. The gel was run at 90 voltages for 90 minutes before a gel picture was 
taken using a gel imager. 20X diluted genomic DNA was measured using picogreen (Tecan). 
In brief, each DNA sample was further diluted based on the starting concentration of the DNA 
samples obtained through Nanodrop measurement. After a second dilution, the plate was then 
shaken for 4 hours at 220 RPM to dilute the DNA thoroughly. After that, 50pl of diluted DNA 
was mixed with 50pl picogreen (Invitrogen Quant-iT PicoGreen dsDNA Reagent (solution in 
DMSO), P7581) before the DNA concentration was measured using a fluorimeter 
(Tecan,place). Details of DNA QC process is illustrated in figure 5.3
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Figure 5.3: DNA quality control procedure. DNA quality was determined by Nanodrop, 
electrophoresis, and picogreen measurements.
5.3.3.3 Genomic DNA plate preparation
DNA samples were diluted with mTE buffer before being added into working plates. Two 
concentrations o f genomic DNA were used for this experiment. For DNA samples that had 
concentrations ranging from 35ug/pl to 80ng/pl, 5pi DNA of each patient or control was 
added into one well of a 96-well plate. 3pi of samples with DNA concentrations of 80 to 
120ng/pl was prepared in another 96 -  well plate.
5.3.3.4 Restriction enzyme digestion
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Restriction enzymes (Nsp I and separately, Sty I) was used to digest the genomic DNA. For 
one 96-well plate, the digestion master mix was prepared on ice as following: 1275.1 pi 
AccuGen®Water, 220.8pl NE buffer 2 (10X), 22.1pl BSA (100X; lOmg/ml) and 110.4pl of 
NspI (or Styl) restriction enzyme. The genomic DNA plate was vortexed for 3 seconds, spun 
for one minute at 2000rpm then kept on a cooling chamber while the digestion master mix was 
prepared. Next, 14.75pl of the master mix was transferred into each well o f the working plate. 
The plate was then sealed with adhesive film, vortexed at high speed for 3 seconds and spun 
down at 2000rpm for 30 seconds. Finally, the plate was loaded into a preheated thermal cycler 
and run with 500K digest program (37°C for 120 minutes, 65°C for 20 minutes and hold at 
4°C). When the program was finished, the plate was spun down at 2000rpm for 2 minutes.
5.3.3.5 Ligation
During this step, the digested DNA samples were ligated using either the Nsp or Sty Adaptor. 
A ligation master mix was prepared then added into the samples. The plate was then loaded 
into the thermal cycler and the 500K ligation program was run. The details of these steps are 
described as below.
The digested DNA plate was put on a cooling chamber while the ligation master mix was
prepared in a 2ml tube 'as follows: 82.8pl Adaptor Nsp I (or Sty Adaptor), 276(il T4 DNA
Ligase Buffer (10X) and 220.8pl T4 DNA ligase (400U/pl ). The ligation master mix was
then mixed at high speed for one second each for 3 times and spun down for 3 seconds. Next,
5.25pl of ligation master mix was transferred into each well o f the digestion plate. The plate
was then sealed with adhesive film, vortexed at high speed for 3 seconds and spun down at
2000rpm for 30 seconds before being loaded into the preheated thermal cycler and run with
500K ligation program as follows: 16°C for 180 minutes, 70°C for 20 minutes and hold at 4°C.
After the ligation program was finished, the plate was taken out, spun down at 2000rpm for 30
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seconds and put on ice before being diluted with 75 pi of cold AccuGenWater. The plate was 
then sealed with adhesive film, vortexed a high speed for three seconds and spun down at 
2000rpm for 30 second in order to keep the samples at the bottom of the wells.
5.3.3.6 PCR for amplification of ligated DNA
During this step, an equal amount of ligated sample was transferred into three new 96-well 
plates before the PCR master mix being added into each plate and 500K PCR program was 
run. After the program was finished, the result would be checked by running 3pl of each PCR 
product on 2% TBE gel.
Firstly, lOpl of the samples in each row of the 96-well plate were transferred into the same 
rows of 3 new 96-well plates (labeled PI, P2 and P3) using 12-channel P20 pipette (row A of 
ligated plate in to row A of PI, P2 and P3, respectively). For the 3 new PCR plates, the PCR 
master mix was prepared into 50ml Falcon tube on ice as follow: 13.082mL AccuGENEwater, 
3.312mL TITANIUM Taq PCR buffer (10X), 6.624mL GC-Mejc (5M), 4.637mL dNTP 
(2.5mM each), 1.490mL PCR primer 002 (lOOmM) and 0.663mL TITANIUM Taq PCR 
Polymerase (50X). Next, the PCR master mix was vortexed thoughtfully in order to distribute 
the reagent evenly then poured in to the solution basin. 90pl of the PCR master mix was then 
transferred into PCR plate (PI, P2 and P3) using 12-channel P200 pipette before the plates 
were carefully sealed with adhesive films, vortexed at high speed for 3 seconds and spun down 
at 2000rpm for 30 seconds. Finally, the plates were loaded into the preheated thermal cyclers 
to run with 500K PCR program as follow: 94°C for 3 minutes; 30 cycles of: 94°C for 30 
seconds, 60°C for 45 seconds and 68°C for 15 seconds; 68°C for 7 minutes and hold at 4°C.
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5.3.3.7 Checking the PCR product
The result of previous steps was checked by running 3pl of PCR products in 2% TBE gels. 3 pi 
of loading dye was added into each well of 3 new plates labeled PI Gel, P2Gel and 
P3GelBefore 3pl of each PCR product from PI, P2 and P3 was transferred to the 
corresponding plates PI Gel, P2Gel and P3Gel. The plates were then sealed with adhesive 
films, vortexed and spun down at 2000rpm for 30 seconds before 6pl of loading dye and 
sample mixture being loaded into 2% TBE gels. The gels were run at 120V for one hour. 
Finally, gel pictures were taken and the product was verified to make sure that it iff distributed 
around 250bp to 1 lOObp.
5.3.3.8 PCR product purification and elution
Firstly, 8pl of diluted EDTA (0.1M) was added into the product before the plates was tightly 
sealed, vortexed and spun at 2000rpm for 30 seconds. The manifold was prepared by 
connecting the manifold and regulator to a suitable vacuum source that able to maintain at 
600mbar. Next, the samples from the same row and well of each PCR product plate was 
transferred and pooled to the corresponding row and well of the Clean-Up Plate before being 
covered to prevent contaminations from outside. The vacuum was then turned on and slowly 
brought up to 600mbar and maintained until the clean-up plate became dry. After that, the 
PCR product was washed 3 times with AccuGENE water by adding 50pl of water into each 
well of the clean-up plate for 30 minutes for the first 2 times and 45 minutes for the third time. 
After the clean-up plate was completely dried, it was removed from the manifold and its 
bottom was immediately blotted on a thick stack of clean absorbent paper to remove any 
remaining liquid and dried with absorbent wipe.
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5.3.3.9 PCR product elution
45pi RB buffer was added into each well of the clean-up plate. The plate was then tightly 
sealed and shaken for 10 minutes at lOOOrpm at room temperature. PCR product was collected 
by transferring of 45 pi of the product from the clean-up plate to corresponding well of a fresh 
96-well.
5.3.3.10 Quantitation and normalization
In this step, three independent dilutions of each PCR product were measured. The average 
concentration of these 3 dilutions was calculated then normalized with RB buffer to acquire 
concentration of 2ug/pl. Firstly, 198pl AccuGENE water was added into each well of each 
optical plates labeled OP1, OP2 and OP3 followed by transferring 2pl DNA product from 
clean-up DNA plate into corresponding wells of the optical plates. Next, the optical plates 
were sealed with adhesive films, vortexed thoughtfully for 3 times at high speed for 5 seconds 
and spun at 2000rpm for 1 minute. This step was repeated 5 times in order to make sure the 
DNA was mixed evenly in each well. Next, lOOpl of diluted DNA from each of the optical 
plates OP1, OP2 and OP3 were transferred to the new plates for OD measurement at the 
wavelength of 260, 280 and 320nm. The three OD readings for every sample were subtracted 
to water blank OD before the average OD of 3 replicates was calculated. Neat DNA 
concentration was calculated as following:
Sample concentration in jig/pl = average sample OD value x (0.05ug/pl) x 100.
0.05 pg/pl is the amount o f  double stranded DNA equivalent to 1 unit o f  OD at 260nm.
The ratio OD260/OD320, which indicates the quality o f  the DNA sample, should be between
1.8 and 2.0. OD320 should be very close to zero.
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DNA concentration was normalized by mixing 90ug of DNA sample with appropriated 
amount of RB buffer in order to bring the concentration to 2ug/pl in total 45pl.
5.3.3.11 Fragmentation
In this step, the purified, normalized DNA product was fragmented using fragmentation 
reagent. Firstly, 5pl of fragmentation buffer was added to each sample followed by 5 pi of the 
fragmentation reagent (0.05U/pl of DNase I). The plate with mixture of DNA and 
fragmentation reagent was then vortexed at high speed for 3 sec and spun down at 4°C at 
2000rpm for 30sec. Finally, the place was then loaded onto preheat block (37°C) thermal 
cycler and run with 500K fragmentation program ( 37°C for 35 minutes, 95°C for 15 minutes 
and hold at 40°C).
5.3.3.12 Checking the fragmentation reaction
After the 500K fragmentation program finished, the plate was spun at 2000rpm for 30 sec to 
keep the fragmentation product at the bottom of the wells. 4pl of the fragmentation product 
was mixed with 4pl of gel loading dye before being loaded onto 4% TBE gel and run for 30 
minutes at 120V. The gel was finally inspected under gel capture machine.
5.3.3.13 Labelling
In this step, fragmented samples were labeled using GeneChip DNA labeling reagent. Firstly, 
the labelling master mix was prepared into a 15ml centrifuge tube with 1545.6pl of TdT buffer 
(5X), 220.8pl of GeneChip DNA labeling Reagent and 386.4pl of TdT enzyme (30U/ml). The 
mixture was then vortexed at high speed 3 times (1 second each time) and spun down for 3 
seconds. Next, 19.5pl of the master mix was then transferred to each well of the fragmented 
plate placed on the other cooling chamber. The reagent and fragmented products was then 
pipetteted up and down for few times to ensure all the labeling mix is added to the fragmented
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product. After tightly sealed, vortexed at high speed for 3 seconds, spun down and 2000rpm 
for 30 seconds, the plate was then loaded onto a preheated (37°C) thermal cycler block and run 
with the 500K labeling program (37°C for 4 hours, 95°C for 15 minutes and hold at 4°C). 
After the labeling program finished, the place was spun down at 2000rpm for 30 seconds 
before proceeded to the next step.
5.3.3.14 Hybridization
Firstly, the hybridization master mix was prepared by adding the reagents into a 50ml 
centrifuge tube then thoroughly vortexed and pulse spun for 3 seconds. Next, 190pl of the 
hybridization master mix was then added into each of labeled samples (the total volume now 
is 260pl). The plate was the tightly sealed then the samples were denatured on a thermal cycler 
(95°C for 10 minutes and held at 49°C). After the denaturation, each sample was loaded onto 
the GeneChip Human Mapping 250K array (Nsp and Sty). The arrays were then placed into a 
hybridization oven that preheated to 49°C for 16 to 18hrs.
5.3.3.15 Washing, staining and scanning
The following hybridization, washing and staining procedures were performed by the Fluidics 
Station 450 (Affymetrix 2006). In brief, the staining protocol for mapping arrays was a three- 
stage process consisting of a Streptavidin Phycoerythin (SAPE) stain followed by an antibody 
amplification step and a final stain with SAPE. After the staining process, the array was then 
filled with Array Holding Buffer and was ready for scanning. After the wash protocols were 
completed, the probe array was scanned by the GeneChip Scanner 3000 7G and the scanned 
probe array image (.dat file) and cell intensity data (.CEL file) were automatically generated 
by GeneChip Operating Software and made ready for analysis by GeneChip Genotyping 
Analysis Software (GTYPE).
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5.3.4 Illumina Golden Gate Assay
After DNA QC, 250ng DNA of 25ng/|il was used for this experiment. The experiment was 
performed according to the manufacture’s instruction (Illumina, Inc. San Diego, CA 92121 
USA). In brief, genomic DNA was first activated for binding to paramagnetic particles. The 
activated DNA was then subjected to a hybridization step in which assay oligonucleotides, 
hybridization buffer, and paramagnetic particles were combined with activated DNA. Assay 
oligonucleotides comprise three types of oligonucleotides: two allele specific oligos (ASOs) 
which hybridize to the alleles and a locus specific oligo (LSO) which hybridizes to several 
bases downstream of the allele site and contains a unique address sequence that target to a 
particular bead type. These three types of oligonucleotide sequence contain regions of 
genomic complementarily and universal primer sites. During hybridization, the ASOs and 
LSO hybridize to genomic DNA sample bound to paramagnetic particles. The hybridization 
occurs before any amplification step so as to prevent introduction of bias amplification into the 
assay. Following the hybridization, several washing steps are performed to reduce noise by 
removing excess and mis-hybridized oligonucleotides. The extension and ligation of ASOs to 
the LSO joins the information about the genotype present at the SNP site to the address 
sequence on the LSO. The joined, full-length products were then used as templates for PCR 
amplification with cy3-labeled PI primer and cy5-labeled P2 primer from 3’ and P3 primer 
from 5’ site. After downstream processing, the single-stranded, dye-labeled DNAs are 
hybridized to their complement bead type through their unique address sequence. This 
hybridization of the products from the solution onto solid surface beadchips allows for 
individual SNP genotype readout. Finally, the BeadArray Reader is used to analyze 
fluorescent signal on the BeadChip and analyzed by software for automated genotyping 
clustering and calling. The diagram in figure 5.4 below summarises the whole procedure.
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5.3.5 SEQUENOME
This method is a universal method for detecting insertions, deletions, substitutions, and 
other polymorphisms in amplified DNA. Firstly, the genomic DNA sequence flanking the 
SNP sequence was amplified followed by the neutralisation of unincorporated dNTPs in 
amplification products using shrimp alkaline phosphatase (SAP). This enzyme cleaves a 
phosphate from the unincorporated dNTPs, converting them to dNDPs and rendering them 
unavailable to future reactions. Next, the iPLEX Gold reaction cocktail (primer, enzyme, 
buffer, mass-modified nucleotides) is added to the amplification products. The mixture of 
amplified products and iPLEX Gold reaction cocktail was then themocycled to process the 
iPLEX Gold reaction which involves the enzymatic addition of mass-modified nucleotides 
into the diagnostic site. In the reaction mixture, all four mass-modified nucleotides -  A, T, 
C and G -  are present. During the iPLEX Gold reaction, the primer is extended by one of 
the nucleotides, which terminates the extension of the primer. The DNA polymerase which 
incorporates nucleotide was used in the iPLEX Gold reaction. The reaction produces 
allelic-specific extension products of different masses depending on the sequence analyzed 
(figure 5.5).
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Figure 5.5: Flow chart of Sequenom genotyping platform.
5.3.6 Genome-wide association data analysis
5.3.6.1 GeneChip Genotyping Analysis Software (GTYPE)
GCOS version 4.0 was used in a genome-wide scan to automate the control of the
GeneChip Fluidics Stations and Scanners. In addition, GCOS also supports GTYPE
generating genotype calls for the GeneChip Mapping Arrays. GTYPE enables importation
of samples attributes, creates custom file sets, exports batch SNP or linkage data, creates
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virtual data sets, assesses sample mismatch and updates SNP annotations from the NetAffx 
Analysis Center. This software generates .CHP files which display a Dynamic Model 
(DM) scatter plots containing genotype calls for each SNP with a confident score. A 
mapping algorithm report is automatically generated in .rpt files when intensity data is 
analyzed from mapping arrays. Report files summarise data from the samples with SNP 
call rate (Number of SNP calls/total number of SNPs on the array) and genotype call rate 
(Number o f genotype calls for the sample/total number of SNPs on the array). Call rate is 
displayed in the DM algorithm and it is an indicator of the overall performance of the 
assay. Report files also provide quality control (QC) performance with Median PM 
(Median intensity value for perfect match cells for the QC probe sets), MCR (Median call 
rate) and common SNP patterns.
5.3.6.2 Data pre-processing
The raw data output from the Affymetrix genotyping consists of measures o f probe 
hybridization intensities. For each individual at each SNP, there are either 6 or 10 probe 
quartets. Each probe quartets consists of four probe cells which assay for a perfect match 
or a mismatch to a specific 25-base oligonucleotide sequence for each of the two possible 
alleles (genetically denoted A and B). The hybridization intensities need to undergo a pre­
processing phase to combine the information across the probe quartets to yield a pair of 
coordinates corresponding to the signal strength for each o f the two possible alleles. The 
.cel files are pre-processed to a format the enables viewing the quality o f the genotyping 
data.
5.3.6.3 QC for genotyping data
Highly accurate and reliable genotype calling is an essential step in a high-throughput SNP
genotyping technique. In this study, we used both Dynamic Model (DM) and Bayesian
Robust Linear Model with Mahalanobis distance classifier (BRLMM) calling algorithms to
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determine genotypes o f each SNP. TheDM has been used for the GeneChip Human 
Mapping 500K. However, the BRLMM was generated to produce a new model which 
provides a significant improvement over DM. Moreover, we also generated cluster plots 
(SNPSignal tool, affymetrix) which allowed us to visualise the quality o f each SNP. 
Genotyping data was first assessed by DM algorithm. Samples with DM call rate of less 
than 90% were subjected to repeat genotyping. This allows us to assess the genotyping 
quickly and decide samples that need to be re-genotyped. Samples with DM call rate of 
over 90% were assessed again using the BRLMM algorithm because this algorithm 
provides improvement in call rate over DM algorithm.
5.3.6.4 BRLMM Analysis tool (BAT) version 2.0
BRLMM (Bayesian Robust Linear Model with Mahalanobis distance classifier) is evolved 
from the Robust Linear Model with Mahalanobis distance classifier (RLMM, 
http://www.stat.berkelv.edu/users/nrabbee/RLMM/) which provided an improvement over 
DM algorithm on the Mapping. An extension o f the RLMM model, developed for mapping 
the 500K gene chip, provides an improvement over DM in two important areas -  it 
improves overall performance (call rate an accuracy), and it equalizes the performance on 
homozygous and heterozygous genotypes. The difference between RLMM and BRLMM is 
the addition o f a Bayesian step which provides improved estimates of cluster centers and 
variances.
5.3.6.5 Principle component analysis (PCA)
Population stratification -  allele frequency differences between cases and controls due to 
systematic ancestry differences -  can cause spurious associations in GWAS studies which 
normally consist o f a lot o f samples and SNPs. Population stratification is the problem for 
large scale association study which includes thousands of samples. PCA analysis allow us 
to assess how homogenous or heterogeneous are the population under studying (cases and
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controls belong to the same population) and how different this population compare to other 
populations such as CHB, JPT, CEU or YRI.
5.3.6.6 RELPAIR
RELPAIR version 2.0.1 is a FORTRAN 77 program that infers the relationships of pairs of 
individuals based on genetic marker data, either within families or across entire samples . This 
is a likelihood-based method for inferring the most likely relationship for putative sib pairs. It 
calculates the multipoint likelihood Of the marker data for each pair conditional on each of four 
possible relationships: full-sibs, monozygotic twin, half sibs, and unrelated pairs. RELPAIR 
was written to evaluate the multipoint likelihoods and to assess the most likely relationship 
between different putative sib pairs. The multipoint likelihood depends on population marker- 
allele frequencies, inter-marker distances and the presumed relationship of the pair. We have 
used this program to test all possible pairs of individuals in our sample. It can indentify 
apparently independent samples that are in fact related and it also indentifies related 
individuals erroneously classified as unrelated because of sample switches or duplications.
5.3.6.7 Cluster plots
We used SNP Signal tool (Affymetrix) to check the quality of each SNP separately. The 
SNP Signal Tool generates cluster drawings of SNP Signals, one drawing per SNP over a 
set of experiments. Each drawing consists of a set of points in “Contrast” vs. “Size” space. 
The points are colored according to the BRLMM-p genotype calls. Experiments with 
different genotypes for the SNP should cluster from left to right in contrast space: BB 
(red), AB (green) and AA (blue). Visual confidence can be assigned to a SNP whose 
experiments are resolved in Contrast space (the X axis), and have few No Calls (grey 
points).
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5.3.6.8 Quartile -  quartile plots (Q-Q plots)
Q-Q plots are constructed by ranking a set of values o f a statistic from smallest to largest 
and plotting them against the expected values (. Under the null hypothesis there should be 
no significant difference in allele frequencies at genetic markers between cases and 
controls. If the observed data are consistent with the null hypothesis, the points should fall
approximately along the reference line. The greater the departure from the 45° reference
• • 2 • • 2line, the greater the evidence that the observed X statistic do not follow the expected X
distribution, suggesting that the measured differences between cases and controls are not 
random.
5.3.6.9 Hardy-Weinberg Equilibrium (HWE)
Deviation from the HWE can arise in the presence o f a common depletion polymorphism, 
because o f a mutant PCR-primer site or because of a tendency to miscall heterozygotes as 
homozygotes. For a large-scale genotyping study, we assessed the HWE in the control 
group as a data quality check. We used Pearson goodness-of-fit test to test for the 
deviations from the HWE. This test was known simply as “the X test” because the test 
statistic has approximately a X null distribution. We used PLINK to check for the 
depature form HWE in the controls
5.3.6.10 Association tests
To identify SNPs that are significantly associated with dengue or with severe dengue in 
GWAS, we applied five models of chi-square tests which are used to examine the form of 
relationship between two discrete variables and to determine if the relationship observed 
was significantly different from what would be expected if there were no relationship 
between variables.
1. Armitage’s trend test was used as a genotype-based test to test the hypothesis of 
zero slope for the line that fits the three genotyping risk estimate best
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2. Allelic test is a 1-df chi-square test which was used to compare allele frequencies in 
cases and controls
3. Genotypic test is a 2-df chi-square which was used to compare three genotypes (the 
two homozygote and the heterozygote)
4. Dominant test is a 1-df chi-square test which was used to compare wild type 
genotypes (the wild type homozygote and the heterozygote) and the mutant 
genotype (the mutant homozygote)
5. Recessive test
5.3.6.11 Helixtree
We used Helixtree to analyze genotyping data from sequenom. This software allow us to 
perform quality control o f the SNP and the samples such as call rate, HWE, MAF. We can 
also perform association test using this software.
5.3.6.12 WGAviewer
This software was used to annotate SNPs that found significant form association analysis. 
It allows us to look at detail annotation of the SNPs such as LD, haplotype, genes that the 
SNPs located.
5.3.6.13 Haploview
We used haploview to investigate the LD patterns between SNPs and also to plot 
association data that exported from PLINK.
5.3.6.14 PLINK
PLINK (http://pngu.mgh.harvard.edu) is a free, open-source tool set for whole genome
association analysis. It is designed to perform analysis ranging from basic to large-scale
analyses in a computationally efficient manner. PLINK can be used to analyze both
genotype and phenotype data so that the raw data needed to be processed. We used PLINK
to perform both data quality control and association analyses.
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5.4 Results
5.4.1 Quality control (QC)
5.4.1.1 DNA QC
Prior to genotyping, DNA samples were stringently checked for quality and quantity by 
different methods. The success of high-throughput SNP genotyping using the 500K Chip 
(250K Nsp and 250K sty) relies on genomic DNA of good integrity and high quality which 
is free of contaminants that would affect the downstream enzymatic reactions. Figure 5.6 
shows an example o f DNA samples used in the experiment visualised by gel 
electrophoresis.
Figure 5.6: Gel electrophoresis on a 1% agarose gel. Lane ladder refers to a Gene Ruler 
1Kb DNA ladder (Fermentas, USA) which is composed of 14 DNA fragments measuring 
up to lOkb. Genomic DNA samples that are >10Kb in size.
5.4.1.2 Quality control for Affymetrix genotyping
5.4.1.2.1 Assessment of PCR
Genomic DNA was digested with Nspl or Sty 1 restriction enzymes, ligated to adaptors 
and PCR amplified using PCR primers. PCR products were electrophoresed on agarose 
gels to check their size. A successful PCR reaction was indicated by DNA fragments with
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the size o f 250 to 1 lOObp when checked by electrophoresis. Figure 5.7 showed an example 
of a successful digestion and PCR amplification to yield amplimers of size 250 to 1 lOObp.
1000 —
500 —
200—
5 0 -
Figure 5.7: PCR products electrophoresed on a 2% TBE agarose gel at 120V for lhrs. 
Average product distribution is between -250 to 1 lOObp. The first and the last lane are 
50bp DirectLoad Wide Range Marker (Sigma, USA) and the remaining lanes are PCR 
products after amplification
5.4.1.2.2 Assessment of fragm entation
After being purified and normalised to 2(ig/pl, 90pg of PCR product was fragmented by 
using DNase I. The result of the fragmentation was checked by agarose gel electrophoresis. 
Successful fragmentation was indicated by an excess o f DNA less than 180bp. Figure 5.8 
shows an example of a successful DNase I fragmentation.
LadderLadder
S a m p l e l  Sample  2 Sample  3 Sample  4  S a m p l e s  Sample  6
135
Chapter 5: Host genetic susceptibility to Dengue
Ladder
Figure 5.8: PCR products digested with DNase I were electrophoresed on a 4% TBE 
agarose gel at 120V for 30 minutes. Average size is <180bp. The first and the last lanes are 
50bp DirectLoad Wide Range DNA Marker (Sigma, USA) and the remaining lanes are 
DNA samples after fragmentation.
5.4.2 GWAS: Dengue versus population controls
5.4.2.1 Sample collection
For the genome-wide association case control study, we collected a set o f samples for use 
as population controls. These were the cord blood samples from babies born to Vietnamese 
Kinh women in Hung Vuong Hospital, Ho Chi Minh City and were collected between 
2003 and 2007. For Affymetrix 250K genotyping, we used DNA from 183 cord blood 
samples and 391 DNA samples from dengue cases. For validation study, we used 1,260 
DNA samples from dengue cases and 1,216 cord blood control DNA samples.
5.4.2.2 SNP QC
The results of SNP QC is summarised in table 5.1. Briefly, we removed from the data set 
11178 SNPs that had call rates of less than 93%, 49472 SNPs that had minor allele
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frequencies of less than one percent (monomorphic SNPs), 5710 SNPs on the X 
chromosome, 710 SNPs for departure from HWE (P < 10‘7 in the controls), and finally, 
6924 SNPs were removed because there was more than 5% differences in SNP call rates 
between cases and controls. After these QC procedures, 194327 SNPs were left for further 
analyses.
Table 5.1: SNP QC for GWAS comparing dengue and population controls
SNP Filter N um ber of SNPs
Total number of SNPs 262264
SNP callrate < 93% 11178
MAF < 0.01 49472
Chromosome X SNPs 5710
Out of HWE (P > le-7) in control 701
SNP call rate difference >5% between cases and controls 6924
SNPs left for analysis 194326
5.4.2.3 Principle component analysis
The principle component analysis was applied for 526 samples with 194,326 SNPs that 
passed the QC. Genotyping data o f SNPs in all the cases and controls were compared with 
those o f SNPs in Caucasian (CEU), African (YRI) and Asian populations (HCB and JPT). 
All of the Vietnamese case and control subjects clustered with the Han Chinese (HCB) and 
Japanese (JPT) (figure 5.9A). The Caucasian and the African SPNs from the HapMap 
database were then excluded leaving only SNPs from the Asian populations (HCB and 
JPT) were used. The PCA plot o f this analysis using only SNPs from Asian population 
showed that the subjects in the study are homogeneous and do not belong to other Asian
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population (figure 5.9B). The PCA result with PCI and PC2 indicated that the case and the 
control samples are homogeneous except four subjects with PC2 >0.19 (Figure 5.9C). The 
result after excluding the 4 subjects was shown in figure 5.9D.
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Figure 5.9: Principle components analysis indicates that Vietnamese population belongs to 
Asian (A) but different to Chinese (HCB) and Japanese (JPT) (B). Analyses o f cases and 
controls showed that they are homogenous. Shown in (C) is the analysis of cases and 
controls before removing the outliers; and in (D) is the result after removing the outliers. 
The X axis shows the principle component 1; the Y axis shows the principle component 2
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5.4.2.4 QC of DNA samples
DNA samples from 361/391 cases and 170/183 controls were sufficient for genotyping. 
The details of sample quality control are summarised in table 5.2. We removed 3 samples 
which had BRLMM call rate less than 93%, 2 samples for being MZ or FS and 4 samples 
that were outliers as Vietnamese by PCA analysis leaving 522 samples (357 cases and 165 
controls) for analysis. The baseline characteristics o f the 357 cases are summarised in table
5.3 .
Table 5.2: SNP QC results
Filtering criteria N um ber of samples
Total number of samples 531
Cases 361
Controls 170
Sample callrate < 93% 3
MZ 1
FS 1
Outlier by PCA 4
Total samples left 522
139
Chapter 5: Host genetic susceptibility to Dengue 
Table 5.3: Baseline characteristics of 357 cases used in GWAS comparing dengue cases 
and population controls
Variants DSS Uncomplicated dengue
N = 179 2 II oo
Sex (% male) 50.8 % 60.6 %
Age Median (range) years 1 0 .8 (7 -1 4 ) 11 .2 (7 -15)
Max hematocrit (%) 50 45.6
Mean (range) 39 - 59 34.7 - 60
Platelet nadir (103 cell/ml) 26242 63707
Mean (range) 5400- 110000 8510-290000
Note: max hematocrit is the maximum percentage of hematocrit between day 3 and day 8 
of illness; platelet nadir is the minimum platelet count between day 3 and day 8.
S.4.2.5 QQ plot
QQ plot is a graphical method that can be utilized to explore the population uniformity. 
The expected P values of the test statistic from the controls were plotted against the 
observed P values in the cases. Under the null hypothesis, we would expect that all the data 
will fix to the 45-degree line. The QQ plot in figure 5.10 shows that majority of the data fix 
with the expected line which means that the population under study is homogenous. The 
red dots that are deviated from the line indicate either that the theoretical distribution was 
incorrect, or that the sample was contaminated with values generated by a true association
140
Chapter 5: Host genetic susceptibility to Dengue
w»
o
2 530 41
-Log (Expected P value)
Figure 5.10: Quartile-quartile plot of trend test o f the observed P values from cases (Y 
axis) and expected P values in controls (X axis) of 194326 SNPs. Majority of the dots fit 
with the 45 degree line indicating that subjects in cases and controls are homogenous. Only 
the SNPs in the extreme tail are those potentially associated with disease.
5.4.2.6 Association test
We applied Armitage’s trend test included in PLINK software to test for association. The 
tests were carried out to analyse 194326 SNPs in 357 cases and 165 controls. The results 
were then visualised by using Haploview software. The P values of the trend test from 
comparison of frequency o f all autosomal markers in cases and controls were plotted 
against the chromosomal SNP position (figure 5.11).
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Figure 5.11: Trend test P value of 194326 SNPs plotted against chromosomes. Frequencies 
of SNPs in 357 cases were compared with 165 controls by Armitage’s Trend test using 
PLINK. The test P values of all SNPs were plotted against the physical position of 22 
autosomal chromosomes by Haploview software. The Y axis shows the -loglO scale of the 
P values. The X axis shows the chromosome clustered into different colours. The most 
significant SNP in this analysis was lower than 10'6 and mapped in chromosome 2.
5.4.2.7 C luster plot of SNPs
To avoid the spurious results that may be derived from genotyping errors, we visually 
checked clusters of potentially associated SNPs. The BRLMM algorithm calls were used 
for drawing the SNP clusters using The SNP Signal Tool (Affymetrix). This software 
generates cluster drawings of SNP signals, one drawing per SNP over a set of experiments. 
It is impossible to check all the SNPs so we only checked the clusters of SNPs in the top 
hits SNPs (P value < 10'3). From the top hits, we chose the top 179 SNPs with good 
genotyping quality for replication in an independent cohort. Figure 5.12 shows the clusters 
of SNPA -2205258 which has good quality.
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Figure 5.12: Cluster plots of SNP SNP A-2205258 called by BRLMM algorithm. Each 
drawing consists of a set of points in “Contrast” vs. “Size” space. The points are colored 
according to the BRLMM genotype calls. Experiments with different genotypes for the 
SNP should cluster from left to right in contrast space: BB (red), AB (green) and AA 
(blue). Visual confidence can be assigned to a SNP whose experiments are resolved in 
Contrast space (the X axis), and have few No Calls (grey points).
5.4.3 Follow-up replication study in an independent cohort
Sequenom genotyping is a genotyping method that allows us to customise the SNPs to be 
genotyped, i.e. the SNPs of interest indentified by other methods can be genotyped with 
this method. It is a widely used method for the validation of GWAS data. We used 
Sequenom to validate the SNPs that were associated with susceptibility to dengue in the 
initial GWAS screening. As the purpose of this study was to identify SNPs associated with 
susceptibility or resistance to dengue, all dengue cases including severe and uncomplicated 
dengue patients were grouped into a “case” group while cord blood samples were used as 
population controls. Beside the top 179 SNPs that were chosen from GWAS screening, we 
decided to genotype an additional 28 SNPs that are mapped to DC-SIGN gene because 
some of these SNPs were demonstrated to be associated with susceptibility to dengue in
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Thai children [137]. In total, we genotyped 207 SNPs in 2476 samples (1260 dengue cases 
and 1216 controls) using the Sequenom platform. The baseline characteristics of dengue 
cases used for this study is summarised in table 5.4. Of the 207 SNPs chosen for 
replication, we failed to genotype 26 SNPs because there was not primer available for the 
SNPs so that the genotyping reactions could not be designed. Data QC and association 
analyses were performed for 181 successfully genotyped SNPs using Helixtree software.
Table 5.4: Baseline characteristics of patients used in the validation study with the 
sequenom genotyping approach.
Variables DSS 
(N = 602)
Uncomplicated dengue 
(N = 658)
Note
Age M edian (range) 1 0 (1 -1 5 ) 1 2 (5 -1 5 )
Sex M ale (% ) 302 (50%) 385 (59%)
M ax H ct 
M edian (range)
Missing N =  137 
50 (37 -60)
Missing N = 54 
4 4 (2 7 .5 -6 1 )
Platelet nadir 
M edian (range)
Missing N = 137 
30800 (6 3 9 0 - 174000)
Missing N = 54 
64250 (8510-379000)
Dengue confirmed cases 
By serology 
By clinical symptoms 
By PC R
602 (100%) 
590(98.2%) 
12(1.8%) 
0(%)
658(100%) 
637 (96.8%) 
3 (0.5%) 
18(2.7%)
Table notes: The platelet nadir was the minimum platelet count from day 3 to day 8 of 
illness. Maximum Hct was the highest Hct between day 3 and day 8 o f illness.
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5.4.3.1 SNPs associated with susceptibility to dengue
We excluded 230 cases for being genotyped in GWAS leaving 1030 cases for further 
analysis. We compared frequencies o f 181 SNPs (discovered in GWAS and DC-SIGN 
SNPs) in all dengue cases (n=1030, severe and mild dengue) with control samples 
(n=1216). O f the 181 SNPs, we removed two SNPs that had HWE P value in controls less 
than 2.8E-04 (Bonferoni multiple testing correction P value: 0.05/181 SNPs) and nine 
SNPs with call rate less than 0.93, leaving 170 SNPs for genetic association analysis. As 
the SNPs were chosen from the most significant SNPs from the trend test in GWAS, we 
also used the trend test to analyse them in this replication study. We identified 11 SNPs 
with trend test P value < 0.05 (without multiple testing corrections). We applied Fisher’s 
test to combine P values from GWAS and from replication study and GWAviewer 
software to annotate the SNPs. The result of Fisher’s combined values and annotation of 
the SNPs is summarised in table 5.5. The most significant SNPs of the combined data from 
GWAS (357 cases and 165 controls) with Sequenome (1030 cases and 1216 controls) was 
rs 1366478 (P = 6.3x1 O'5) which maps to intergenic region on chromosome 5 and 
rsl7061643 (P = 8.7xl0'5) which maps to intronic region of the KLF12 (Kruppel-like factor 
12) gene on chromosome 13. The protein encoded by this gene is a member of the Kruppel- 
like zinc finger protein family. Other SNPs that also showed evidence for genome-wide 
association but with lower significance included rsl0204649 (P = 2.9xl0'4) and rs298917 (P = 
6x1 O'4) which respectively maps to the intron and exon of VWA3B gene (von Willebrand factor 
A domain containing 3B) on chromosome 2. Other SNPs mapping to intergenic regions with 
less significance were rs7611871 (P = 1.8x1 O'4) mapping to the DPPA2 gene on chromosome 
3, rs l863943 (P = lxlO'4) on chromosome 5, rsl2661760 (P = 2.7xl0'4) mapping to the 
K1AA1244 gene on chromosome 6, rsl485306 (P = 3.2xl0'4) mapping to the COLEC10 on 
chromosome 8, r s l885261 (P = 3X1CT4) mapping to the NPAS3 gene on chromosome 14 and 
rs9788917 (P = 4x10^) on chromosome 16. Functions of these genes in infectious diseases,
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particularly in dengue are unknown and further investigations are needed in order to confirm 
the association of this gene with dengue.
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5.4.3.2 The association of DC-SIGN SNPs with dengue
Previously, the SNPs rs4804803, rs8105483 and rsl 1465391 were demonstrated to be 
associated with protection for DF in Thai children [137]. We wanted to know if these DC- 
SIGN SNPs were also associated with disease status in Vietnamese Kinh with dengue. To 
answer this question, we investigated 28 SNPs in DC-SIGN in 1260 cases (uncomplicated and 
severe dengue) and 1216 controls. We successfully genotyped 16/28 SNPs in the total of 2476 
samples. 12 SNPs failed to genotyped because we could not design the genotyping reaction. 
All of the 16 SNPs that were successfully typed were also typed in the previous study of Thai 
children [137]. To compare our results with previous published results, we applied a similar 
data analysis strategy. The frequency of these 16 SNPs in 1260 dengue cases and 1216 cord 
blood controls were also compared to identify SNPs associated with susceptibility to dengue. 
Statistical tests including Armitage’s Trend test, basic allelic test, basic genotypic test, 
dominant test and recessive test were performed using Helixtree. The statistical results are 
summarised in Table 5.6. We identified four significant SNPs (P < 0.05, before multiple 
testing corrections) from comparison between dengue cases and controls. These SNPs which 
map to 3’-UTR region are rs4804802 (recessive P = 0.028), rsl544767 (recessive P = 0.042), 
rsl544766 (recessive P = 0.025) and rsl 1465413 (recessive P = 0.028). All of the significant 
SNPs were derived from recessive test with very marginal P values. This was not obtained 
from the study in Thai populations.
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5.4.3.3 DC-SIGN SNPs and disease status: Severe dengue and uncomplicated 
dengue comparison
The frequencies o f 16 SNPs in 602 patients with DSS in 658 patients with uncomplicated 
dengue (DF, DHF grade I and II) were analysed using Helixtree software. We applied 
Armitage’s Trend test, basic allelic test, basic genotypic test, dominant test and recessive 
test to analyse the data. Statistical results in comparison with previous study from Thai 
populations are summarised in table 5.7. From the tests performed, we did not identify any 
significant SNP (without multiple testing correction P < 0.05).
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Chapter 5: Host genetic susceptibility to Dengue
5.4.4 GWAS: Severe dengue versus uncomplicated dengue
5.4.4.1 Sample collection and QC
We selected 376 samples (187 DSS and 189 uncomplicated dengue controls) to genotype 
with the Affymetrix 500K platform. All the patients were children (less than 15 year olds) 
and Vietnamese Kinh ethnicity. All patients were diagnosed with DENV infection by 
serology, by PCR (see Chapter 2, section 2.2.1) or by clinical syndromes. All severe and 
uncomplicated dengue patients were classified based on newly updated WHO guidelines 
(see Chapter 2, section 2.1.2). The base-line characteristics of these patients are 
summarised in table 5.8. From the total of 376 samples, we removed 3 samples with 
BRLMM call rate of less than 93%. By RELPAER (see section 5.3.6.6), we identified 
relationships between samples and removed another 26 samples. In the end, 29 samples 
were excluded, leaving 347 samples for further analysis (173 cases and 174 controls).
Table 5.8: Base line characteristics of patients used in GWAS (affymetrix 500K 
genotyping)
Variables DSS Mild dengue
2 II h—
* oo (N = 189)
Age Mean (range) 1 0 .8 (7 -1 4 ) 1 1 .2 (7 -1 8 )
Sex Male (%) 50.8 (%) 59.7 (%)
Dengue confirmed cases (%) 100% 99.45 %
By serology (%) 90.3 (%) 94.7 (%)
By PCR (%) O ' . 4.2 (%)
By clinical symptoms (%) 9.7 (%) 0.55 (%)
Unknown (%) 0 0.55 (%)
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5.4.4.2 Association analysis
To identify SNPs that were associated with severe dengue, we used Exampler to perform 
statistical tests comparing DSS cases with uncomplicated dengue controls. These tests 
including:
a. Allelic chi-square test (details in section 5.3.5.9)
b. Genotypic chi-square test (details in section 5.3.5.9)
c. Armitage’s trend test (details in section 5.3.5.9)
From each test, the top 2000 most significant SNPs were chosen and pooled together. The 
SNPs were ranked by lowest P values and the 2000 SNPs with the lowest P values (the 
most significant) were selected. After choosing the SNPs, we performed SNP QC by 
looking at their call rate, HWE P value and MAF. All of the 2000 SNPs had a call rate over 
93% by BRLMM and MAF >1%. We removed SNPs which deviated from HWE (HWE P 
< lx l0 '7) in the controls and SNPs on the X chromosome. Finally, we chose 1536 SNPs for 
replication in an independent sample set using Ulumina Golden Gate genotyping platform.
5.4.5 Nested analysis of severe dengue versus uncomplicated dengue cases
5.4.5.1 Sample and SNP QC
The Illumina Golden Gate platform was used to genotype a set of 1536 SNPs in the 2nd
sample set. From the total o f 1,144 samples, DNA from 1107 samples was sufficient and
qualified for genotyping by the new platform. Of the 1107 samples, we excluded 15
samples that could not be genotyped, 34 samples with sex discrepancies between
genotyping results and clinical database, and 28 samples for being MZ or FS (most of
which were duplication due to samples were collected twice) leaving 1030 samples (542
uncomplicated dengue controls and 488 DSS cases) for further analysis. The details of
sample QC results are summarised in table 5.9. The base-line characteristics o f these
'153
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samples are summarised in table 5.10. From the total o f 1,536 SNPs discovered in GWAS, 
81 SNPs were removed for having MAF <0.01, call rate <93%, and for deviation from 
Hardy-Weinberg equilibrium (P < 7e-4) in controls leaving 1455 SNPs for further analysis.
Table 5.9: QC results o f samples used in replication study
Filtering criteria Sample filtered
Total samples 1107
Genotyping failed 15
Sex discrepancies 34
MZ or FS 28
# samples passed QC 1030
Table 5.10: Base-line characteristics of 488 severe cases and 542 uncomplicated dengue 
controls used for replication with OPA golden gate technique.
Variants DSS Mild dengue
(N = 488)
<N-3-II
Age Mean (range) 9 .4 (1 -1 5 ) 1 1 ( 5 - 1 5 )
Sex Male (%) 50.4% 57.4%
Dengue confirmed cases (% ) 100% 100%
By serology (%) 99.4% 98.9%
By PCR (%) 0% 0.7%
By clinical symptoms (%) 0.6% 0.4%
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5.4.5.2 SNPs associated with severe dengue
We genotyped and compared frequencies o f 1455 SNPs in 542 uncomplicated dengue and 
488 severe dengue patients. Statistical tests including trend test, genotypic test and allelic 
tests were performed using PLINK software. Figures 5.13 to 5.15 show Haploview plots of 
trend test P values of the 1455 SNPs against the chromosomal physical position. For 
consistency, P values of SNPs from the replication study were derived from the same 
statistical test performed in the GWAS. We identified 30 SNPs with P values < 0.05 
(before multiple testing correction) in the replication study. By using Fisher’s test, we 
combined P values in the GWAS and in the replication study. The list o f these 30 SNPs 
and their annotation results are shown in table 5.11. The most significant SNP was 
rsl2595534 (P = 6.97xl0'6, OR (95%CI) = 0.61 (0.5 -  0.76)) which maps to the intergenic 
region o f the KLF13 (Kruffel-like factor 13) gene on chromosome 15. Rsl3294631 and 
r s l6928238 were two significant SNPs that mapped to the intron of the PTPRD gene 
(protein tyrosine phosphatase, receptor type, D) on chromosome 9 with significance levels 
at P = 2 .3xl0 '5 and P = 1.2xl0'4 respectively. The distance between these two SNPs is 
84kb apart indicating that they were independently identified. SNPs that map to the 3’- 
UTR and the intergenic region of the MBIP  (MAP3K12 binding inhibitory protein 1) on 
chromosome 14 were rs4900833 (P = 3.5xl0‘5; OR (95CI) = 1.92 (1.35 -2.74)) and 
rs3844013 (P = 2X10"4; OR (95CI) = 1.81 (1.25 -  2.62)), respectively. Rs4796751 (P = 
5.8xl0 '5, OR (95%CI) = 0.63 (0.49 -  0.84)) which maps to 3 ’-UTR region of the CNP 
(2',3'-cyclic nucleotide 3') gene on chromosome 17 was also identified.
5.4.5.3 IPA Gene network analysis
We used IPA to explore relationships7 between the genes in which significant SNPs were
identified as associated with severe dengue. This analysis allows us to investigate the
interactions of genes in which the SNPs themselves were found (n=14), or the closest
155
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genes up to 25kb up or downstream of the candidate SNPs (n=7) and biological pathways 
based on its knowledge databases. Of the 21 genes, only 16 genes were mapped to the IPA 
knowledge databases which in turn, fonned two networks. The first network contains 8/16 
genes and was associated with cellular movement, cell signalling, nervous system 
development and function with the network score of 22 (equivalent to P = 10'22). This 
indicates that the network was highly unlikely fonned by chance. The key molecules of the 
network were TNF (Tumour Necrosis Factor), HPS90 (Heat Shock Protein 90kDa) and 
HTT (Huntingin). Genes in the network that contain or near by the associated SNPs are 
PTPRD, CNP, OPCML, NK1RAS2, M B1PPLA2G, DNAJC7 and DNAH9. The network is 
shown in figure 5.16. Collectively, the results suggest that there may be biologically 
plausible functional relationships exist between genes that contain or near by the 
association SNPs.
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Figure 5.13: Trend test P values of 1455 SNPs plotted against physical chromosome 
position. The P values were derived from comparison between 488 severe dengue cases 
and 544 uncomplicated dengue controls. The Y axis is the logarithm scale of P value, the X 
axis is the chromosomal position indicated by different colours. Red lines is the cut-off at P 
= 0.05.
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Figure 5.16: Gene network formed by genes that contain significant SNPs between severe 
dengue and uncomplicated dengue patients identified by IPA. From the list of 30 SNPs, we 
identified 21 genes which contain the SNPs or the closest genes up to 25kb up or 
downstream of the SNPs. Only 16 genes were recognised by IPA software. 11/16 genes 
directly or indirectly interact with each others to form the network. Direct interactions 
between genes were indicated in solid arrows. Indirect interactions were indicated by dash 
arrows. The network score given by IPA was 22 (equivalence to P value = 10‘22, the 
network’s Score = -log (Fisher's Exact test result) indicates the network was highly 
significant (not by chance). This is the number that ranks the network according to their 
degree of relevance to the Network Eligible Molecules in the dataset.
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5.5 Discussion
Chapter 5: Host genetic susceptibility to Dengue
This is the first GWAS to look at host genetic susceptibility to dengue and dengue shock 
syndrome. We demonstrated for the first time that Vietnamese Kinh is distinct from other 
Asian populations such as the Chinese and Japanese. The most significant SNPs that were 
associated with susceptibility to dengue were rsl366478 (P = 6.3xl0 '5), rsl7061643 (P = 
8.7xl0 '5), rs 10204649 (P = 2.9xl0 '4) and rs298917 (P = 6x l0 '4). The most significant 
SNPs that were associated with severe dengue are rsl2595534 (P = 6.97xl0'6), rsl008405 
(p -  2.3x1 O'5), r s l3294631 (P = 3.03xl0'5), rs4900833 (P = 3.5xl0 '5), and rs4796751 (P = 
5.8xl0 '5). None o f these SNPs reached a level that is currently regarded as significant in a 
GWAS (10‘7) [195]. We also identified a network that suggests biologically plausible 
functional relationships, which are extremely unlikely to have occurred by chance exist 
between genes that contain or are in the intermediate vicinity of the SNPs that are 
associated with severe dengue.
The limitation o f this study was that power calculation was not performed. This was 
because the study was conducted in 2007 when the knowledge on the effect size of the 
disease was not available and that this was among the first GWAS in infectious disease 
when only very limited data on population structure and allele frequency in the Asian 
population was available. Infectious diseases are complex and an individual’s 
susceptibility to the disease may be determined by multiple variants in multiple genes with 
small effect. It was shown recently that a sample size of 2000 cases and 2000 controls is 
needed to obtain sufficient power to detect associations with a modest effect size (O.R =
1.5) with a minor allele frequency greater than or equal to 5% [196]. This indicates clearly 
that our study with small sample size has insufficient power to detect any associated SNPs 
with an allele frequency of less than 5% and a minimum effect size of 1.5 . Nevertheless,
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the data from this chapter provide insight into certain aspects o f genetic susceptibility to
dengue infection.
Understanding host genetic predisposition in other infectious diseases has lead to an 
improved understanding of pathogenesis of TB, HIV and malaria [197-203]. The genetic- 
based discovery that CCR5 is a co-receptor for HIV has lead to the development of 
therapeutic drugs that block CCR5. In dengue, an understanding of host genetic 
susceptibility could also assist in the development of antiviral drugs that prevent virus 
infection or modulate the host response. We identified several genes by GWAS that are 
implicated in susceptibility to dengue, but studies on the functions of the genes in the 
context of dengue are warranted.
Studies on HLA region s [121, 122, 129-133, 194], DC-SIGN, FcyR, Vitamin D receptor, 
and TAP [136-138] identified polymorphisms that were putatively associated with dengue. 
Unfortunately, none of these HLA polymorphisms have been replicated in independent 
cohorts. Moreover, many of these studies had small sample sizes with uncertain of case 
ascertainment and with unknown levels of population stratification. Surprisingly, we did 
not identify any MHC-related SNPs that were associated with dengue or with severe 
dengue. The inability to replicate previous cases-control studies of the HLA region in 
Vietnamese population [131] and Thai population [130, 132] might be because of the 
differences in genetic background between populations. Other possible explanations 
include the small sample size of previous studies and heterogeneous case mix.
Quality control is very important in GWAS because without stringent QC, spurious results 
could emerge given the huge number of tests required for analysis. We performed very 
stringent QC for every experimental step and also for data analysis. The genomic DNA 
was carefully QC’d to ensure that they were of good quality for the genotyping process. 
The genotyping data was assessed twice with DM algorithm and BRLMM algorithm to
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assure that the SNP and sample call rates were high enough (>93%) for downstream 
analysis. Population stratification in GWAS is a common problem but by Q-Q plots and by 
PCA, we showed that our cases and controls were homogenous. Sample mislabelling, 
sample duplication or samples from closely related relatives were also excluded through 
checking the IBD proportion that were shared between any pair of case-case, control -  
control or case - control. We also visually checked the potentially associated SNPs by 
looking at the clusters o f genotype of SNPs (AA, AB and BB) called by the BRLMM 
algorithm. Spurious results could emerge in GWAS so that replication o f GWAS results 
with an independent larger sample set is crucial. We performed a follow-up replication 
with a 2nd cohort o f larger sample size to look at a smaller number of SNPs.
We successfully validated ten SNPs from the GWAS (P < 0.05) in the replication set with 
a larger sample size, with P values ranging from 6x1 O'5 to lxlO ’4. The most significant 
SNP was rsl366478 (P = 6.3xl0‘5) on the intergenic region o f chromosome 5. The second 
most significant SNP was rs 17061643 (p = 8.7x1 O’5) which maps to the intron of the 
KFL12 (Kruppel-like factor 12) gene on chromosome 13. The protein encoded by this gene 
is a member of Kruppel-like zinc finger protein family of which several members such as 
KLF2, KLF4 and KLF6 have been postulated to play an important role in mediating the 
function of endothelial cell. KLF2 null mice died as a result of haemorrhage caused by 
incorrect vessel stabilization and defective tunica media formation (reviewed in [204, 
205]). Furthermore, Kruppel-like factors are also expressed in endothelial cells during 
vasculogenesis and early angiogenesis (reviewed in [204]). Another SNPs that also showed 
evidence of genome-wide association but with lower significance included rs 10204649 (P 
= 2.9xl0’4) and rs298917 (P = 6xl0‘4) which mapped to the intron of the VWA3B gene 
(von Willebrand factor A domain containing 3B) on chromosome 2. Von Willebrand 
factor, primarily synthesised in vascular endothelial cells, is a multimeric plasma protein 
that mediates platelet adhesion and aggregation at the site of vascular injury which in turn
Chapter 5: Host genetic susceptibility to Dengue 
results in thrombocytopenia (reviewed in [206]). Further studies on the functions of KLF12 
and VWA3B are warranted. It is striking that 3/10 SNPs that were validated in the 2nd 
sample set were linked to genes involved in coagulation and endothelial cell function, both 
of which are central to the pathogenesis of dengue.
In a nested study, we also tried to indentify SNPs that were associated with severe dengue 
by comparing frequencies of SNPs between DSS and uncomplicated dengue patients. We 
identified 30 SNPs that showed strong evidence for association with severe dengue 
(uncorrected P value < 8x1 O'4) in both GWAS and replication study. The most significant 
SNP was rs 12595534 (P = 6.9x1 O'6), which maps to the intergenic region o f approximately 
160kb upstream of the KLF13 (Kruppel-like factor 13) gene on chromosome 15. This gene 
belongs to a family of transcriptional factors and is involved in B and T cell development 
[207]. Rsl3294631 and rsl6928238 were two significant SNPs that map to the intron of 
the PTPRD gene (protein tyrosine phosphatase, receptor type, D) on chromosome 9 with 
significance level at P = 2 .3xl0 '5 and P = 1.2x1 O'4 respectively. The distance between these 
two SNPs was 84kb apart indicating-that they were independently identified. The protein 
encoded by this gene is a member o f the protein tyrosine phosphatase (PTP) family. PTPs 
are known to be signalling molecules that regulate a variety o f cellular processes including 
cell growth, differentiation, mitotic cycle, and oncogenic transformation. However, the 
functional effect of this protein in dengue has not been documented.
We used IP A in an unsupervised manner which allows identification of gene - gene 
relationships without a priori assumptions to investigate the interconnectedness of genes 
contain or near by the significant SNPs. This analysis linked eight of the 21 genetically 
associated genes that contains or near by the associated SNPs (25kb up or downstream) in 
a network that was associated with cellular movement, cell signalling, nervous system 
development and function. The key molecules of the network were TNF (Tumour Necrosis
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Factor), hsp90 (Heat Shock Protein 90kDa) and HTT  (Huntingin). TNF-a has been well 
documented in terms of its suspected contributions to dengue pathogenesis (reviewed in 
[208-210]). Hsp90 is an ATP dependent molecular chaperone which can regulate more 
than 100 proteins most of which are related to signal transduction. Many signal 
transduction systems use their interaction with hsp90 as an essential component o f the 
signalling pathway. Several protein kinases, including the Src and Raf components of the 
MAP kinase system, are also bound to hsp90 (reviewed in [211]). PLA2G3 belongs to the 
family of secreted phospholipase A2 which was postulated to play important roles in 
systemic inflammatory processes such as sepsis and acute lung injury [212]. DNAJC7 
(hsp40) is another heat shock protein which is demonstrated to have disease-suppressive 
activities. In PBMCs of patients with rheumatoid arthritis, hsp40 can induce secretion of 
IL-10 and reduce TNF-a secretion [213]. NKIRAS2, a member of NFkB pathway, was 
demonstrated to be regulated by mir-29B which negatively regulates expression of 
extracellular matrix related genes in chronic oxidative stress conditions [214]. OPCML 
(opioid binding protein/cell adhesion molecule-like) encodes a member of the IgLON 
subfamily in the immunoglobulin protein superfamily which was postulated to have tumor 
suppression function [215]. Investigations of the contribution of this gene network to 
dengue pathogenesis are warranted.
The DC-SIGN polymorphisms (rs4804803, rs8105483 and rsl 1465391) were
demonstrated to confer protection to mild dengue against DHF in Thai patients [137]. 
However, our result for these DC-SIGN polymorphisms in Vietnamese dengue patients did 
not show any association with severe dengue. The reasons for these differences most likely 
reflect the different disease phenotype defined in our study versus the Thai study, where 
they defined “cases” as patients with DHF grade I and II and controls were DF, while our 
study defined “cases” was those with DSS and controls were DHF grade I and II and the
different in genetic background of Thai and Vietnamese.
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GWAS for infectious diseases are at an early stage with very limited of success because of 
the fact that infectious disease is polygenic and multi-factorial and limitation in the current 
approaches. Although several polymorphisms have been identified as susceptibility 
variants for infectious disease such as TB (SLC11A1 and several others in CCL1) [197, 
198], HIV-1 (CCR5, HLA, HCP5, RNF39/ZNRD1 and PROX1) [199-202] and malaria in 
African (HbS) [203], many other genes and environmental factors as well as the gene-gene 
or gene-environment interactions that are potentially associated with the diseases are 
unidentified. To our knowledge, no GWAS study has been performed in dengue. For this 
reason, we did not have a chance to compare our data with data from other groups.
In conclusion, this is the first genome-wide association study in dengue in which all the 
cases were classified based on the most up-to-date WHO guideline. We also applied 
rigorous quality controls in every step o f the genotyping experiment and also in data 
analysis. We are confident that our cases and controls were genetically homogenous. For 
potentially true associations, we visually checked their genotyping quality to assure that 
they were not genotyping errors. We identified several SNPs that showed evidence for 
significant association with dengue relative to controls or severe dengue relative to 
uncomplicated dengue. None of the SNPs was significant at suggestive genome-wide level 
but ontology analysis of genes implicated by associated SNPs suggests biologically 
plausible functional relationships between genes. Our study also suggested that much 
larger sample size is needed to be able to detect associations at genome-wide significant 
level but its preliminary findings provide basic knowledge of host genetic susceptibility in 
dengue and are valuable for future studies.
165
Chapter 6: General Discussion
CHAPTER 6
6 . GENERAL DISCUSSION
166
Chapter 6: General Discussion 
This thesis filled several significant gaps in our understanding of dengue pathogenesis. 
First, we defined the whole-blood transcriptional profile in acute dengue patients with mild 
and severe clinical outcomes. These are some of the first reports of the molecular response 
in dengue patients and shed light on the host response to systemic viral infections. An 
understanding o f global gene expression in acute DENV infection could be useful for the 
evaluation of dengue vaccines as a successful vaccine could be expected to elicit a host 
response that mimics wild-type infection but without clinical signs. An improved 
understanding o f the host response in acute infection should also be useful when 
considering clinical interventions in dengue. In particular, our data from chapter 3 and 4 
suggested that the “host defense” transcriptional profile is observed well before the point 
of defervescence and cardiovascular decompensation in DSS patients. This may explain 
why adjuvant corticosteroid use in patients with established DSS [161] has little efficacy- 
in simple terms the inflammatory immune response “horse” has already “bolted" by the 
time cardiovascular decompensation occurs. A better approach is therefore to give adjuvant 
corticosteroid therapy early in the infection, at a time when the major elements of the host 
anti-viral and inflammatory immune response are most prominent and which possibly 
drive the capillary permeability syndrome that characterizes severe dengue. To this end, 
the OUCRU is currently conducting a randomized controlled trial of prednisolone, a 
corticosteroid, for the early treatment of dengue in children with <3 days of fever. This 
initial trial in 225 children trial will seek to determine if prednisolone is safe and can 
attenuate the host inflammatory response. In the future, it is possible that we will conduct 
larger trials with a view to determining if prednisolone prevents the development of 
important clinical complications such as DSS. In more general terms, it is plausible that 
insights into the host response to dengue as illuminated by the gene expression studies in 
this thesis will be relevant to other systemic viral infections, in particular flavivirus
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infections with systemic phases such as Yellow Fever or Japanese encephalitis virus 
infection.
One of our major aims in characterising the transcriptional profile in children with dengue 
was to identify signatures that were associated with progression to DSS. Intriguingly, our 
findings identified several neutrophil-associated transcripts as more abundant in 
Vietnamese patients who progressed to DSS, suggesting a hitherto unrecognised 
association between neutrophil activation, pathogenesis and the development of DSS. We 
postulated that neutrophil adherence to endothelial cells and the secretion o f soluble 
mediators o f vascular permeability may represent a small step in the inflammatory cascade 
that synergises with other adaptive host responses to mediate capillary permeability in 
severe secondary infection. In infants with primary infection and severe dengue, an innate 
response that includes neutrophil activation, together with an inherently permeable 
vascular endothelium, might be sufficient to trigger clinically significant vascular leak. Our 
preliminary findings hinted that further studies on the contributions of neutrophils to 
dengue pathogenesis are required. Such studies of might be conducted in animal models of 
dengue, which have improved recently [216-218]. Alternatively, studies of DENV and 
neutrophil interactions the might also be performed on patient blood samples ex vivo using 
flow cytometry or in vitro using neutrophils irt culture.
A lesson from our studies on global gene expression (Chapter 3 and Chapter 4) was that
large patient sample sizes, with serial samples collected early on in the infection, offers the
best way to gather further insights into the host transcriptional response. Such studies are
difficult in children and complicated by the fact that outcomes such as DSS are relatively
rare event. Nevertheless, studies similar to ours should be conducted in other populations
of patients with different ethnic backgrounds and different circulating viruses. Alternative
approaches to microarrays for gene profiling are also become available. Recently, a new
high-throughput sequencing-based technique allowing whole transcriptome surveys from
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subnanogram RNA quantities in an amplification-free manner was developed [219]. This 
technique could be a first choice for the coming years to replace gene expression 
microarrays. This approach would overcome some of the limitations of microarrays, e.g. 
this is an amplification-dependent method in which RNA has to be amplified before being 
hybridized onto the probes with possible introduction of bias.
Dengue, like other infectious diseases, is a complex disease in which outcome may not be
decided by one factor but it may be the combination of multiple factors such as viral
factors and host immunological and genetic factors. In Chapter 5 we conducted a genome-
wide case -  control association study to identify genetic variants that are associated with
susceptibility to dengue or DSS by a GWAS approach. One of the limitations of GWAS is
that it skewed toward common variants in the human genome with at least 1 % so that if the
disease is caused by one or combination of rare variants, it is impossible to detect them
using current technology. Nonetheless, we demonstrated for the first time that Vietnamese
Kinh ethnicity is homogenous and that they are not belong to other Asian populations such
as Han Chinese and Japanese. This indicated also that cord blood samples could be used as
population controls for GWAS with other infectious diseases. We identified ten and 30
SNPs that showed evidence for significant association with susceptibility to dengue and
with DSS, respectively. However, none o f the SNPs reached a genome-wide significant
level (which is 1 O'7) [195], and the functional contributions of the related genes to dengue
pathogenesis are unclear. Further replication studies focused on these variants are
warranted, as are more functional studies o f these genes during DENV infection. To this
end, using the results from this thesis as a foundation, the OUCRU has recently
commenced a GWAS with 2000 DSS cases and 2000 cord blood controls in collaboration
with the Genome Institute of Singapore and funded by a Wellcome Trust project grant. It is
possible then that some o f the SNPs identified in this study will be replicated in this 2nd
samples set o f patients. In general terms, future research into host genetic predisposition to
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dengue and severe dengue could help not only to understand the disease pathogenesis but 
also to identify avenues to develop anti-DENV drugs. For example, the finding that 
individuals with functional deletions in their CCR5 receptor were highly resistant to HIV 
infection (reviewed in [220, 221]) subsequently led to the development and 
commercialisation of a small molecule drugs that block this virus-receptor interaction and 
thereby reduces HIV viral loads [222, 223]. A similar outcome is conceivable for dengue 
and would represent the ultimate justification for genomic research into the pathogenesis of 
this globally important disease. .
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